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Summary 
Single Nucleotide Polymorphisms (SNPs) are used as markers in association 
studies and may contribute directly to inherited disease. Here, we investigated high 
throughput in silico and in vitro methods for identifying SNPs and applied these to 
large scale genomic projects. We evaluated the utility of the Transgenomic 
NavigatorTM software to facilitate automated detection of aberrant denaturing high 
performance liquid chromatography (dHPLC) elution profiles. 3,747 dHPLC profiles 
were analysed with this software and 98.3% of products with profiles distinct from 
wild type harboured novel variants (Chapter 3). We applied this software to 
investigate whether rare inherited variants in genes that play a role in oxidative DNA 
damage repair (OxDR) predispose to colorectal adenomas (CRA) and found that 
unlike MUTYH, inherited variants in other OxDR genes are unlikely to be a frequent 
cause of CRA (Chapter 4). We evaluated the sequence analysis packages 
Sequencher, InSNP, Mutation Surveyor and Staden to identify variants in patients 
with CRAs (using >4,000 chromatograms). Staden and Mutation Surveyor correctly 
identified 76/77 (98.7%) SNPs and 96.7% and 99.3% of the genotypes respectively 
(Chapter 5). We compared an optimised version of Staden against Sequencher for 
variant detection over a 2.5kb region of the adenomatous polyposis coli (APC) gene 
in 969 healthy controls. We found 100% concordance between these packages and 
found that rare nonsynonymous variants in APC were significantly over-represented 
in patients with CRAs as compared to healthy controls (32/480 vs. 37/969, 
P=0.0166) (Chapter 5). We evaluated data held in dbSNP (build 129) for common 
variants in the Caucasian population by examining ten DNA repair genes and 
subsequently developed software for automatically extracting selected information 
from dbSNP (Chapter 6). This program was used to rapidly identify 221 common 
nonsynonymous SNPs in every DNA repair gene in the human genome; these were 
subsequently typed in 480 publically-available human lymphoblastoid cell lines 
generating a resource for functional analyses (Chapter 6). We also assessed the 
role of these SNPs in susceptibility to CRC and response to therapy by exploiting 
data and samples for the randomised controlled trial COIN (Chapter 7). Finally, we 
used Next Generation Sequencing (NGS) to discover SNPs in the exomes of 10 
patients that exhibited peripheral neuropathy in response to chemotherapy and 
discovered that ERCC4 nonsense mutations may contribute to this toxicity (Chapter 
8). NGS is likely to become the key SNP discovery technique over the next decade 
due to its potential to comprehensively search an entire genome at a comparatively 
low cost. 
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1 Chapter One 
 
General Introduction 
 
1.1 Single Nucleotide Polymorphisms 
When a nucleotide locus within a genome deviates from the expected 
sequence the feature is described as a Single Nucleotide Polymorphism (SNP). 
Technically the term polymorphism only describes such variations that occur within 
a population at a frequency of at least 1%; however, the interpretation seems to 
have broadened recently to include less frequent variation, perhaps as a result of 
these rare loci becoming of greater interest to the research community. 
SNPs account for the majority of sequence variation observed in the human 
genome, their distribution is fairly random but they occur frequently (on average 
every 1,200 bases). SNPs exist in coding and non-coding DNA and there are 
numerous techniques for determining their distribution in sample cohorts (Cotton et 
al., 1998, Taylor and Day, 2005). These factors make SNPs ideal as candidates to 
study the relationship between an individual’s genotype and phenotype.  
The impact of a SNP can vary from being completely neutral to completely 
pathogenic and they can have a dramatic effect on drug response, if genetics is to 
achieve the goal of delivering ‘Personalised Medicine’ it is crucial to be able to 
identify and understand the SNPs of individual genomes, recently termed the 
‘Variome’. 
The recent data explosion in genetics has not come without problems, the 
NCBI short read archive (SRA) is set to be phased out though 20121 as sequencing 
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genomes has become cheaper and faster to such an extent that the SRA cannot cope 
with the submissions. One suggested solution to this problem is not to store 
individual genomes but rather to store ‘diff’ files. diff is a computer programme that 
outputs the difference between two files, in the case of genetics this can be the 
difference between an individual’s genome and a reference genome, naturally the 
files are smaller and more manageable but this also demonstrates that it is an 
individual’s differences that have relevance. 
 
1.2  SNP Discovery 
Genetic variations have always been sought in order to identify the 
underlying cause of hereditary disease but they are also significant in identifying 
disease susceptibility and latterly as bio-markers for drug response/suitability. Early 
research focussed on simple Mendelian disorders and small numbers of genes but 
current studies deal with entire genomes and millions of SNPs. The expansion of 
research projects has driven development of many techniques which can identify 
samples that contain variation without incurring the costs of large scale sequencing 
projects, sensitivity and specificity of each technique is widely debated (Gross et al., 
1999, Lin et al., 2008, Schwaab et al., 1997). The chosen method for a project is not 
necessarily the most sensitive as compromises must be made to achieve a 
reasonable rate of discovery within a budget and consideration must be given to the 
available skills and technology of each research group. 
Discriminating between samples with different genotypes at a SNP locus is 
achieved by one of two methods; demonstrating a conformational difference 
between molecules or identifying heteroduplexes. 
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1.2.1 SNP Discovery Techniques - Conformational Discrimination 
1.2.1.1 Denaturing and Temperature Gradient Gel Electrophoresis  
Denaturing Gradient Gel electrophoresis (DGGE) was one of the first 
described methods for detecting SNPS within a PCR fragment (Fischer and Lerman, 
1979) and Temperature Gradient Gel electrophoresis (TGGE) was a development of 
the same principal (Riesner et al., 1989). PCR fragments between 200 and 700bp in 
length are designed with terminating GC clamps to reduce the risk of complete 
denaturation. Fragments ideally have a simple melt profile which could be 
determined by programmes such as MELT94 (http://web.mit.edu/osp/www/ 
melt.html) and latterly uMelt (http://www.dna.utah.edu/umelt/um.php) which 
predict the likely melt profiles of fragments based on sequence composition. 
A polyacrylamide (PAC) gel is created which contains a denaturing agent that 
increases in concentration through the gel such that the highest concentration is 
nearest to the positive electrode. The negative charge of the DNA is utilised to draw 
the double stranded DNA (dsDNA) fragment through the gel from the negative 
towards the positive electrode there by exposing it to the increasing concentration 
of denaturant as it migrates. Sequence differences cause fragments to denature at 
different concentrations and denatured fragments travel through PAC gel at a 
significantly reduced rate therefore when running samples in parallel a difference in 
an individual band’s position is indicative of a sequence difference. 
DGGE is a non-destructive technique, individual fragments can be extracted 
from the gel for further analysis and only basic laboratory equipment is required. 
The gradients themselves cannot be precisely replicated which means different 
sample sets cannot be tested under identical conditions also if the denaturant 
becomes concentrated enough to completely denature a fragment all resolution is 
lost. TGGE over comes these problem as it possible to control temperature (the 
denaturant) with greater accuracy therefore generating the same conditions 
between runs.  
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In theory these techniques are capable of detecting all SNPs within a 
sequence but the technique has largely been replaced by higher throughput 
alternatives, more recent publications that do report the technique are largely 
microbiology based but there are exceptions (da Costa Aguiar et al., 2011) who are 
investigating human variation. 
 
1.2.1.2  Single Stranded Conformational Polymorphism  
Single Stranded Conformational Polymorphism (SSCP) analysis (Orita et al., 
1989) is a technique that works on the principal that two strands of DNA which differ 
by a single nucleotide will form distinct 3D structures that migrate at different rates 
through a non-denaturing matrix. Sensitivity has been reported over a wide range (3 
to 90%, (Sheffield et al., 1993)) with 150bp fragments giving the optimal results. 
With traditional ‘radioisotopic label/slab gel’ approach it was found that 
environmental changes such as apparatus temperature were key to obtaining a good 
rate of detection and so multiple temperatures would be run to achieve maximum 
sensitivity (it is thought that these ‘environmental’ conditions altered the molecular 
interactions of the single strands (Cotton et al., 1998). As new technologies became 
available the isotopic method was replaced by fluorescent detection (Makino et al., 
1992) which was carried out on DNA sequencing instruments that had effective 
temperature control built in (Iwahana et al., 1996). This technology made it easier to 
perform multiple analysis at the range of temperatures required and improved the 
sensitivity of the process. The CCD camera system within the DNA Sequencers meant 
that multiple fragments could be run in the same lane by using different 
fluorophores to label the fragments, increasing the potential throughput.  
This technique does not exploit the existence of heteroduplexes directly as 
they are a feature of double stranded DNA; however, as samples are loaded onto 
non denaturing gels dsDNA reforms and homoduplexes and heteroduplexes may 
resolve at the bottom of the gel. Despite the greater molecular weight compared to 
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single stranded DNA (ssDNA) dsDNA migrates faster due to the simplified 3D 
structure. Though technically heteroduplexes are artefacts of the technique they can 
be informative. 
 
1.2.2 SNP Discovery Techniques - Heteroduplex Identification 
Heteroduplex fragments occur naturally during PCR when a sample is 
heterozygous at a given locus (Figure 1.1). When an amplicon from a paternal 
chromosome anneals to a complimentary amplicon from a maternal chromosome at 
the point at which that sample exhibits heterozygosity there will be a mismatch 
between bases and hydrogen bonds will not form. This feature is known as a 
heteroduplex and it reduces the stability of the double strand compared to those 
with complete matches.  
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   A. Wild Type  B. Recessive  C. Heteroduplex 1  D. Heteroduplex  
 
Figure 1.1: Homo and Heteroduplex molecules. 
A PCR product generated from a heterozygous sample contains two alleles at a SNP 
locus. During PCR the amplicon is heated and cooled cyclically, as the reaction cools 
double stranded products are re-formed. Complimentary strands may form 
homoduplexes (A and B) or heteroduplex containing mismatched bases (C and D) 
where the strand pairs originate from different parents. All four species occur 
naturally during PCR. 
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1.2.2.1 Chemical Cleavage 
By cleaving a heteroduplex fragment at the point where the mis-match 
occurs the heterozygosity of a sample can be evidenced by the presence of 2 bands 
on a gel, this is known as Chemical Cleavage of Mismatch (CCMM). Cotton (1988) 
originally described this process as a modification of the Maxam and Gilbert 
sequencing technique (Maxam and Gilbert, 1977). Hydroxylamine and Osmium 
tetroxide are used to modify C or T mismatches respectively, the modified 
mismatches are cleaved by piperidine and the resulting fragments are separated by 
gel electrophoresis to determine their sizes.  
With the original isotopic technique the sizes of the fragments would provide 
an indication of where the SNP occurs within the fragment but before end labelling 
was possible this would not be definitive. The original PCR is cleaved at the SNP 
locus so when two bands are observed on a gel the SNP locus it is possible to that 
the locus is ‘n’ bases from one end of the original PCR fragment but from which end 
would be unknown. 
The technique is highly sensitive (Whittock, 2005) but the methodology is 
complicated by the toxicity of the chemicals used (requiring multiple ethanol 
precipitations to be carried out in a fume hood) and by the fact that every fragment 
requires separate tests to identify C and T mismatches. Developments of the original 
technique successfully removed some of the more toxic compounds (Potassium 
permanganate and tetraethylammonium chloride replaced Osmium tetroxide 
(Roberts et al., 1997)) but with the development of the enzyme cleavage technique 
the toxic compounds were no longer required. 
 
1.2.2.2 Enzymatic Cleavage 
Enzymatic cleavage (Youil et al., 1995) works on the same principal as CCMM 
but is more readily adapted to fluorescent analysis and therefore offers improved 
throughput and a simplified, less hazardous procedure when compared to the 
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chemical method. The combination of fluorescent end labelling and fluorescent 
ladders improves the accuracy of determining SNP location as a locus can be 
determined as being ‘n’ bases from the fluorescently labelled end of the fragments. 
The technique requires equipment that is widely available in genetics laboratories. 
To improve the throughput seen with capillary electrophoresis Schmalzing (2000) 
applied microchip technology to the analysis of the digested products, where micro-
channel structures etched into glass replaced polymer filled capillaries and allow for 
a faster electrophoresis. 
 
1.2.2.3 Denaturing High Performance Liquid Chromatography (dHPLC) 
dHPLC uses the principals of chromatography to separate different molecules 
based on the length of time they are retained on the ‘stationary phase’ (Oefner and 
Underhill, 1998). The Transgenomic WAVE ™ DNA Fragment Analysis System uses a 
DNASep® column which contains a polystyrene-divinylbenzene (DVB) copolymer 
creating a stationary phase for chromatography. The mobile phase is comprised of 
the ion-pairing agent triethylammonium acetate (TEAA) which mediates binding of 
DNA to the stationary phase and the organic solvent Acetonitrile (ACN). Under 
specific conditions heteroduplex fragments elute at a lower concentration of solvent 
than homoduplexes. 
Sensitivity of the system is determined by selection of a column temperature 
which creates partially denaturing conditions for the PCR that is bound by the TEAA 
to the solid phase. Several programmes, are available for predicting the melting 
profile of a particular PCR fragment (MELT95, uMELT, DNAmelt) which may also be 
empirically determined (Rudolph et al., 2002) by processing an aliquot of PCR 
product at a series of sequential temperature increments and plotting the resulting 
retention time against temperature. Both the computer based and empirical 
approach produce a ‘melt profile’ for the fragments from which a temperature (or 
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temperatures) is selected at which the dsDNA is partially denatured so that the 
effect of the mismatch on the retention time can be maximised. 
Within the temperature controlled column the hydrophobic groups of the 
TEAA (from the TEAA-DNA complex) interact with the hydrophobic C-18 chains on 
the DVB beads immobilising the DNA, the ACN concentration increases through a 
range specific to each fragment. As the ANC concentration increases the first 
fragments to elute will be those where the binding between the DNA and TEAA is 
weakest. If there are no heteroduplexes elution will occur at the same point for all 
amplicons but if heteroduplexes are present the mismatches will weaken the bond 
between the negative phosphate group of the DNA backbone and the positive 
ammonium group of the TEAA. More weakly bonding heteroduplexes will elute 
before the homoduplexes which will require a higher concentration of solvent to 
overcome the bonds with the TEAA molecules (Figure 1.2). 
The eluting PCR products are detected by measuring the UV absorbance of 
the eluting solution and because the PCR is completely un-modified it is possible to 
collect this solution, purify it and use the DNA for downstream analyses such as 
cloning or sequencing. 
When the dHPLC temperature is optimal, all four double stranded products 
may be separated (two homoduplexes and two heteroduplexes (Figure 1.3 B) but 
this level of sensitivity is not necessary for SNP detection. Often the only difference 
between a homozygous and heterozygous product is to observe two peaks or a 
single ‘split’ peak (Figure 1.3 A) heterozygotes can even be identified from a small 
change in the leading edge of a single peak. 
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Figure 1.2: dHPLC. 
(A) Double stranded PCR is mixed in solution with the solvent Acetonitrile (ACN, red) 
and the ion pairing agent Triethylammonium Acetate (TEAA, yellow) which binds the 
DNA. (B) TEAA also binds to the solid phase divinybenzine beads (DVB, blue) 
immobilising the DNA. (C) The ACN concentration increases. (D) ACN reaches a 
particular concentration where heteroduplexes elute as their binding to the TEAA is 
weakened by the mismatch. (E) The ACN concentration increases to a particular 
point where the homoduplexes are eluted. (F) The eluent passes a UV detector and 
absorbance is measured and related to retention time.
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1.2.2.4 Spiking  
Where SNP detection is performed on the basis of identifying heteroduplexes 
samples homozygous for the minor allele are not necessarily identified as they may 
elute with wildtype homozygotes under sub-optimal conditions. By introducing a 
small quantity of PCR that has come from a known reference sequence to every 
sample we enable heteroduplex molecules to form in samples that are homozygous 
for a minor allele without affecting samples with other genotypes (Kaler et al., 2000, 
Pirulli et al., 2000, Schaeffeler et al., 2001). Our own unpublished data has shown 
that a ratio of 4:1, sample to reference is optimal to identify homozygotes without 
affecting homozygous calls when using dHPLC to screen sample sets for SNPs (Figure 
1.4). 
 
1.2.2.5 High Resolution Melt Profile Analysis 
Melt profile analysis provides a ‘real time’ sample analysis with parallel 
processing of 96 or 384 well plates analysis time is a matter of minutes making this 
new technology one of the highest throughput formats (Gundry et al., 2003). PCR 
fragments are generated in the presence of the intercalating Dye ‘LC Green’ with 
which they become saturated. Analysis occurs by measuring the fluorescence given 
off by each well as the sample plate is gradually heated from 750C to 950C over a 
period of 5 minutes during which time the PCR fragments denature releasing the 
dye. Fragments with heteroduplexes will release their dye more quickly on reaching 
a certain temperature due to the instability caused by the mismatch and this change 
in the rate of ‘fluorescent decay’ can be used to separate samples that carry 
heterozygous SNPs from those which do not. Unlike dHPLC all samples are run with 
the same conditions and the optimum temperature does not need to be calculated 
as it will be covered by the dynamic temperature range of the system. Though high 
resolution Melt (HRM) has a lower sensitivity compared to dHPLC (Lin et al., 2008) 
its throughput is considerably greater due to its parallel processing, in certain cases 
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a researcher may accept a proportion of false negative results in return for the 
ability to analyse greater sample sets and more amplicons. 
 
1.2.2.6 Sequencing and SNP Calling Software 
DNA sequencing (Section 1.4) is the most comprehensive method for 
identifying and characterising new mutations. Until recently its cost has necessitated 
the use of the above mentioned techniques to screen samples for those which 
contain variation; however, where cost is not an issue modern capillary sequencing 
combined with SNP calling software provides a fast and comprehensive method for 
screening samples.
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Figure 1.3: Elution of homo- and hetero- duplexes. 
(A) The Heterozygous sample (grey) differs in shape from the wildtype sample 
(purple) the smaller ‘peak’ on the left is indicative of heterozygosity. (B) All four 
species of PCR fragment may be resolved with precise conditions, this image shows 
the 2 heteroduplex and 2 homoduplex peaks produced during PCR of a heterozygous 
sample. 
 
 
Figure 1.4: Spiking. 
When wild type PCR is used to ‘spike’ PCR products then samples heterozygous for a 
recessive allele will be able to produce heteroduplexes with the introduced PCR 
product making the recessive allele detectable by dHPLC. The scatter plot shows that 
the homozygous recessive alleles (green) appear with a similar but less pronounced 
shape as the genuine heterozygous samples (red). 
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Figure 1.5: SNP Discovery Technique Time Line. 
 
1.3 Genotyping 
SNP discovery is still an essential part of genetic research and identifying 
personal SNPs and haplotypes will always be necessary; however, for projects such 
as association studies sufficient information regarding common variation is likely to 
exist in resources such as the NCBI dbSNP database. Where the necessary SNP 
information is available genotyping assays are used to test for allele distribution 
within sample cohorts in a fast and cost effective manner. 
 
1.3.1 Specific Oligo Hybridisation 
Under sequence specific conditions an oligo probe will anneal to an exactly 
complimentary sequence, even a single mismatch can be sufficient to prevent this. 
By testing samples in duplicate with separate probes for the reference and 
alternative alleles it is possible to determine genotypes. The process of 
discriminating between alleles in this way is termed ‘specific hybridisation’ and it is 
common to several genotyping techniques. 
In the original technique (Wallace et al., 1979) probes were designed to span 
a SNP loci, ideally with the SNP site towards the centre of an 18 to 25mer to 
maximise the effect of a mismatch, ideally probe ends with high GC content are 
avoided as they may stabilise a hybridisation even in the presence of a mismatch. 
G:A and G:T mismatches are the least disruptive heteroduplexes but can be avoided 
by designing probes on the assay on the alternative strand which will exhibit C:T and 
C:A mismatches respectively. 
The assay was commonly performed by immobilising sample PCRs on a 
membrane (hybridisation dot blot) and probing with a radio-labelled oligo though it 
is also possible to immobilise the probes instead and test them with labelled PCR 
products. The former process is used to test multiple samples for a single SNP the 
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later tests one sample for multiple SNPs. As with all assays where annealing 
complimentary sequences is the mechanism of discrimination, annealing conditions 
must be titrated exactly which necessitates a lot of preparatory work before an 
assay can be run and numerous sets of different conditions where multiple loci are 
being tested. 
In 1996 Gen-Probe described a variation of the process (Nelson et al., 1996) 
where probes were labelled with a highly chemiluminescent acridinium ester (AE). 
Complete annealing of a probe would prevent it from being hydrolysed, the 
hydrolysis step destroyed the chemiluminescence capability of probes that were not 
bound hence identifying alleles. Nelson was able to demonstrate the detection of 12 
different mismatches in HIV-1 but the technique was not widely used, possibly 
because of the popularity of other assays available at that time with more simplified 
methodology. 
 
1.3.2 Restriction Fragment Length Polymorphism (RFLP) 
Restriction enzymes recognise and cut specific DNA sequences (Figure 1.6 A). 
If a locus of interest happens to create or disrupt a naturally occurring restriction 
site the corresponding enzyme can be used to test for the presence or absence of 
alleles (Figure 1.6 B). 
Originally RFLP analysis was carried out on genomic DNA which was 
hybridised to membranes and probed with radio-labelled oligos, this technique is 
described in the landmark DMD paper which investigated 11 X chromosome RFLP 
markers (Bakker et al., 1985). As PCR was developed it became possible to digest 
amplicons measuring the sizes of resulting fragments with agarose gel 
electrophoresis, this made the assay more accessible as more commonly cutting 
enzymes could be utilised which were not practical to use when digesting very large 
fragments (due to the number of restriction sites that would occur) with PCR 
fragments ubiquitously occurring sites can be avoided or accounted for in the 
interpretation of the results. 
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RFLP is arguably the most simple genotyping technique, digestion conditions 
relate to the chosen enzyme reducing the need for comprehensive assay titration; 
however, it is reliant on the locus of interest creating or destroying a restriction site 
limiting the number of loci it can be applied to. It is possible to use primers which 
will change or insert a nucleotide within the primer portion of a PCR therein creating 
a new restriction site (Figure 1.6, C); however, this is not always possible as the 
surrounding sequence may still be limiting. 
A significant risk of RFLP analysis is that the partially digested PCR product 
when run out on a gel for analysis can create a false result making a sample which is 
homozygous for a cut site appear to be heterozygous and while controls can be 
added to a sample set, individual digestion reactions are not easily controlled.  
 
1.3.3 Oligo Ligation Assay  
When primers anneal immediately adjacent to each other on the same 
template strand they can be joined together using a ligase to form a single stranded 
molecule. By designing one of those primers such that the 3’ base is a compliment to 
one allele of a SNP and applying stringent annealing conditions, ligation will only 
occur where that 3’ base finds a true compliment, this forms the basis of the OLA 
technique.  
The original technique (Landegren et al., 1988) uses a discriminating probe 
with a 5’ biotin moiety and the common probe with a 3’ radiolabel. Following the 
ligation reaction streptavidin is used to isolate the biotin probes and only those 
molecules where ligation has been successful will be radio labelled. The results of 
individual reactions are hybridised to a specific location on a membrane and the 
results of an assay can be determined. Several developments have improved the 
throughput whilst retaining the core technique. 
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Figure 1.6: RFLP. 
(A) The natural cut site for EcoRI. (B) Allele 1 will be cut by EcoRI but allele 2 does not 
match the EcoRI cut site, digestion will demonstrate the sequence at this loci. (C) 
The PCR primer is designed with a base that is not complimentary to the template 
sequence (C in the primer). In subsequent rounds of amplification the C allele 
becomes incorporated into the product in place of the naturally occurring A and a 
corresponding G allele is created on the opposite strand producing an EcoRI cut sit 
which includes the SNP locus ‘Y’. 
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1.3.4 Amplification Refractory Mutation System (ARMS) 
Several acronyms are used to describe this technique including ARMS, PASA 
(PCR Amplification of Specific Alleles), ASA (Allele Specific Amplification) and ASPE 
(Allele Specific Primer Extension), the assay uses a three primer system similar to 
that of the SNPlex technique with 2 allele discriminating primers and a common 
primer for the opposite strand. The DNA template dictates which discriminating 
primer anneals during the PCR cycle, where annealing is successful a product can be 
generated, where the discriminating primer does not anneal to the template no 
product is produced (Newton et al., 1989). 
Separate reactions are set up to test for the presence of a reference allele 
and alternative allele, where both assays produce a fragment the sample is 
heterozygous, where only one PCR is generated the sample is homozygous for the 
respective allele. The assay uses simple lab techniques and equipment and individual 
reactions can be controlled for by the inclusion of a separate set of PCR primers with 
a different overall size, this control will identify failed PCRs from those where one 
allele is not present in the template. 
Optimisation is critical for these assays as a low annealing temperature can 
lead to a primer binding in spite of a 3’ mismatch, it is common to introduce a 
mismatch at the n-2 position of the discriminating primers so that this instability 
increases the likelihood of a primer not binding where the 3’ match is not perfect 
(Figure 1.7). The internal control can also be problematic as a result of competition 
for PCR reagents; however, this remains a widely used technique that has 
contributed significantly to the discovery of disease genes (Johannsson et al., 1996). 
An ARMS assay generally requires 2 assays to test a sample though a 
variation on the technique which tests for both alleles in one reaction has been 
described and termed Tetra –ARMS-PCR (Piccioli et al., 2006).  
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1.3.5 FRET-OLA 
Fluorescence resonance energy transfer (FRET) has been used to distinguish 
between ligated and un-ligated probes. In this technique one primer carries a 
‘donor’ molecule the other carries a ‘reporter’ molecule both of which will emit a 
specific frequency of light when excited. When the two primers are ligated the 
donor and reporter molecules are brought into close proximity where energy may 
transfer between them, excitation of the donor with a specific light frequency will 
cause it to emit light at a frequency that excites the reporter, this in turn emits light 
at a new frequency, the presence of this new frequency of light demonstrates 
successful ligation (Chen et al., 1998). 
 
1.3.6 Padlock Probes 
Nilsson et al (1994) described the use of ‘padlock’ probes where two end of a 
single DNA molecule align at the SNP loci. Ligation causes circularisation of the 
molecule and Rolling Circle Amplification (RCA) is used to produce PCR product. SNP 
assays are carried out in duplicate testing for each allele separately with specific 
probes, the technique is also known as Ligation-Rolling Circle Amplification (Qi et al., 
2001). 
 
1.3.7 Minisequencing / Primer Extension 
As the name suggests this is a version of a standard Sanger sequencing 
reaction that Sokolov (1990) published whilst working with CFTR. With the absence 
of normal deoxynucleotides (dNTPs) which would be present in a standard 
sequencing reaction, the polymerase can only extend a sequencing primer by a 
single fluorescent di-deoxynucleotide (ddNTP). By designing the sequencing primer 
so that its 3’ nucleotide is adjacent to a SNP locus the single incorporated 
fluorescent ddNTP will be the compliment to the SNP allele of the template 
effectively creating an oligo with a 5’ fluorescent label specific to the amplified 
allele. Subsequent analysis of the products can be performed in several different 
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ways and the chosen technique is likely to depend upon the technology that is 
already available within a laboratory. 
 
1.3.8 Taqman 
The Taqman assay determines the genotype of a SNP locus during PCR 
amplification, techniques that do this are known as ‘real-time’ assays. A set of 
normal PCR primers are designed which span the region of interest and an allele 
specific probe is designed which anneals between them. Covalently bound to the 5’ 
end of the allele specific probe is a fluorophore and at the 3’ end there is a quencher 
molecule, the close association of these two molecules when they are bound to the 
probe prevents the fluorophore from emitting light. As the polymerase travels along 
the nascent strand its inherent 5´→3´ exonuclease activity means the fluorophore is 
cleaved from the probe releasing it from the inhibiting effects of the quencher. Light 
is released where an allele specific probe had hybridised successfully demonstrating 
the presence of the corresponding allele (Figure 1.8) (Holland et al., 1991). 
Assays are now available for over 4.5 million SNPs, the set up process is 
simple and the technology required for analysis is relatively common in genetics labs 
as numerous ‘real time’ PCR machines are suitable making this a very popular format 
for screening individual SNPs; however, the assays cannot be easily multiplexed so 
for genome wide studies other techniques are more widely used. 
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Figure 1.7: Designing primers for an ARMS assay. 
The 3’ nucleotide in primers 1 and 2 are complimentary to the different alleles of the 
SNP loci. The n-2 base of both primers (red) is a deliberate mismatch to the template 
sequence, this introduces instability that reduces the chance that a product will be 
created where the 3’ nucleotide is a mismatch. 
 
 
Figure 1.8: Taqman Genotyping Assay. 
An allele specific Taqman probe is labelled with a fluorescent molecule at the 5’ and 
a quencher at the 3’, the quencher inhibits fluorescence while the molecules are in 
close proximity. During a PCR the polymerase incorporates dNTP along the template 
until it reaches an annealed probe at which point the 3’ exonuclease activity of 
polymerase digests the probe DNA separating the quencher and fluorophore and 
allowing the fluorescence to be detected. Different fluorophores are used for each 
allele of the SNP allowing the reaction to occur in a single tube. 
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1.3.9 Molecular Beacons 
DNA probes are designed with complimentary sequence at the 3 and 5’ ends 
so that in their native form the ends hybridise creating a stem/loop structure. The 
sequence within the loop is specific to one allele of a SNP locus and as it is longer 
than the complimentary stem sequence, when it binds a template the new structure 
is more stable than the stem-loop. Covalently bound to the probe ends are a 
fluorescent molecule and a quencher, in the native form these are held in close 
proximity but where hybridisation occurs the molecules are separated sufficiently by 
the intervening sequence that the fluorophore can emit light when excited hence 
demonstrating a sample genotype. 
In solution the probes bind the template, if the sequence is fully 
complimentary the fluorophore is released from the quencher, the alternative 
allele’s probe will remain in its native form and its fluorescence is quenched. As the 
temperature increases the template/probe hybrid molecules will denature causing a 
reduction in the fluoresce associated with that allele as the probe returns to its 
native form, eventually all of the probes will become denatured and fluorescence of 
both alleles will be detected (Tyagi and Kramer, 1996). 
Molecular Beacon assays require the same equipment for analysis as TaqMan 
assays (a real time PCR machine) and have therefore been ‘competing’ against an 
established and well supported TaqMan community hence the technique is not as 
well used as it might otherwise have been. 
 
1.3.10 Fluorescent Minisequencing 
Fluorescently labelled ddNTPs enable the use of standard PAC gel technology 
to detect the incorporated fluorophore. The size resolution of the polyacrylamide gel 
enables a certain amount of sample pooling to be used for the purpose of increasing 
throughput, this can be achieved by designing assay primers with different lengths 
and using an internal size standard to separate the results during analysis (Kobayashi 
et al., 1995). 
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1.3.11 Matrix-Assisted Laser Desorption/Ionization (MALDI) 
 Also known as Mass-spec, this technology ‘fires’ DNA molecules along a 
tube, the Time-of -flight (TOF) is recorded and can be used to detect the difference 
between primers molecules that have incorporated either the reference or 
alternative allele during the extension reaction. 
Samples or ‘analytes’ are mixed with an organic matrix molecule which forms 
a co-crystallised product when spotted onto a metal MALDI plate, the plate is then 
placed into an ionisation chamber which contains a vacuum. A single spot on the 
plate is targeted with a laser of a specific wave length (depending upon which matrix 
was chosen). The matrix absorbs the laser energy whilst protecting the analyte 
molecule from direct exposure to the laser. Energy is transferred between the 
matrix and analyte which becomes ionised and evaporated into the gas phase within 
the vacuum. The ionised analytes charge is used to draw the molecules through the 
mas spec flight tube to the detection plate at the far end. Mass spec has sufficient 
resolution to detect the difference between molecules with differing bases at their 
3’ end hence deducing genotypes (Braun et al., 1997). 
Unlike the fluorescent method no labels or internal ladders are required and 
though samples are analysed sequentially run times are a fraction of a second. The 
negative charge of the phosphate backbone of a DNA molecule complicates the 
sample preparation and ultimately leads to a reduced signal when compared to 
analysis of other peptides with a similar mass. Complicated preparation steps are 
more difficult to automate which can make MALDI-TOF a less attractive option for 
genotyping but where the skills and equipment are available the technique is still 
utilized (Roberts et al., 2011). 
 
1.3.12 Fluorescent Polarisation 
Polarised light can be used to excite fluorescent molecules in solution. If the 
molecules are relatively small (such as an unincorporated fluorescent dNTP) they will 
be rotating as they are excited and emit scattered light. If the molecules are large 
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(such as the products of minisequencing reaction) then they will be rotating more 
slowly and the light which is emitted will remain polarised. This emitted polarised 
light can be detected making it is possible to distinguish incorporated and free 
fluorescent dNTP and therein identifying which dNTP is incorporated following a 
minisequencing reaction (Chen et al., 1999). 
 
1.3.13 dHPLC Genotyping 
Hoogendorn et. al. (2000) described a variation of the process which 
removed the need for fluorophores. Assay specific mixtures of dNTP and ddNTP are 
created such that the presence of one allele will result in the immediate termination 
of extension and the presence of the other allele will result in extension of a small 
number of bases which can be limited by excluding specific dNTPs from the reaction 
mixture. The two molecules can be run on a dHPLC machine to resolve the sizes 
therein detecting the genotype. 
This technique is relatively low throughput and complicated by the fact that 
separate reaction mixes are used for each SNP. In theory any technique that 
measures the sizes of small oligos precisely could be used if dHPLC equipment was 
not available. 
 
1.3.14 Dynamic Allele Specific Hybridisation (DASH) 
Based on the same principal as the SNP discovery technique HRM (Section 
2.3.4) DASH uses the release of an intercalated dye to demonstrate which SNP allele 
a DNA strand contains. PCR of a region containing a SNP is carried out where one of 
the primers is biotinilated, this adapter molecule can then be used to fix PCR 
products to a surface that has been coated with streptavidin such as the bottom of a 
well in a microtitre plate. The fixed PCR product is denatured to remove the 
complimentary strand which is washed away, a specific probe can then hybridise to 
the fixed single strand in the presence of an intercalating dye. This probe must cover 
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the SNP of interest where it will either form a fully complimentary double strand 
structure or a mismatch will form creating a heteroduplex, when the sample is 
slowly heated the heteroduplex fragments will be first to release their dye enabling 
genotypes to be determined (Howell et al., 1999). 
 
1.3.15 Pyrosequencing 
The incorporation of a nucleotide during a Pyrosequencing reaction is 
followed by an enzyme cascade that ultimately results in a flash of light (Ahmadian 
et al., 2000, Nordstrom et al., 2000). Detection of light confirms incorporation of the 
nucleotide that was introduced at that point and the process is repeated to generate 
a short DNA sequence read. As nucleotides are added in turn it is possible to detect 
the presence or absence of an allele at a given location and because the quantity of 
light is proportional to the number of incorporations it is also possible to detect 
heterozygosity where half the quantity of a homozygous allele is available. 
In choosing the sequencing primer location and order in which nucleotides 
will be added it is possible to have a negative control within each well of a plate of 
samples where an allele is added to the reactions knowing that it is absent in the 
template. Likewise, before the SNP locus is interrogated a positive control can be 
created by testing for known sequence that lies between the primer and SNP. 
Internal control reactions are unique to this genotyping technology though there is a 
cost to every nucleotide addition which needs to be considered. 
The process of determining sequence by detecting the release of phosphate 
was originally described by Ronaghi (1999) who identified the problem that 
homopolymer runs of greater than 4 bases were difficult to accurately convert into 
sequence. Though the chemistry has been improved in recent years the linear 
relationship seen between light intensity and homopolymer runs breaks down after 
8 bases (Margulies et al., 2005). This creates a problem for a small number of SNPs 
but like many assays the opposite DNA strand can be used to avoid difficult 
sequence. 
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1.3.16 Invader Assay 
The Invader® assay is based on the unique cut site of Flap Endonuclease 
(FEN) which recognises a specific DNA structure rather than a specific DNA sequence 
and is highly sensitive to sequence mismatches. The assay has an invader probe 
which binds sequence immediately upstream of the SNP locus and has a 3’ non 
matching base which overlaps but does not bind the SNP locus. Allele specific probes 
are designed to hybridise immediately downstream of the SNP locus but also 
extends in the opposite direction creating a ‘flap’ over the location where the 
Invader probe has already aligned. The discerning base of the allele specific primer is 
towards the centre of the sequence, if it matches the template the two probes bind 
with the template creating a 3 molecule structure that FEN recognises and cuts such 
releasing the 3’ end of the allele specific primer (the flap) which is covalently 
labelled with a fluorophore. As with the molecular beacon technology a 
fluorophore/quencher arrangement can be used to detect the separation of this 3’ 
fragment but fluorescent polarisation and MALDI techniques have also been used 
(Lyamichev et al., 1999). 
In its original form each allele has to be tested for separately but 
developments describe by Hall (2000) utilised a secondary FEN digestion step to 
allow detection of both alleles in one tube and array technology to enable both 
alleles and multiple assays to be tested simultaneously. 
 
1.3.17 SNPlex 
The SNPlex assay by Applied Biosystems (Tobler et al., 2005) is considerably 
more complicated than the other OLA based techniques but OLA is still at the core of 
the discrimination. A single reaction is used to test for both alleles so three probes 
are used for the allele discrimination stage; one for each of the alleles (the 
discriminating probes) and a common probe which can be ligated to which ever 
probe overlaps the SNP locus successfully during the hybridisation. The two 
discriminating probes have 5’ ‘Zipcode’ sequences that can later be used to identify 
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which allele was present at a specific locus. The 5’ sequence of the common probe 
and the Zipcode sequences are recognised by a second set of three probes which 
attach common primer sequences to the ends of the ligated products so that 
multiple assays can undergo PCR with one set of conditions. The PCR includes a 5’ 
biotin molecule which can be used to fix the amplicons (containing the allele and 
assay specific Zipcode sequence) onto a solid surface. Fluorescent ZipChute ™ 
probes which are specific to one allele of a given locus are allowed to hybridise to 
the immobilised DNA molecules, those that do not bind are washed away and those 
retained can be separated from their compliments and identified using 
electrophoresis. 
 
1.3.18 KBiosciences Competitive Allele‐Specific PCR (KASPar) 
The KASPar assay starts with a three probe system similar to that used in an 
ARMS assay. The first primer is specific to one allele, the second is specific to the 
alternative allele and the third is a common PCR primer. During amplification both 
discriminating primers are available but will only be incorporated if there is a 
suitable allele at the SNP locus which is complimentary to the 3’ nucleotide of the 
discriminating probe. Where there is a match, the primer anneals, PCR occurs and a 
fragment is generated. As well as their specific 3’ nucleotide, each discriminating 
probe has a specific 5’ sequence, when a round of amplification is complete this 
sequence is used as an annealing site for a fluorescent primer which is initially 
bound to a complimentary sequence carrying a quencher molecule. When the probe 
and compliment separate the probe can be used as an amplification primer and the 
light signal can be detected as the association with the quencher has been 
disrupted. Subsequent PCR cycles will strengthen the fluorescent signal (Figure 1.9) 
(Cuppen, 2007). 
As with the Taqman assay the whole process is completed in a single tube; 
however, as the fluorescent probes are generic and the assays specific probes are 
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unlabelled the overall cost is very low, what is more KBioscience (the provider for 
the assay) have a very high assay conversion rate (>90%). 
 
1.3.19 Array Techniques 
Microarrays were the first technology to provide a global view of the genome 
due to the number of assays that can be simultaneously genotyped. The techniques 
used to discriminate between alleles are simply developments of those described 
above; however, array technology has enabled the miniaturisation and 
parallelisation of assays to provide greater genotyping throughput than any of the 
previously described techniques. Modern arrays are capable of analysing hundreds 
of thousands of assays simultaneously; however, in the case where a small number 
of SNPs need to be assayed they tend to be impractical. 
An array is a solid surface to which oligo probes can be attached, commonly 
used materials include glass slides or polystyrene microspheres or ‘beads’. DNA 
sequences are covalently bound to the surface; they may span SNP loci and use 
allele specific hybridisation or terminate at the base upstream of the loci and use a 
minisequencing reaction to create a discriminating molecule. The two most 
commonly used SNP chips are; Illumina’s Infinium II technique which uses a 
combination of assay specific beads and minisequencing to analyse 500,000 assays 
in parallel, and Affymetrix SNP Chips which use glass slides and specific 
hybridisation, over 900,000 SNPs. 
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Figure 1.9: KASPar assay. 
(A) Two allele specific primers and one common primer are mixed under specific 
annealing conditions such that the SNP allele determines which specific primer binds 
(red). (B) The primers are extended. (C) Subsequence rounds of PCR generate 
products that include the allele specific primers 5’ sequence. (D) The allele specific 
double stranded quencher-fluorophore complex is added to the single stranded PCR 
template. (E) Where the probe binds to the allele specific 5’ sequence the quencher-
fluorophore complex is separated and fluorescence can be detected. 
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1.3.20 Golden Gate Genotyping Assay (Illumina) 
As with an ARMS assay the Golden Gate (Fan et al., 2006) reaction starts with 
three primers; discriminating primers will anneal to the SNP adjacent sequence and 
the 3’ base will be specific to one allele of the SNP locus. In addition to this there is a 
further section of sequence upstream which does not align to the genomic DNA but 
will later be used as a generic amplification target. This target sequence identifies 
which allele lies at the 3’ end of the discriminating primer (the wild type or 
alternative). The third primer anneals immediately adjacent to the SNP locus and has 
three sections, the first is the assay specific sequence, in the middle is an ‘address’ 
sequence which will be used to link the ultimate product to a specific array location 
(and hence a particular assay) and the 5’ sequence is a generic amplification target 
sequence. 
During the reaction the probes anneal around the SNP locus, the template 
sequence determines which of the discriminating primers is incorporated and the 
rest of the sequence from both primers remains free from the template. A ligase 
connects the two primers under stringent annealing conditions to create a single 
product which can be pooled with hundreds of similar products from other assays. 
The pooled products are amplified with a set of three generic primers, the 
discriminating primers are fluorescently labelled and anneal to the 5’ end of the 
discriminating primers from the ligation reaction hence demonstrating the presence 
of a reference or alternative allele. When amplification is complete the mixed pool is 
hybridised to an array which contains assay specific probes to bind the ‘address’ 
section of the products, now the pooled assay products are separated out to specific 
locations the fluorescent label can be translated back into sequence information 
(Figure 1.10). 
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Figure 1.10: Golden Gate. 
(A) Two allele specific primers and one common primer are mixed under specific 
annealing conditions such that the SNP allele determines which specific primer 
binds. (B) The primers are extended and ligated. (C) Generic primers amplify the 
single stranded template; this can be done in a single tube for multiple assays. (D) 
The PCR products include a fluorescent 5’ molecule which relates to the template 
SNP allele and the locus address sequence. (E) The address sequence binds specific 
compliment sequence at a given location, when the fluorescence is read the allele is 
determined for a specific locus. 
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Figure 1.11: Genotype Assays Time Line.  
 
Specific Oligo Hybridisation 1979 
Oligo Ligation Assay 1988 
Molecular Beacons 1991 
1977 
1987 
1997 
2007 
1982 
1992 
2002 
2011 
Amplification Refractory Mutation System 1989 
Minisequencing (Fluorescent) 1995 
Padlock probes 1994 
Restriction Fragment Length Polymorphism 1985 
Minisequencing 1990 
Taqman 1991 
MALDI 1997 
Dynamic Allele Specific Hybridisation 1999 
Fluorescent Polarisation 1999 
Pyrosequencing 2000 
SNPlex 2005 
KASPar 2007 
Minisequencing –DHPLC (Hoogendoorn) 2000 
Invader assay 2000 
Golden Gate 2006 
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1.4 DNA Sequencing 
Central to the field of genetics is the ability to determine the order of 
nucleotides in a DNA molecule. For the past three decades a single method has been 
the dominant approach (Sanger Sequencing); however, the field is currently 
undergoing a revolution with numerous new techniques due to appear over the next 
few years. 
 
1.4.1 Sanger Sequencing 
DNA Sequencing is considered the ‘gold standard’ SNP discovery technology 
and though ‘Next Generation Sequencing’ (NGS) platforms have recently become 
available, re-sequencing of PCR amplicons is still primarily performed using the 
Sanger method (Sanger et al., 1977). 
Sanger Sequencing utilises the properties of the chain terminating ddNTPs, 
once a ddNTP has been incorporated into a strand of nucleotides, no further 3’ 
extension of that strand can take place.  
During thermal cycling of a sequencing mixture a primer will attach to 
template DNA (e.g. cleaned PCR) and the polymerase will drive extension using the 
normal dNTPs, as soon as a ddNTP is incorporated extension of the strand is 
terminated leaving a single strand that is fluorescently labelled at the 3’ end with a 
fluorophore that corresponds in colour to the type of ddNTP (A, C, G or T). The 
reaction mixture is set up with enough template, primer and reaction mix so that 
multiple fragments will be created that terminate at every base of the template and 
by separating these fragments by size, the sequence may be determined (Figure 
1.12). 
By using fluorescently labelled ddNTPs Sanger sequencing can be analysed by 
capillary electrophoresis, each fragment that passes the CCD camera is a single base 
longer than the previous and that base is the 5’ fluorescently labelled ddNTP. The 
CCD Camera emits the laser light and ‘captures’ the fluorescence emitted from the 
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‘excited’ fluorophore. The data is fed back to the computer where the software 
converts the observed fluorescence into chromatograms which can be viewed and 
screened for polymorphisms. 
Size separation of these fragments can be achieved by capillary 
electrophoresis, the fluorophores are excited by a laser and the specific fluorescence 
given off is captured with a CCD camera that translates the data into a 
chromatogram (Figure 1.13). As genomic DNA templates contain both a maternal 
and paternal allele a single ‘peak’ actually represents the product of both alleles and 
where heterozygosity occurs two peaks of different colour occur at the same loci 
with reduced heights (compared to the peaks seen in a wild type sample). 
Each ‘peak’ represents the product from the maternal and paternal 
chromosomes, where the alleles match one peak is observed, but where the alleles 
differ two ‘half height’ peaks are observed at the same location with different 
colours, these characteristics are indicative of a heterozygous allele. 
 
1.4.2 Maxam and Gilbert 
Maxam and Gilbert devised a method of determining DNA sequence by 
placing the same DNA sample in four separate tubes and performing a different 
chemical cleavage reaction in each tube. The incomplete cleavage reactions cause 
the fragments in each tube to all terminate in the same base (or combination 
thereof) the combination of bases are; G, G and A, C and T or T (Maxam and Gilbert, 
1977). 
The technique was initially very popular as template preparation was more 
simplified than the Sanger method (Section 1.4.1) which initially required cloned 
single stranded templates; however, as the Sanger reaction improved it became the 
dominant sequencing technology for the next three decades.  
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Figure 1.12: Sanger Sequencing. 
A DNA template is mixed with dNTP, fluorescent ddNTP, DNA polymerase and a 
single sequencing primer. During a thermal cycle products will be generated that 
terminate in fluorescent ddNTPs. Sufficient cycles of amplification are carried out 
such that all loci are represented by fragments terminating at that position. 
Fragments are separated by size to determine DNA sequence order. 
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Figure 1.13: Heterozygous SNP locus. 
The upper chromatogram shows a normal homozygous ‘T’ allele at the highlighted 
SNP loci. The lower chromatogram shows heterozygosity at the same locus.
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1.4.3 Next Generation Sequencing 
The name ‘Next Generation Sequencing’ was given to the first group of 
techniques that represent a significant departure from Sanger Sequencing. The 
techniques are radically different from each other in how they generate sequences 
but there is a common approach in that fragmented genomic DNA is sequenced in a 
massively parallel manner before being re-assembled in software for analysis. The 
first publication of a genome that was sequenced by NGS (Roche -454) was that of 
James Watson (Wheeler et al., 2008) at a cost of $1.5 Million it was a significant 
improvement on the Sanger sequenced human genome (Levy et al., 2007) which has 
been reported as costing over $100 million with some estimates as high as $4 billion. 
The techniques described below are by no means comprehensive, there are several 
other techniques in development, but those described represent the most 
commonly used techniques to date. 
 
1.4.3.1 Roche – 454 
All NGS techniques start with shearing a genomic DNA sample selecting 
fragments of a specific size and tagging the ends with primer sequences which will 
be used for amplification and sequencing, this collection of fragments is known as a 
library. With the 454 technique the library is denatured and mixed with primer 
coated beads in an oil/water emulsion. A specific ratio is used to achieve the 
maximum number of beads binding a single library fragment whilst minimising the 
quantity of beads with multiple templates. Titrations of ‘bead to template’ are 
undertaken to minimise the creation of polyclonal beads (where 2 or more 
fragments attach) whilst reducing the number of un-templated beads. Un-templated 
beads can be removed by an enrichment process but polyclonal beads will carry 
through to the sequencing phase and ultimately reduce the amount of high quality 
data that can be produced. 
The primer sequence of the bead anneals to one of the two sequence tags 
that tail each fragment of the library. The second tag on the library template is used 
39 
 
to generate a complimentary strand which will become covalently attached to the 
bead. The template strand is then washed off to leave a bead with a single stranded 
covalently attached template or a ‘library bead’. In using both tags in this process 
library fragments that incorporated the same tag at both in the initial tagging library 
preparation fail to amplify, the process is known as enrichment as it positively 
selects beads with the products that are suitable for sequencing. 
The 454 technique then utilises emulsion PCR (emPCR) to amplify the 
template strand such that each primer on the bead becomes elongated by the same 
sequence (clonal amplification). The aqueous phase of the emPCR contains the PCR 
reagents and when mixed with oil forms droplets or ‘micro-reactors’. Those micro-
reactors containing a library bead plus the necessary reagents and one template 
strand will replicate their product to cover the bead in single stranded template 
DNA. The library beads are used to fill a picotitre plate containing picolitre volume 
wells created such that a single well may only contain a single library bead, once the 
library beads are in place the wells are packed with beads which are coated with the 
enzymes required for the sequencing phase. 
The Sequence reaction occurs within the sequence instrument, the core 
technology is the Pyrosequencing technique (1.3.15). Reagents buffers and 
nucleotides are distributed across the plate in a sequential fashion by a microfluidics 
system the picotitre plate is heated to induce the chemical cascade and the quantity 
of light produced within an individual well is recoded. For each well 1 unit of light 
translates as the presence of a single template base, where homopolymer runs 
occur within a template strand there is a linear relationship between the quantity of 
light and the number of alleles up to a run of 8 after which sequence becomes 
unreliable (Margulies et al., 2005). 
The 454 instrument has the lowest output of the three main NGS 
instruments (currently up to 750Mb per day) but read lengths of 700bp are 
considerably larger than the Illumina and SOLiD systems and comparable to Sanger 
technology. Comparatively long reads make the 454 particularly suitable for 
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Metagenomics and deNovo sequencing where fragment length simplifies the 
downstream sequence mapping and assembly process. 
 
1.4.3.2 Illumina Sequencing 
The Illumina platform was the first available short read sequencer and has a 
considerable market lead over the Applied Biosystems instrument, the current read 
length is 100bp and the instrument is capable of generating 50Gb of data per day. 
Following the creation of a library the molecules are denatured and allowed 
to anneal to a ‘lawn’ of oligos which are covalently attached to an array surface. The 
array bound oligos then act as primer sites to the adaptors on the annealed strand 
and are extended by a polymerase to create a covalently bound template, the 
original strand is washed away. These covalently bound single stranded template 
molecules then under go ‘bridge-amplification’, the free end of the molecule is 
encouraged to anneal to another oligo on the array which again acts as a primer and 
creates a strand of sequence that is a compliment to the template, both strands are 
now covalently bound to the surface and the process is repeated cyclically until a 
‘cluster’ of clonal fragments is created. 
As the library is of a fixed length there is a natural limit to the cluster size that 
bridge amplification will tend to produce before clusters start to overlap, this 
introduces an inherent limit on the maximum theoretical length of a sequence that 
can be determined with this technique. 
Once the clusters have been formed a primer is introduced which anneals to 
a section of the original tag that was added to the sheared DNA, a single fluorescent 
nucleotide is incorporated to each strand and the entire array is imaged. Each 
nucleotide is a reversible terminator, which prevents multiple incorporations and 
means that the sequence strands can be built up and imaged one base at a time, the 
process is named ‘sequencing by synthesis’ (Figure 1.14).
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Figure 1.14: Illumina Sequencing. 
Legend on following page. 
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(A) Adapters (red and orange, green and orange) are added to each end of a DNA 
fragment (blue) to create a library. (B) i. Library fragments bind to an oligo that is 
bound to the array surface, ii. The oligo is used as a primer for extension and a 
compliment (black) to the library fragment is generated on the surface, iii. The 
fragments are encouraged to form ‘bridges’ with complimentary oligos, iv. Both 
strands of a fragment are attached to the slide in close proximity. (C) Clusters of 
fragments are generated. (D) One of the two complimentary strands in each cluster 
is removed. (E) i, Primers, polymerase and fluorescent ddNTP are added, ii. The 
primer is extended by a single base and an image is recorded, iii. The incorporated 
ddNTP is modified so that a second ddNTP may be incorporated, iv. Subsequent 
cycles build up a sequence of colours at each location on the array surface.
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1.4.3.3 Sequencing by Oligonucleotide Ligation and Detection (SOLiD) 
The Applied Biosystems instrument produces the shortest read length (75bp) 
and claims to generate 15Gb per day but the method of sequence generation leads 
to the lowest error rate and the most reliable SNP calling (Liu et al., 2012). The 
technique is based on ligation of short oligos rather than extension by incorporation 
of individual nucleotides. 
Libraries are prepared for sequencing by emPCR the process is very similar to 
that of the 454 technique with the ultimate goal of producing beads with covalently 
bound, single stranded, clonally amplified products. The templated beads are then 
immobilised onto a glass slide where the sequence reactions take place.  
In the first step the array is treated with a mixture of sixteen eight-mer oligo 
probes which represent the sixteen possible combinations of sequence in the first 
two bases of each probe, (AA, AC, AG, AT, CA, CC, CG, CT, GA, GC, GG, GT, TA, TC, TG 
and TT). Each probe is labelled with one of four fluorescent moieties so each 
fluorophore represents four of the probes. The probes align to the template 
sequence according to the complementarity of their first two bases, the next three 
bases are degenerate bases and the last three are universal bases but none of these 
affect binding. When the eight-mer is bound to the template an enzyme ligates the 
3’ end of the probe to the 5’ end of the primer the entire array is scanned and the 
colour of the fluorophore is recorded. The scanned fluorophore relates to one of 
four possible sequences of the first two bases of the template. The last three bases 
of the probe along with the fluorophore are then cleaved and washed away ready 
for a new ligation reaction. For this second round of ligation bases 6 and 7 of the 
template are interrogated, followed by 11 and 12, 16 and 17 etc. Once the reaction 
has reached the end of the possible 75 bases of sequence the strand made up of 
ligated probes is removed and the process is repeated with a new primer that is one 
base shorter that the first, this is termed the ‘n-1 primer’. The n-1 read determines 
the sequence of the most 5’ base of the tagging primer sequence and the first base 
of the genomic DNA (bases ‘0’ and 1) subsequent rounds of ligation the identify the 
44 
 
sequence at 5 and 6, 10 and 11, 15 and 16 etc. In total there are 5 rounds of cyclical 
probe ligation each round is staggered by one base, eventually each loci of the 
template is interrogated twice leading to very high sequence accuracy. Individual 
incorporation errors are readily spotted and a true SNP will cause two adjacent 
colour changes in two separate reads. Translation of the colour codes into bases is 
possible as the n-1 sequences (the last base of the tagging primer) are known. When 
the first base is known and the colour is observed the second base of that probe can 
be determined, in turn this ‘second’ base relates to the first base of the next probe, 
the colour is known and the subsequent base is identified so by knowing the first 
base and viewing the colours from all five rounds of ligation DNA sequence can be 
determined. 
Though determining sequence in ‘colour-space’ is a strength of the technique 
it can also be considered a hindrance in terms of analysis as the raw data is not in 
the ‘base-space’ format that the majority of analysis tools require limiting the 
number of applications that can be used. 
 
1.4.3.4 Ion Torrent 
The Ion Torrent system is commercially available technique that utilises the 
properties of semiconductors. The approach to generating sequence is similar to 
that of the Pyrosequencing technique but instead of detecting light, pH changes are 
detected. Nucleotide incorporation releases Hydrogen ions which are converted into 
an electrical signal that can be detected by the semiconductor sensor. As with 
Pyrosequencing the array is treated with nucleotides in sequence and the number of 
Hydrogen molecules has a linear relationship with the number of sequential 
incorporations at a single location on the array making the technique prone to the 
same homopolymer run issue as Pyrosequencing (a 5-mer is called with greater than 
97.5% accuracy) http://www.iontorrent.com/lib/images/PDFs/performance_overvi 
ew_application_note_041211.pdf. The current run length is 100bp but that is set to 
increase to 400bp in 2012. 
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1.4.3.5 Polony Sequencing 
The Polonator G.007 is a completely ‘open’ system for next generation 
sequencing all aspects of the software and protocols are open-source, and the 
chemistry is composed of ‘off the shelf’ items making the system very low cost. Read 
length is very short (13bp) so the system has never really challenged for a significant 
market share. The technique is similar to SOLiD in that beads are coated in clonally 
amplified template during an emPCR stage and then attached to a glass slide. The 
sequencing chemistry follows the Illumina method of incorporation a single 
fluorescent molecule, imaging the array, cleaving the fluorescence and repeating he 
process. Throughput is 1 to 2Gb per day. 
 
1.4.4 Capture Technology 
Genome sequencing identifies around 3.5 million SNPs per sample (Wheeler 
et al., 2008) the majority of which are in non-coding DNA. By sequencing only the 
coding regions of a genome sequence costs are reduced, sample throughput is 
increased and the data sets generated are of a more manageable size.  
There are currently two main providers of capture technology which extracts 
fragments of DNA that contain coding sequence from fragmented genomes. The 
Roche Applied Science “SeqCap EZ Library” and Agilent Technologies – ‘Sureselect’ 
each work by creating biotinilated oligo ‘baits’ which are mixed with the fragmented 
DNA. The baits are designed to anneal to exomic sequence so when hybridisation 
occurs it is possible to isolate the fragments of DNA that have become bound and 
therefore sequence only the exonic sequence of a sample (Figure 1.15) (Ng et al., 
2009). 
 
1.4.5 Third Generation Sequencing 
The term “Next Generation” has already become somewhat dysfunctional as 
a new wave of techniques are starting to come to the market, the term ‘Third 
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Generation’ is sometimes used but there is some discussion over what constitutes a 
Third Generation technology, whether it is those that can determine the sequence 
of single DNA molecules or those which do not use light for detection. Possibly the 
‘Generation’ categories are no longer suitable as there are techniques available 
which are not universally considered Second or Third Generation (e.g. Life 
Technologies ‘Ion Torrent’ system). 
 
1.4.5.1 Heliscope 
The Helicos Heliscope was the first ‘single molecule’ instrument to be placed 
in research laboratories but problems soon lead to their recall. The system has many 
similarities to the Illumina technique, attaching a library to a glass array covered 
with a lawn on oligos and undertaking sequence by synthesis; however, this is a 
single colour system so one reversible terminator is added a time and the array is 
scanned to see where single incorporation events have occurred.  
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Figure 1.15: Exome Capture. 
(A) A representation of genomic DNA with exons shown as colour blocks. (B) 
Genomic DNA is randomly fragmented. (C) Biotinilated probes that bind exonic 
sequence are allowed to anneal complimentary sequence. (D) The Biotinilated 
probes are drawn out of solution by their interaction with magnetic streptavidin 
coated beads. (E) Fragments of DNA are eluted, now enriched for exonic sequence. 
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1.4.5.2 Single Molecule Real Time (SMRT) 
Pacific Bioscience SMRT technology works by immobilising a polymerase 
within a ‘nano photonic visualisation chamber’ on a microarray. While a fluorescent 
dNTP is being incorporated into a strand it is held in place for several milliseconds by 
the polymerase enzyme during which time the fluorescence is detected before being 
cleaved from the nucleotide by the polymerase (as part of the incorporation 
process) and released into solution. The technical term for a ‘chamber’ is Zero Mode 
Waveguide (ZMW) they have a glass surface at the base through which fluorescence 
is detected and a total volume of 20 zeptolitres. Fluorescent nucleotides that 
naturally diffuse into and out of the chamber move in and out in microseconds 
enabling the difference between noise and incorporation to be easily separated. 
Thousands of ZMWs are analysed simultaneously compared to hundreds of millions 
clusters (Illumina) or beads (SOLiD) but the rate of sequencing is 10 bases per second 
and read lengths can reach 1,000bp in length enabling whole human genomes to be 
read in a matter of minutes. 
 
1.4.5.3 Nanopores 
Oxford Nanopore Technologies (ONT) are developing two different methods 
both based around a nanopore which is created between a lipid bi layer (Howorka et 
al., 2001). In the original approach the nanopore is coupled with an enzyme which 
cleaves single stranded molecules. The cleaved nucleotides are drawn through the 
nanopore in sequence by an electrical current. Within the pore an adapter molecule 
transiently binds nucleotides as they pass through, when this occurs the binding 
disrupts the electrical current in a characteristic way enabling identification of that 
molecule and therefore the sequence. Their second approach may have been in 
response to a problem that was observed where by the cleaved nucleotides did not 
always pass through the pores, this second technique has a polymerase attached to 
the pore, a single stranded DNA molecule passes through the pore and into the 
polymerase, as that polymerase incorporates nucleotides the single strand is 
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‘ratcheted’ through the pore one base at a time controlling movement though the 
pore and allowing detection based again upon disruption to the electrical current 
that has been created to pass through the pores. 
The method of passing a DNA molecule through a pore and detecting 
nucleotides at they pass through is also at the heart of several other developing 
third generation technologies (e.g. Bionanomatrix (Das et al., 2010) NABsys, IBM, 
Noblegen, Graphene Nanopres and Stratos [all unpublished]). 
 
1.4.5.4  Others 
Visigen technology is based on the transfer of energy between a donor 
fluorophore attached to a polymerase and different coloured fluorophores attached 
to each nucleotide. Transfer of light between the two molecules produces a 
characteristic signature which is detected and recorded. The technology promises to 
sequence over a million bases per second. 
Halcyon Molecular are developing a technology where ‘ultra-high-
throughput’ transmission electron microscopy (EM) will be used to literally see the 
order of bases in the DNA chain when it is stretched over an EM substrate. There is 
little available detail on the technology but they aim to sequence reads of up to 4Mb 
in length. ZS Genetics is also developing a method based on EM but their method 
focuses on determining sequence by observing DNA strands constructed from 
“heavy-atoms/modified dNTPs”. 
Complete Genomics have a proprietary technology and provide sequencing 
as a service. The technique involves concatenating identical fragments and causing 
those molecules to ‘ball up’ creating nanoballs of DNA which are tightly packed onto 
a glass substrate. A ligation based technology (Combinatorial Probe-Anchor 
Ligation [cPAL™]) determines the sequence. 
GnuBio, Lightspeed Genomics, Mobious and QuantuMDx are also developing 
technology but little information in available on their approaches.
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Figure 1.16: Sequencing Technology Time Line. 
Sanger 1977 1977 
1987 
1997 
2007 
1982 
1992 
2002 
2011 
Fluorescent Sanger 1986 
Roche - 454 2005 
Polony sequencing 2003 
Maxam and Gilbert 1977 
Illumina - 2006 
Ion Torrent 2011 
SOLiD 2008 
Pacific Biosciences 2011 
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1.5 Databases 
As sequence technology developed from slab gels to capillary arrays even 
relatively small research groups were able to discover large numbers of SNPs and 
other genetic variation as thousands of amplicons could be scanned each week. 
Throughout the 1990’s several online resources were created in order for 
researchers to share that information via the internet. e.g. The Human Gene 
Mutation Database (HGMD) - (Cooper et al., 1998) GenBank (Benson et al., 1993) 
and dbSNP (Sherry et al., 2001) followed by HapMap (Couzin, 2002) 1000 genomes 
(2010) and UK10K (to be released) (Table 1.1). 
HGMD grew out of a project to identify mutational mechanisms in human 
genes (Cooper and Krawczak, 1993) in 1996 it was made publically available and 
contained information on 11,972 instances of genetic variation that had been shown 
to underlie human disease. The database covers a broad range of variation types 
including SNPs, small and large indels, duplications, complex rearrangements, 
inversions and repeat expansions. Data is acquired by manual publication searches 
and submission from journals and the utility has grown to contain information on 
over 113,000 disease loci, though the full data set can now only be accessed via a 
subscription. 
The GenBank database (Benson et al., 1993) is an annotated sequence 
repository (protein and DNA) set up by the National Centre for Biotechnology 
Information (NCBI) in the USA though it also has collaborations with the UK EMBL 
data Library (Stoesser et al., 1998) and the Databank of Japan (Tateno and Gojobori, 
1997). Sequencing centres and authors submit data to the utility where it is 
annotated and made publically available. The project came from the Los Alomos 
Sequence Database and underwent exponential growth between 1982 and 2009. 
The database currently 126,551,501,141 bases of information and 62,715,288 
sequence records. 
dbSNP was created to supplement the GenBank sequence database by 
providing information exclusively for genetic variation. Despite the title, a broad 
52 
 
range of variation is included (e.g. SNPs, insertions, deletions and microsatellite 
markers). The database is open to submission from many sources; industrial and 
academic, individual research groups and international collaborations. It has been 
designed to deal with multiple submissions of the same variation by recording each 
submission with a submitted sequence (ss) number and attaching that information 
to a variation page with a Reference SNP (rs) number. An algorithm within the 
database uses the Basic Local Alignment Search Tool (BLAST) tool to search the 
surrounding sequence identifies other NCBI resources that are relevant, therein 
creating a vast web of interconnected data. The rs number has become accepted by 
most databases as the definitive identifier for a SNP in many cases databases use 
direct hyperlinks from their own web sites to the dbSNP rs pages. 
The PharmGKB database has accumulated the information generated in 
research labs regarding the relationship between DNA and drug efficacy (Hewett et 
al., 2002), the information held draws relationships between; genes, variants, 
pathways, drugs and diseases. As genomics enters a phase where its relationship 
with pharmacology is regularly being investigated this facility will continue to 
provide a valuable insight into the complexities of the relationships between drugs 
and genotypes. 
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Table 1.1: On-line Databases. 
Database Content 
1000 genome 
All genetic variation with a 1% minor allele frequency 
in a pre-determined population. 
dbSNP A DNA sequence variation repository. 
Encode (UCSC) 
A comprehensive parts list of functional elements in 
the human genome. 
Ensemble Genome databases for vertebrates. 
GenBank A DNA sequence repository. 
GWAS central (formerly 
HGVbase) 
A centralized compilation of summary level findings 
from genetic association studies. 
HapMap Compares haplotypes between defined individuals. 
HGMD A list of disease causing mutation. 
JSNP SNPs from the Japanese population. 
OMIM 
A comprehensive, authoritative, and timely 
compendium of human genes and genetic 
phenotypes. 
PharmGKB 
Knowledge about the impact of human genetic 
variations on drug response. 
SNP500Cancer (NGS related) Genomes for 102 reference samples. 
SRA Raw sequencing data from NGS platforms. 
UK10K 
The genomes of 10,000 UK samples with and without 
disease. 
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1.6 Colorectal Cancer 
One third of colorectal cancers are thought to be caused by inherited factors 
(Kinzler and Vogelstein, 1996) but less than 6% of cases carry known high-
penetrance mutations (Aaltonen et al., 2007) such as those found in the APC gene 
which cause Familial Adenomatous Polyposis Coli (FAP; MIM 175100) (Fearnhead et 
al., 2001) several mismatch repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2) 
which cause hereditary non-polyposis CRC (HNPCC; MIM 114500) (Peltomaki, 2001) 
and the BER gene MUTYH which causes MUTYH associated polyposis (MAP; MIM 
608456) (Al-Tassan et al., 2002, Sampson et al., 2003). 
Current approaches to understanding the remaining proportion of inherited 
CRC have focused on Genome Wide Association Studies (GWAS) looking at 
thousands of cases and controls and identifying low-penetrance SNPs that may 
confer increased susceptibility.  
 
1.6.1 FAP (MIM 175100) 
FAP is an autosomal dominant disorder with a population incidence of 
1:8,000. It is caused by mutations in the APC (Chromosome 5) gene which are the 
first stage in the progression to malignancy for FAP patients and are also critical in 
sporadic CRC occurring in almost 85% of all colorectal tumours (Hisamuddin and 
Yang, 2004). FAP is characterised by the development of hundreds to thousands of 
pre-malignant, benign adenomatous polyps in the epithelium of the large colon and 
the rectum from the third decade of life onwards (Kinzler and Vogelstein, 1996). 
Numerous extra colonic features may also develop such as congenital hypertrophy 
of the retinal pigment epithelium (CHRPE) desmoids and upper gastro intestinal (GI) 
tract tumours (especially following surgery), Gardner's syndrome and Turcot 
syndrome. Without clinical intervention and given the number of adenomas that 
occur a few will inevitably progress to become tumours. 
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1.6.1.1 The APC gene 
APC is expressed in a variety of different human tissue but only appears to 
have a ‘gatekeeper’ function in the gut, other tissues expressing a mutant allele will 
not necessarily produce adenomas. APC is known to function in numerous pathways 
the most important of which (in relation to CRC) is to act as an antagonist to Wnt 
signalling preventing the inappropriate proliferation of cells in the colon by 
suppressing the activity of the β-catenin oncogene. 
Normal β-catenin regulated transcription occurs when the Wnt peptide 
stimulates the cell transmembrane receptor ‘LRP’ to recruit Frizzled, Discheveled, 
Axin and GSK- β3 to form a membrane bound complex that dephosphorylates β-
catenin. This prevents APC recognising and degrading the protein as it would 
phosphorylated β-catenin. Dephosphorylated β-catenin builds up in the cytoplasm 
and eventually enters the nucleus to drive appropriate transcription of factors such 
as the oncogene c-myc and cyclin D1. APC’s normal roll in the Wnt signalling 
pathway is to degrade β-catenin when the Wnt signalling pathway is not activated 
and therefore prevent proliferation in the absence of the Wnt peptide. 
Mutation of the APC gene leads to aberrant regulation of β-catenin and 
consequently constituently active transcription of β-catenin regulated factors 
leading do dysplasia of epithelium cells. Damaging mutations tend to occur in the 
Mutation Cluster Region (MCR) towards the centre of the gene and most often 
causing truncation of the coded protein via nonsense mutation or small 
insertions/deletions (Indels) (though Loss if Heterozygosity (LOH), whole exon 
deletion and splicing errors are also known(Aretz et al., 2004)). Centrally located 
Non-synonymous changes (such as p.I1307K) have been shown to lead to the 
disease with non-synonymous SNPs towards the 3’ and 5’ ends of the gene tending 
to lead to Attenuated FAP (AFAP) where the adenomas observed in the bowel are 
less florid and less frequent than when mutations are found towards the centre of 
the gene. 
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Germline mutation in APC leads to FAP being inherited in an autosomal 
dominant fashion with the most common mutations at residues 1061 and 1309, 
(within the MCR). Mutations downstream of residue 1600 are extremely rare.  
Predisposition to CRC is conferred by a single inherited germline mutation in 
APC, for the disease to progress a second mutation is required to alter the inherited 
wild type copy of the gene (Knudson’s “2 hit hypothesis” (Knudson, 1971)), with no 
fully functioning APC protein produced by a cell, the suppressor function is removed 
and normal epithelium become dysplasic, the first step towards malignancy. 
Somatic mutation in APC is the more common cause of CRC, as sporadic 
mutations affect the epithelium later in life the number of adenomas resulting from 
sporadic mutation tend not as high as seen in FAP patients. 
 
1.6.2 Hereditary nonpolyposis colorectal cancer (HNPCC; MIM120435) 
HNPCC is a heterogeneous disorder that is characterised by increased risk of 
Colorectal (and other GI tract), brain, skin, ovarian and endometrial cancers and is 
diagnosed using the revised ‘Amsterdam criteria’ (AC II) (Vasen et al., 1999). It is not 
known whether the number of colonic polyps in these patients is greater than in the 
general population but the development of a malignant adenoma in an HNPCC 
patient is considerably faster taking 1 to 2 years instead of 10 or more (Knowles and 
Selby, 2005). The disease occurs where there is a breakdown in the Mis-Match 
Repair (MMR) pathway due to a mutation in one of the highly conserved MMR 
genes. 
 
1.6.2.1 MisMatch Repair (MMR) 
MMR (specifically short patch MMR) works by excising and replacing only the 
incorrect base from a mismatch, this is where the process differs from BER. The two 
strands of DNA can be referred to as ‘parental’ and ‘daughter’ where the daughter 
strand is the one that is produced during replication from the ‘parental’ template, 
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during DNA replication mismatches are introduced by the polymerase, most are 
dealt with by the ‘proof reading’ but a few may escape this corrective process. Via 
an unknown mechanism MMR recognises mismatches and critically excises the 
incorrect nucleotide(s) exclusively from the daughter strand replacing it with a 
correct match according to the parental strand therefore maintaining the integrity of 
the sequence, significantly in HNPCC MMR also undertakes the correction of 
mismatches that are introduced by mutation events when DNA is not replicating. 
In the normal MMR pathway MSH2 and MSH6 combine to form a 
heterodimer in the presence of ATP, this molecule is described as a ‘sliding clamp’ 
which can travel in either direction along the double strand until it locates a 
mismatch at which point it combines with a MLH1/PMS2 heterodimer (again 
utilising ATP) and stimulates exonuclease activity of the daughter strand, short patch 
MMR results in the replacement of approximately 10 nucleotides, long patch can 
replace a few kilobases. There are few physical differences between a daughter and 
parent strand Stojic ((Stojic et al., 2004)) suggests that the Okazaki fragments are the 
basis for discrimination; small sections of single stranded DNA correctly paired with 
their parental template but with gaps in the phosphate backbone. 
Because HNPCC mutations affect a repair pathway (as opposed to cell cycle) 
adenomas are only formed when chance mutation occurs in a suitable location such 
as a tumour suppressor or oncogene hence the number of adenomas observed (as 
with MYH associated polyposis) is considerably lower than in FAP however the ratio 
of progression of adenoma to carcinoma in HNPCC patients is very high (1:1) as 
opposed to FAP patients (30:1) (Jass et al., 2002) probably due to the increased rate 
of somatic mutations that will occur in a cell with germline MMR mutation. 
 
1.6.2.2 Mutations in HNPCC Genes 
Mutations in the MMR Glycosylase genes MLH1 and MSH2 account for 90% 
of all cases but mutations in MLH3, MSH6, PMS, PMS2 and TFGBR2 can also cause 
the disease by preventing the MMR. Unlike APC there are no known mutation ‘hot 
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spots’ and the position of the mutation in not known to affect the phenotype. 
Missense, nonsense, small insertions and deletions are all known to cause the 
disease (Papadopoulos and Lindblom, 1997).  
An important feature of the mutations in HNPCC genes is that they lead to 
Microsatellite instability (MI) in tumour tissue whereby small repetitive sequences 
(most often di-nucleotide CA repeats) are no longer reliably copied during DNA 
replication and the tracts can expand or contract. Expansions in oncogenes or TGSs 
lead to frame shift mutations and eventually adenomas. 
 
1.6.3 MYH Polyposis (MIM 608456) 
Multiple Ademoa Polyposis (MAP) (also known as MUTYH Associated 
Polyposis or FAP,2) is caused by mutations in the MUTYH gene (Sampson et al., 
2005) and in contrast to FAP, AFAP and HNPCC, it is an autosomal recessive disorder. 
The clinico-pathological features are very similar to FAP but the disease tends to be 
less severe (Sieber et al., 2003b). Carcinoma is more common that in HNPCC but 
progression from the adenoma stage is slower. 
The MUTYH gene was originally identified as playing a significant role in CRC 
in by looking at three British Siblings who were negative for APC mutation and 
showed no signs on MI in their tumour tissue. A higher than expected number of 
G:C>T:A transversions were noticed in the APC gene from tumour tissue which 
suggested a Base Excision Repair (BER) gene may be involved. The human 
homologues of the E.Coli oxidative damage genes (including MYH as the homologue 
to MutY) were sequenced in the siblings who were found to be compound 
heterozygous for MUTYH mutations (Al-Tassan et al., 2002). 
 
1.6.3.1 Base Excision Repair (BER) 
MUTYH is involved in the BER process of the DNA repair pathway. Reactive 
Oxygen Species (ROS) such as free radicals (oxygen molecules with a single unpaired 
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electron in an outer shell) are generated by aerobic metabolism, these molecules 
can damage guanine nucleotides so that they form a base pair ‘mismatch’ with 
adenine instead of cytosine. During DNA replication incorporation errors will 
become permanent mutations and left unchecked the accumulation of mutations in 
a cell’s DNA can lead to aberrant growth and eventually the development of cancer.  
Within the BER pathway the function of MUTYH is to remove the normal 
adenine base that incorporates opposite the damaged guanine before replication 
perpetuates the error. Glycosylases ‘tag’ affected guanine nucleotides by breaking 
the β-N glycosidic bond, separating the base from the deoxyribose backbone, the 
break is then recognised by an exonuclease which cuts the affected or ‘abasic’ site at 
the 5’ phosphodiester and leaves a free 3'-OH, this site is recognised by DNA 
polymerase (POL I) which replaces the nucleotide by virtue of its inherent 
exonuclease activity. DNA Ligase completes the process by connecting the newly 
added nucleotide to the nucleotide upstream. Where mutations in MUTYH lead to 
the accumulation of mutations in the APC gene, FAP like pathology is observed 
known as MYH associated polyposis.  
Naturally other BER glycosylases such as OGG1, MTH1, NTH1 are considered 
candidates to explain at least some of the inherited CRC not explained by the known 
high penetrance mutations. 
 
1.6.3.2 MUTYH Mutations 
The first two mutation identified by Al-Tassan (2002), (p.Y176C and p.G393D, 
originally described as p.Y165C and p.G382D respectively) are conserved residues in 
the E.Coli homologue MutY and their mutation in known to lead to a large reduction 
in the Adenine removal stage of the BER. Nonsense mutation and small deletions 
have also been shown to cause the disease as well as individuals who are 
homozygous for a mutant such as p.Y165C (Jones et al., 2002, Sieber et al., 2003b). 
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1.7 Aim of the project  
1. To assess the specificity of the Transgenomic Navigator software for the 
identification of genomic variation following dHPLC analysis of DNA. 
2. To apply this approach to analysis of the base excision repair genes, OGG1, 
NEIL1, NEIL2, NEIL3, MTH1 and NTH1 in patients with a multiple colorectal 
adenoma phenotype. 
3. To assess the sensitivity and specificity of software for mutation calling of 
automated Sanger sequencing in comparison to manual inspection. 
4. To investigate whether rare missense variants in the β-catenin down-regulating 
domain of APC are associated with the phenotype of multiple colorectal 
adenomas. 
5. To investigate SNP representation in build 129 of the dbSNP database 
6. To profile 480 reference human cell lines in ECCAC for non-synonymous SNPs in 
134 human DNA repair genes and to use in silico approaches to investigate their 
potential functional significance. 
7. To investigate non-synonymous SNPs in DNA repair genes as potential 
determinants of CRC predisposition and safety and efficacy of therapy. 
8. To investigate genetic determinants of severe peripheral neuropathy after 
oxaliplatin-based chemotherapy using exome re-sequencing.
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2 Chapter two 
 
Materials and Methods. 
 
2.1 Commercial Materials and Suppliers 
Item       Supplier 
10X Capillary Electrophoresis Running Buffer Sigma  
10X PCR Buffer     Applied Biosystems 
100bp DNA Ladder     NEB 
3100 Injection Solution    GRI  
5X Sequencing Buffer     Applied Biosystems 
Agarose MP      Roche 
Ampli Taq Gold     Applied Biosystems  
AmpliTaq Gold 10 X reaction Buffer    Applied Biosystems 
BigDye Terminators     Applied Biosystems 
BigDye Terminator 5X Reaction Buffer  Applied Biosystems 
dHPLC Buffers (A, B, C and D)    Transgenomic 
dNTP       Amersham (GE HealthCare) 
Ethidium Bromide     Sigma (Fluka) 
Ethylenediaminetetraacetic acid   Sigma 
Exonuclease I      New England Biolabs  
Gene Amp 10X Buffer     ABI 
Mutation Standards     Transgenomic 
Oligonucleotides     MWG  
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Orange G      Sigma 
POP6 3100 Polymer     Applied Biosystems 
Restriction Enzymes     New England Biolabs 
Shrimp Alkaline Phosphatase    Amersham (GE HealthCare) 
Sterile Water      Fresenius Kabi 
Sucrose      Sigma 
Tris       USB 
 
2.1.1 Kits 
Item       Supplier 
Nimble Gen Exome capture kit   Roche 
Illumina Sequencing kits    Illumina 
DNAeasy Blood and Tissue Kit   Qiagen  
 
2.2 Solutions 
Gel Loading Buffer - Orange G (trace), 40% Sucrose 
TAE buffer - 40mM Tris-acetate, 1mM EDTA, pH to 8.0 
 
2.3 Equipment  
Item       Supplier 
96 well plate Vacuum Manifold   Millipore 
ABI 3100 Genetic Analyser    Applied Biosystems  
Agarose Gel Electrophoresis tanks   Abgene 
Beckman Biomek FX     Beckman Coulter 
Covaris S series     Covaris 
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Genome Analyser II     Illumina 
CFX965TM Real-Time PCR Detection System  Bio Rad 
MJ Research DNA Engine Tetrad PTC-225  GRI/MJ 
Power Supplies       Bio Rad 
Vacuum Pump      Millipore 
Wave HT3500      Transgenomic 
 
2.4 Methods 
2.4.1 Primer Oligonucleotide Primer Design 
All primers were designed manually. The following criteria were applied 
where possible: 
1 – Primers were designed with a 50% G:C content 
2 – An annealing temperature of 600C was targeted with pairs not differing by more 
than 3 degrees 
2 – The 3’ end would have a high GC content 
3 – Repetitive and palindromic sequences would be avoided 
4 – Between primer pairs complimentary should be avoided particularly at the 3’ 
end. 
 
2.4.2 Polymerase Chain Reaction (PCR) 
Thermal cycling conditions consisted of an initial denaturation at 94°C for 10 
minutes, followed by 35 cycles of 94°C for 30 seconds, 30 seconds at the annealing 
temperature and 72°C for 30 seconds, followed by a final elongation stage of 72°C 
for 10 minutes. Reactions were carried out on MJ Tetrads. 
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Each 20ul reaction contained; 0.2U AmpliTaq gold (ABI), 0.2mM dNTPs 
(Amersham), 25pmol of each primer (MWG), 10X reaction Buffer (ABI) and 20ng of 
DNA. 
 
2.4.3 PCR Purification 
PCR products were purified using ExoSap, in which 10 to 15µl of PCR product 
was incubated with 2U of exonuclease I (New England Biolabs) and 2U of shrimp 
alkaline phosphatase (GE Healthcare). The reaction mixture was incubated at 37°C 
for one hour, followed by denaturation at 80°C for 15 minutes. 
 
2.4.4 Sanger Sequencing 
PCR products were sequenced using the BigDye™ v3.1 Sequencing kit 
(Applied Biosystems). Thermal cycling parameters consisted of 24 cycles of 94°C for 
10 second, 50°C for 5 seconds and 60°C for 3 minutes and 30 seconds.  
Each reaction consisted of 2ul of PCR template 2.5pmol of sequencing primer 
and 1ul BigDye reaction mix and 5X Sequence Reaction Buffer. Cleaned sequence 
reactions were run on ABI 3100 or 3730 genetic analysers (Applied Biosystems). 
 
2.4.5 Sequencing Clean Up 
Purification of sequencing products was carried out using the Millipore 
Montage SEQ96 Sequencing Reaction Cleanup kit under the recommended 
conditions.  
 
2.4.6 Agarose Gel Electrophoresis 
2% Agarose gels were run in 1xTAE buffer. Approximately 0.05ug/ml of 
Ethidium Bromide was used as an intercalating dye to allow visualisation of PCR 
products under UV exposure. 2 to 10ul of product was mixed with 5ul of Gel loading 
Buffer. 
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Electrophoreses was carried out between 80 and 120 volts in a BioRad Gel 
tank. 100bp ladder (NEB) was added to each gel to determine fragment sizes. 
 
2.4.7 Denaturing High Performance Liquid Chromatography (dHPLC) 
dHPLC (Section 1.2.2.3) was carried out using the 3500HT WAVE nucleic acid 
fragment analysis system (Transgenomic).  
To allow the detection of samples harbouring homozygous variants, 5μl of 
wild type PCR product was added to 20μl of sample product, denatured at 95ºC then 
cooled to 50ºC at a rate of 0.5ºC per 30 seconds. dHPLC was carried out using the 
melting temperatures predicted using the Transgenomic Navigator software 
(Version 1.5.4, Build 23). A 10 - 12% ACN gradient was run over 2 – 2.5 minutes. 
 
2.4.8 Restriction Digestion Assay 
20ul of PCR product was digested under the recommended conditions (NEB) 
for each enzyme (usually 1U of enzyme with a 2 hour, 370C incubation in an 
appropriate digestion buffer). Digested products were analysed by size separation 
on an agarose gel (Section 2.4.6). 
 
2.4.9 Amplification Refractory Mutation System (ARMS) 
Allele specific ARMS primers were designed with a mismatch at the n-3 base. 
PCR reactions were set up as described in Section 2.4.3. Optimum amplification 
temperature was determined by using a temperature gradient on the MJ tetrad. 
 Each ARMS assay contained a second set of PCR primers to act as a control. 
These primers would amplify a PCR fragment with a significant size different to the 
assay fragments but have the same annealing temperature. 
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2.5 Suppliers 
ABgene, Surrey, UK. 
Amersham Bioscience, Amersham, Aylesbury, Buckinghamshire, UK. 
Applied Biosystems, Cheshire, UK. 
Bio-Rad, Watford, Hertfordshire, UK. 
Covaris, Inc. Woburn, Massachusetts, USA. 
GRI, Braintree Essex/ MJ Research, Massachusetts, USA. 
Illumina, Chesterford Research Park, Little Chesterford, Essex, UK. 
Millipore, Hertfordshire, UK. 
MWG-Biotech, Buckinghamshire, UK. 
Myriad Genetics, Salt Lake City, USA. 
New England Biolabs, Ipswich MA, USA. 
Roche Biochemicals, East Sussex, UK. 
Sigma, Chemical Company Ltd, Poole, Dorset, UK. 
Transgenomic, Cheshire, UK. 
United States Biochemical (USB), Cambridge Bioscience, UK. 
 
2.6 Websites 
1000Genomes  http://www.1000genomes.org/ 
Align-GVGD   http://agvgd.iarc.fr/  
CGAP   http://cgap.nci.nih.gov/ 
DAVID   http://david.abcc.ncifcrf.gov/home.jsp 
dbSNP   http://www.ncbi.nlm.nih.gov/snp 
Ensembl  http://www.ensembl.org/index.html 
GeneSNPs   http://www.genome.utah.edu/genesnps/ 
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HapMap  http://hapmap.ncbi.nlm.nih.gov/ 
homologene  ftp://ftp.ncbi.nlm.nih.gov/pub/HomoloGene/current 
HWSIM software  http://krunch.med.yale.edu/hwsim/ 
Koask prediction http://www.cbs.dtu.dk/services/NetStart 
MutationDiscovery.com        
   http://mutationdiscovery.com/md/MD.com/home_page.jsp 
NCBI Blast  http://blast.ncbi.nlm.nih.gov/Blast.cgi  
Polyphen   http://genetics.bwh.harvard.edu/pph/ 
Pupasuite  http://pupasuite.bioinfo.cipf.es/ 
SNPper  http://snpper.chip.org/ 
SNPHunter  http://www.hsph.harvard.edu/ppg/software.htm 
t-coffee   http://www.igs.cnrs-mrs.fr/Tcoffee/tcoffee_cgi/
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3 Chapter three 
 
Assessment of the Transgenomic NavigatorTM software to rapidly 
detect aberrant dHPLC elution profiles 
3.1  Introduction 
Mutation detection is a key tool in both clinical diagnostic settings and 
research environments. A number of techniques have been developed including 
single-stranded conformational polymorphism analysis, denaturing gradient gel 
electrophoresis, heteroduplex analysis, chemical or enzymatic cleavage, denaturing 
dHPLC and DNA sequencing [reviewed (Cotton et al., 1998), discussed in Section 
1.2]. Despite the availability of numerous technologies, only a few of these methods 
have been formatted to facilitate automated mutation calling and, to-date, most 
attention has focused on automated heterozygote detection by DNA sequence 
analysis [(Hattori et al., 1993, Nickerson et al., 1997, Versluis et al., 1993)]. dHPLC is 
a highly sensitive technique, that resolves homo- and heteroduplex DNA molecules 
by using ion-pair reverse phase HPLC under conditions of partial helix denaturation 
[reviewed in (Xiao and Oefner, 2001), discussed in Section 1.2.2.3]. Several 
investigators have shown that samples carrying sequence variants often generate 
characteristic dHPLC elution profiles which may be used to facilitate mutation 
detection [(O'Donovan et al., 1998, Young et al., 2002)]. Recently, Transgenomic Inc. 
(www.transgenomic.com) has developed software for automated dHPLC-based 
mutation calling using customisable pattern recognition capabilities. Here, we 
evaluate the utility of the Transgenomic Navigator software to facilitate automated 
detection of aberrant dHPLC elution profiles after analysing amplicons from MSH6, 
NEIL2, NEIL3 and OGG1 in 172 patients with multiple colorectal adenomas with or 
without cancer. These genes were selected from on-going projects and were 
selected as they were known to contain polymorphisms and rare variants. DNA 
fragments harbouring both a polymorphism and a mutation often generate complex 
elution profiles that may hinder mutation detection. Therefore, we also assessed the 
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utility of the software to rapidly detect samples carrying novel sequence variants in 
addition to common polymorphisms 
Data in this chapter was presented in the manuscript “Rapid recognition of 
aberrant dHPLC elution profiles using the Transgenomic Navigator software” (Colley 
et al., 2005) of which James Colley was the primary author and as a consequence 
there are some overlaps in parts of the text. 
 
3.2 Materials and Methods 
3.2.1 Samples 
DNA was extracted from the venous blood samples of 172 patients with 
multiple colorectal adenomas with or without cancer.  
 
3.2.2 PCR 
We analysed fragments that were known to be polymorhpic spanning exons 
2, 3, 4 (fragments 1-4, 6, 8, 11), 5 (fragments 1-2), 6 and 9 of MSH6 (NM_000179.); 
exons 1, 2 (fragment 2), 3 and 4 (fragment 1) of NEIL2 (NM_001135746); exons 1, 2, 
5, 8 (fragment 1) and 10 of NEIL3 (NM_018248); and, exons 5 and 7 of OGG1 
(NM_002542).  
Reaction and thermal cycling conditions are described in Section 2.4.2, 
primers and annealing temperatures are in Appendix A. Fragments were designed to 
span exons with 50bp excess on either side (to account for the poor sequence often 
seen at the start of sequence traces), where these fragments would exceeded 600bp 
multiple overlapping fragments were designed.  
 
3.2.3 Sequencing 
Where Sanger sequencing was required PCR products were purified as 
described in Section 2.4.3 and sequenced as described in Section 2.4.4. 
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Purification of sequencing products was carried as described in Section 2.4.5. 
Samples were run on an ABI 3100 genetic analyser (Applied Biosystems) and 
sequence data viewed using Sequencher v4.6. 
 
3.2.4 Denaturing High Performance Liquid Chromatography (dHPLC) and Analysis 
with the Navigator Software 
dHPLC was carried out as described in Section 2.4.7 at the melting 
temperatures predicted by Navigator (Version 1.54) software (Appendix C).  
3.2.5 Assays for Common Polymorphisms and Automated Sequencing 
Common polymorphisms were typed using ARMS (Section 2.4.9) or 
restriction digestion based assays (Section 2.4.7) (Assay details in Appendix B). 
 
3.2.6 Navigator Analysis 
dHPLC elution data was imported into the analysis page of the Navigator 
software and samples with weak amplification profiles were excluded. Three levels 
of analysis were performed: Level 1 – elution profiles were automatically normalised 
and grouping information was collected from the affinity tree. Level 2 – whilst 
observing the overlaid profiles and 3D plot, a slide tool on the left axis of the 3D 
scatter graph was manually adjusted to alter the grouping parameters (profiles lying 
immediately adjacent to a major group were incorporated into that group) grouping 
information was collected from the affinity tree. Level 3 – the user re-assessed the 
outlying profiles from Level 2, and, if necessary, manually re-assigned them using 
the ‘discrimination tool’ (Figure 3.2).  
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3.2.7 Author’s Contribution 
 
Figure 3.1: Author’s contribution to Chapter 3.
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Table 3.1: dHPLC Analysis Temperatures. 
Amplicon dHPLC 
Temp 
1(ºC) 
dHPLC 
Temp 
2(ºC) 
  Amplicon dHPLC 
Temp 
1(ºC) 
dHPLC 
Temp 
2(ºC) 
MSH6X2newF 
MSH6X3F 
57 
58 
60 
59.5 
NEIL2X1new 61 62 
 NEIL2X2.2 62 / 
MSH6X4.1 
MSH6X4.2 
57.5 
59.5 
59 
/ 
  NEIL2X3new 59 60.5 
  NEIL2X4.1 59 62.5 
MSH6X4.3 56 58.5      
MSH6X4.4 57.5 59   NEIL3X1 62.5 64.5 
MSH6X4.6 56 58   NEIL3X2 57 / 
MSH6X4.8 56.5 58   NEIL3X5 57 / 
MSH6X4.11 57 58.5   NEIL3X8.1 53 55.5 
MSH6X5.1 57 58.5   NEIL3X10 55.5 56.5 
MSH6X5.2 54.5 58      
MSH6X6 
MSH6X9 
57 
55 
58.5   OGG1X5 63 / 
57   OGG1X7 62 / 
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Figure 3.2: Three levels of Analysis. 
Columns a, b, and c show the analyses of different fragments, rows 1, 2, and 3 show 
those fragments at different levels of analysis. 1) MSH6 exon 4 fragment 4 analysed 
at 57.5ºC (sample 76 is heterozygous for p.Y214 (642C>T). The fully automated Level 
1 analysis (1a) provides sufficient separation between the wild type and variant 
traces; (2) MSH6 exon 3 analysed at 58ºC (common SNP p.D180 (540T>C). Level 1 
analysis (1b) has obvious errors, adjusting the slide tool (Level 2) gives correct 
separation (2b); (3) MSH6 exon 3 analysed at 59.5ºC (common SNP p.D180 (540T>C). 
Levels 1 and 2 (1c and 2c respectively) have obvious errors manually altering the 
automatic data points Level 3 analysis (3c) separates the three trace types.
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3.3 Results 
3.3.1 Evaluation of the Navigator Software to Detect Rare Variants 
We sought germline variants in MSH6 (exon 4 fragments 2-4, 6, 8, 11; exon 5, 
fragment 1; exon 6; and exon 9), NEIL2 (exon 1; and exon 2, fragment 2) and NEIL3 
(exon 2; and exon 10) in 172 patients with multiple colorectal adenoma with or 
without carcinoma. In total, thirteen different fragments were amplified and all 
except three were analysed at two dHPLC temperatures (Table 3.1), thereby 
generating twenty-three data sets (consisting of 3,747 elution profiles) for analysis 
with the Navigator software (Table Table 3.2). Under Level 1 analysis, 138 products 
were identified as having profiles outlying the wild type group. Direct sequence 
analysis showed that 60 (43.5%) of these products harboured novel variants 
(heterozygous and homozygous) and the remaining 78 were wild type. One of the 
analysis conditions (for exon 9 of MSH6 at 57ºC) resulted in poorly resolved elution 
profiles in which only one of the sixty outlying product profiles was confirmed as 
carrying a genuine variant. Repeat dHPLC analysis on independent PCR products 
from this amplicon again yielded poorly resolved elution profiles with a high 
proportion of outlying samples (under Level 1 analysis) that were shown to be wild 
type upon sequencing. Excluding this result, 59/78 (75.6%) products with outlying 
profiles were confirmed as harbouring novel variants under Level 1 analysis. Repeat 
dHPLC analysis of 16 of the remaining 19 PCR products (3 samples had insufficient 
DNA for repeat amplification) characterised as having outlying profiles but no 
sequence variant, showed that all were subsequently classified correctly to the wild 
type group under Level 1. 
The results from Level 2 and 3 analyses were identical to each other, with 60 
products identified as having outlying profiles, 59 of which (98.3%) were shown by 
sequence analysis to carry genuine sequence variants (examples are shown in Figure 
3.4 and 3.6). Only a single product (from exon 4 fragment 3 of MSH6 analysed at 
56ºC) was incorrectly classified, displaying an outlying trace but proven wild type on 
sequence analysis. This profile lay close to the wild type profile and was correctly 
identified as wild type under repeat dHPLC analysis of a fresh PCR product and at the 
alternative dHPLC conditions using the original product. 
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All 3,747 dHPLC elution profiles were also analysed by visual inspection, by an 
independent investigator, to allow for a direct comparison to the results generated 
using the software. In total, 58 products with outlying profiles were identified, all of 
which were shown to harbour novel variants upon sequence analysis. In comparison 
to the Level 3 analyses using the Navigator software, one product with a novel 
variant (p.H388 [c.1164C>T] in exon 4, fragment 3 of MSH6 at 56ºC) was missed by 
visual inspection of the traces because the elution profile was very similar in shape 
to a sample that was heterozygous for p.Y397F only; this product was identified as 
having a unique profile by manual analysis at the second temperature used for 
dHPLC (Figure 3.3).  
In contrast, the single product identified as an outlier under Level 3 analysis but 
shown to be wild type upon sequencing was not misclassified by manual inspection. 
We assessed the level of false negatives identified using the Navigator software by 
comparing dHPLC classifications and sequencing results for four rare variants (c.157-
18A>G, c.278+50G>A and p.A547S [c.1639G>T] in NEIL3 and p.G289E [c.866G>A + 
c.867C>A] in MSH6) that were identified during this study. Ten out of 113, 1/115, 
1/162 and 1/158 samples were correctly classified as carrying the variants c.157-
18A>G, c.278+50G>A, p.A547S (c.1639G>T) and p.G289E (c.866G>A + c.867C>A), 
respectively – no false negatives were identified at any of the Levels of analysis. 
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Figure 3.3: MSH6 exon4, fragment 3. 
(A) MSH6 exon 4, fragment 3 Navigator plot. Manual analysis incorrectly identified 
the red and green trace as being the same variant. Images B and C show the two rare 
SNPs that cause the dHPLC trace profiles. (B) MSH6 exon 4, fragment 3, p.H388. (C) 
MSH6 exon 4, fragment 3, p.Y397F. 
 
 
A 
B 
 
 
A 
C 
 
 
A 
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Table 3.2: Evaluation of the Navigator Software to Detect Rare Variants. 
Gene Exon dHPLC 
Temp (oC) 
No. of products 
analysed 
Level 1 Level 2 Level 3 
MSH6 4(Fr.2) 59.5 161 2/2 2/2 2a/2 
MSH6 4(Fr.3) 56 170 2/3 2/3 2b/3 
MSH6 4(Fr.3) 58.5 171 2/3 2/2 2b/3 
MSH6 4(Fr.4) 57.5 169 1/2 1/1 1c/1 
MSH6 4(Fr.4) 59 169 1/2 1/1 1c/1 
MSH6 4(Fr.6) 56 172 1/3 1/1 1d/1 
MSH6 4(Fr.6) 58 171 1/3 1/1 1d/1 
MSH6 4(Fr.8) 56.5 165 1/2 1/1 1e/1 
MSH6 4(Fr.8) 58 169 1/1 1/1 1e/1 
MSH6 4(Fr.11) 57 149 1/1 1/1 1f/1 
MSH6 4(Fr.11) 58.5 156 1/1 1/1 1f/1 
MSH6 5(Fr.1) 57 169 1/1 1/1 1g/1 
MSH6 5(Fr.1) 58.5 169 1/1 1/1 1g/1 
MSH6 6 57 146 3/3 3/3 3h/3 
MSH6 6 58.5 149 3/3 3/3 3h/3 
MSH6 9 55 168 1/1 1/1 1i/1 
MSH6 9 57 170 1#/60 0/0 0/0 
NEIL2 1 61 154 3/3 3/3 3j/3 
NEIL2 1 62 159 3/4 3/3 3j/3 
NEIL2 (2Fr.2) 62 159 1/6 1/1 1k/1 
NEIL3 2 57 162 13/13 13/13 13l/13 
NEIL3 10 55.5 162 8/12 8/8 8m/8 
NEIL3 10 56.5 158 8/8 8/8 8m/8 
       
Total   3747 60/138 
(43.5%) 
59/60 
(98.3%) 
59/60 
(98.3%) 
Three levels of analysis (Levels 1-3) were undertaken for all 3,747 products and results 
are presented as the number of products that contained a novel variant (shown by 
sequence analysis) out of the total number of products with ‘outlier’ profiles. Seventy 
eight outlier products identified under Level 1 analysis and one outlier product under 
Level 2 and 3 analyses were shown to be wild type (none of the twelve sub-options 
assessed under Levels 1-3 affected the results of this analysis).  
Legend continued on following page. 
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#The variant 4001+12_15del was not detectable by dHPLC at 57ºC (identified by 
sequence analysis). Novel variants identified were: ap.K295R (c.884A>G), p.G289E 
(c.866G>A + c.867C>A); bp.Y397F (c.1190A>T), p.H388 (c.1164C>T); cp.S503C 
(c.1508C>G); dp.A630 (c.1890A>C); ep.L758 (c.2272C>T); fp.R1005X (c.3013C>T); 
gp.T1102 (c.3306T>A); hc.3439-16C>T (2 cases), c.3439-57_58del; ic.4001+12_15del; 
jp.Q38 (c.114G>A) (3 cases); kp.R164T (c.491G>C); lc.157-18A>G (12 cases), 
c.278+50G>A; mc.1636-73A>G (7 cases), p.A547S (c.1639G>T). Fr. – fragment. 
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Figure 3.4: Evaluation of the Navigator software to detect rare variants. 
Under both Level 2 and Level 3 analysis conditions, 59/60 (98.3%) products with 
outlying profiles were shown to harbour novel sequence variants. Examples 
shown are: (a) exon 4 fragment 11 of MSH6 analysed at 57ºC (sample 62 is 
heterozygous for p.R1005X [c.3013C>T]); (b) exon 6 of MSH6 analysed at 57ºC 
(sample 56 is heterozygous for c.3439-57_58del, and samples 61 and 68 are 
heterozygous for c.3439-16C>T); (c) exon 4 fragment 2 of MSH6 analysed at 
59.5ºC (sample 28 is heterozygous for p.G289E [c.866G>A + c.867C>A] and 
sample 89 is heterozygous for p.K295R [c.884A>G]); (d) exon 4 fragment 4 of 
MSH6 analysed at 57.5ºC (sample 76 is heterozygous for p.S503C [c.1508C>G]) - 
sample 13 was identified as an outlier under Level 1 analysis conditions but 
shown to be wild type by sequence analysis; this sample was not considered an 
outlier under Level 2 analysis conditions. Each figure shows a 3D plot (bottom 
left) an affinity trees (bottom right) and the overlaid, normalised dHPLC profiles 
(top). For each image Level 2 and 3 analysis was identical. 
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3.3.2 Evaluation of the Navigator Software to Detect Common Polymorphisms 
To determine whether the Navigator software could be used to reliably 
detect samples carrying common polymorphisms, the 172 samples were analysed for 
selected regions of MSH6 (exon 2, exon 3, exon 4 fragment 1 and exon 5 fragment 
2), NEIL2 (exon 3 and exon 4 fragment 1), NEIL3 (exon 1, exon 5 and exon 8 fragment 
1) and OGG1 (exons 5 and 7) – all of which were known to harbour polymorphisms 
with minor allele frequencies between 8 and 40% (our unpublished data). All 
samples were typed for the polymorphisms using ARMS or restriction digest based 
assays, the accuracy of the genotypes was confirmed by sequence analysis: 952/952 
(100%) genotypes from restriction digestion assays, 427/427 (100%) genotypes from 
ARMS-based assays and 100/100 (100%) genotypes from Genescan size analysis 
assays were identical to results generated by DNA sequencing, genotypes were 
compared to dHPLC profile classes determined using the Navigator software. 
Samples heterozygous or homozygous for the minor allele were considered identical 
for these analyses (i.e. ‘variant’), since all samples underwent dHPLC analysis in the 
presence of 20% wild type PCR product. (Kaler et al., 2000, Pirulli et al., 2000, 
Schaeffeler et al., 2001). Eight of the eleven amplified fragments were assayed at 
two melt temperatures which resulted in nineteen data sets (consisting of 2,784 
dHPLC elution profiles). We found discrepancies between the Navigator elution 
profile classes and the genotypes at each of the levels of analysis and with each of 
the selected sub-options; however, by selecting the ‘rightmost peak’ and ‘trailing 
edge’ sub-options, we achieved the highest concordance between dHPLC groupings 
and genotypes. Using these optimal parameters, Level 1 showed 85.1% concordance, 
Level 2 showed 95.5% concordance, and Level 3 showed 97.2% concordance. If we 
excluded products with profiles that were obvious outliers to the main groups and 
that were subsequently shown to also harbour novel variants, then under Level 3 
analysis, 1,573/1,580 (99.6%) products were correctly called as wild-type and 
1,137/1,145 (99.3%) products were correctly identified as harbouring the 
polymorphism under assessment (Table 3.3). The 15 incorrect calls were either due 
to samples homozygous for the rare polymorphic allele being identified as outliers (2 
cases), samples carrying a novel variant being classified as carrying a common 
polymorphism (1 case), or, samples carrying common polymorphisms being poorly 
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resolved due to non-optimal melting conditions (12 cases); 13 of these products 
were assayed at a second temperature and all were subsequently called correctly. 
When considering data from both melt temperatures together, there was 99.9% 
(1,597/1,599) concordance between Navigator elution profile classification and 
genotype under Level 3 analysis conditions. 
 
3.3.3 Evaluation of the Navigator Software to Detect Rare Variants in Fragments 
Harbouring Common Polymorphisms 
The presence of two or more sequence variants within a single DNA fragment 
often results in a complex elution profile. Therefore, we determined the specificity of 
the software to correctly identify profiles corresponding to the presence of a rare 
variant in the context of a co-existing frequent polymorphism. Among the 2,784 
dHPLC elution profiles analysed for common polymorphisms, we identified 61 
products as having distinct profiles under our optimal parameters within a Level 3 
analysis. Direct sequencing showed that 59 (96.7%) of these harboured novel 
variants (Table 3.3) (examples are shown in Figure 3.6). Both remaining outlier 
products (in exon 5 of NEIL3 at 57ºC) were shown to correspond to rare 
homozygotes for the polymorphism present within that exon (c.701+34_40del). 
All 2,784 elution profiles were also analysed by visual inspection. In total, 56 
products with outlying profiles were identified, all of which were shown to harbour 
novel variants upon sequence analysis. In comparison to the analyses using the 
Navigator software, three products with novel variants (all heterozygous for both 
p.R15 [c.45C>A] and p.R38C [c.112C>T] in exon 1 of NEIL3]) were missed by visual 
inspection because the elution profiles lay very close to the profile for the common 
polymorphism p.R15 [c.45C>A]. In contrast, the two products identified as outliers 
using the software, but shown to be homozygous for the rare allele of the 
polymorphism c.701+34_40del in exon 5 of NEIL3, were correctly classified to the 
polymorphic group upon manual inspection. 
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3.3.4 Sensitivity 
In identifying the optimum conditions for Navigator analysis a single variant 
(p.R103Q) was discovered in a fragment that was previously thought to be non-
polymorphic (NEIL2 exon 2, fragment 1) and had therefore not been included as part 
of this study (Figure 3.5).
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Table 3.3: SNP Discovery Summary. 
Gene Exon dHPLC 
Temp 
(oC) 
No. of 
products 
analysed 
SNP Assayed Wild types Variants Outliers 
MSH6 2 57 147 p.P92 (c.276A>G) 93/95 46/52 2a/2 
MSH6 2 60 150 p.P92 (c.276A>G) 94/96 54/54 2a/2 
MSH6 3 58 150 p.D180 (c.540T>C) 69/69 81/81 - 
MSH6 3 59.5 152 p.D180 (c.540T>C) 72/72 80/80 - 
MSH6 4(Fr.1) 57.5 160 p.Y214 (c.642C>T) 129/129 31/31 - 
MSH6 4(Fr.1) 59 156 p.Y214 (c.642C>T) 126/126 30/30 - 
MSH6 5(Fr.2) 54.5 157 c.3438 + 14A>T 59/61 96/96 2b/2 
MSH6 5(Fr.2) 58 156 c.3438 + 14A>T 59/61 95/95 1c/1 
NEIL2 3 59 95 p.P188 (c.564A>G) 45/47 45/48 5d/d 
NEIL2 3 60.5 118 p.P188 (c.564A>G) 54/58 55/60 9e/9 
NEIL2 4(Fr.1) 59 144 c.689 - 13C>T 79/79 62/65 3f/3 
NEIL2 4(Fr.1) 62.5 144 c.689 - 13C>T 79/79 63/65 2g/2 
NEIL3 1 62.5 151 p.R15 (c.45C>A) 68/82 62/69 15h/15 
NEIL3 1 64.5 151 p.R15 (c.45C>A) 74/82 65/69 12i/12 
NEIL3 5 57 135 c.701 + 34_40del 113/113 20/22+ 0/2+ 
NEIL3 8(Fr.1) 53 159 c.1040 - 85T>C 85/86 72/73 2j/2 
NEIL3 8(Fr.1) 55.5 154 c.1040 - 85T>C 82/83 70/71 2j/2 
OGG1 5 63 151 c.748 - 15C>G 94/95 55/56 2k/2 
OGG1 7 62 154 p.S326C 
(c.977C>G) 
99/99 55/55 - 
Total   2784  1573/1612 
(97.6%) 
1137/1172 
(97.0%) 
59/61 
(96.7%) 
#excl. 
outliers 
    1573/1580* 
(99.6%) 
1137/1145^ 
(99.3%) 
 
Analyses were performed by selecting the ‘rightmost peak’ and ‘trailing edge’ sub-
options under Level 3; dHPLC profiles were classified as wild types, variants or outliers. 
The wild type and variant columns show the number of products classified by the 
Navigator software out of the number of products genotyped to a category. The outlier 
column shows the number of products that contained a novel variant (shown by 
sequence analysis) out of the total number of products with outlier profiles (+two 
products were identified as outliers, but genotyping and sequencing showed that they 
were homozygous for minor allele of the polymorphism 701+34_40del).  
Legend continued on next page. 
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 #Analyses excluding 59 products with outlying profiles and proven to harbour novel 
sequence variants: *7 incorrect calls were from the wild type group (exon 5 fragment 2 
of MSH6 at 58ºC in 1 case and exon 1 of NEIL3 at 62.5ºC in 6 cases), and, ^8 incorrect 
calls were from the variant group (exon 2 of MSH6 at 57ºC in 6 cases and exon 5 of 
NEIL3 at 57ºC in 2 cases). Novel variants identified were: ap.S144I (c.431G>T) (2 cases); 
bc.3438+17G>C, p.T1102 (c.3306T>A); cc.3438+17G>C; dc.492–50G>C (2 cases), c.492–
50G>C and p.P188 (c.564A>G) heterozygote (2 cases), c.492–8C>T and p.P188 
(c.564A>G) heterozygote; ec.492–50G>C (4 cases), c.492–50G>C and p.P188 (c.564A>G) 
heterozygote (4 cases), c.492–8C>T and p.P188 (c.564A>G) heterozygote; fp.R257L 
(c.770G>T) and c.689-13C>T homozygote (3 cases); gp.R257L (c.770G>T) and c.689-
13C>T homozygote (2 cases); hc.1–37G>A heterozygote (6 cases), c.1–37G>A and p.R15 
(c.45C>A) (4 cases), p.R38C (c.112C>T) and p.R15 (c.45C>A) (3 cases), c.1-37G>A 
homozygotes (2 cases); ic.1-37G>A heterozygote (6 cases), c.1-37G>A and p.R15 
(c.45C>A) (4 cases); and c.1-37G>A homozygotes (2 cases); jc.1040–181A>G and p.R381 
(c.1143G>A), c.1040–107A>G and c.1040–85T>C; kp.A288V (c.863C>T) (2 cases).  
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Figure 3.5: Navigator Sensitivity.  
The dark green trace (3) in the left image contains the variant NEIL2 p.R103Q which 
was detected by the software and missed by the manual analysis when looking at 
traces individually. The overlaid plots (right) clearly show 6 outlying samples which 
were subsequently shown to contain the SNP.  
 
Figure 3.6: Detecting novel variants in fragments harbouring common 
polymorphism.  
Fifty nine out of 61 (96.7%) outliers from the main polymorphism groups harboured 
novel variants (Level 3 analysis). Examples shown are: (a) exon 3 of NEIL2 at 59ºC - 
Five outlier products were identified (samples 3 and 63 were heterozygous for 
c.492-50G>C; samples 47 and 84 were heterozygous for c.492-50 G>C and p.P188 
(c.564A>G); and sample 36 was heterozygous for c.492-8C>T and p.P188 
[c.564A>G]). (b) exon 1 of NEIL3 at 64.5ºC – Twelve outlier products were identified 
(6 samples [marked A] were heterozygous for c.1-37G>A, 4 samples [marked B] were 
heterozygous for c.1-37G>A and p.R15 (c.45C>A) and 2 samples [marked C] were 
homozygous for c.1-37G>A). 
1 
2 
3 
 4 
 
86 
 
3.4 Discussion 
Our analyses of over 6,500 amplicons generated from four different genes 
have shown that the Transgenomic Navigator software is an excellent tool for the 
assessment of dHPLC elution profiles, although some user input is necessary. For 
example, in fragments that do not harbour common polymorphisms, Level 1 
analyses revealed that only 43.5% of outlier products were correctly identified as 
containing new sequence variants, whereas under Level 2 and 3 analyses that 
require more operator input, 98.3% were correctly called. Similarly, for complex 
profiles such as those generated from fragments harbouring common 
polymorphisms, we found that a high level of operator input was necessary to 
achieve accurate grouping of dHPLC profiles (we achieved 97.2% concordance 
between dHPLC grouping and polymorphism genotype under Level 3). 
An initial concern was that by increasing the stringency for calling outliers 
(from Level 1, to Levels 2 and 3), we might miss a large number of mutations lying 
close to the main groups. Our data does not support this concern since of the 138 
products classified as having outlying profiles under Level 1 analysis, 60 were shown 
to harbour novel sequence variants and 78 were wild type upon sequencing. By 
comparison, 59/60 products classified as outliers under Level 2 or 3 analyses (Table 
3.2), were confirmed to contain sequence variants and only one outlier product was 
wild type upon sequence analysis; the only mutation missed by this more stringent 
analysis was correctly classified at the alternative dHPLC temperature. 
We have assessed the utility of the software in comparison to manual 
inspection of the dHPLC elution profiles. Under Level 3 analysis with the Navigator 
software, a total of 118/121 products with outlying profiles were shown to harbour 
novel sequence variants. In comparison, by visual inspection, 114/114 products with 
outlying profiles were shown to harbour novel sequence variants. Therefore, four 
(3.4%) products with novel variants were missed by manual inspection. However, the 
software also identified three products with outlying profiles that did not contain 
new sequence variants and these products were correctly classified by manual 
inspection. In our experience, for fragments with complex elution profiles (such as 
those harbouring common polymorphisms), the Navigator software allows for a 
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more rapid analysis of the data when compared to manual inspection, and reduces 
the possibility of operator error. 
Although dHPLC cannot be used as a genotyping technology (since it cannot 
always discriminate between samples heterozygous and homozygous for a rare 
allele), we show that the Navigator software can be used to rapidly group samples 
containing common polymorphisms and allow outliers to be easily recognised. 
Indeed, we showed that 96.7% of products with profiles outlying the main groups 
harboured new variants. Furthermore, of those fragments that did not contain a 
second variant, 99.4% were classified correctly in relation to common 
polymorphisms. We conclude that the Navigator software provides a powerful tool 
for automating the identification of novel variants irrespective of the complexity of 
the dHPLC elution profiles.  
While dHPLC has been replaced in our institution by higher throughput HRM 
(Section 1.2.2.5) technology it is still widely used in for SNP discovery, PubMed 
details over 20 publications in the first quarter of 2012. Zahary (2012) describes use 
of the technology in identify germline mutation in Malaysian HNPCC patients in the 
MMR genes MLH1 and MSH2 as part of an expression profile experiment 
demonstrating the current value of the technique where equipment is available.
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4 Chapter four 
 
Using the Transgenomic NavigatorTM software to identify novel 
germline variants in the OGG1, NEIL1, NEIL2, NEIL3, MTH1 and NTH1 
genes and investigating their potential role in susceptibility to 
colorectal adenomas 
 
4.1 Introduction 
Established predisposition genes account for only a small proportion of 
familial colorectal cancer (CRC) (Kinzler and Vogelstein, 1996). We recently showed 
that biallelic germline defects in MUTYH predispose to multiple colorectal adenoma 
(CRA) and carcinoma [(Al-Tassan et al., 2002), (Jones et al., 2002), (Sampson et al., 
2003), reviewed in (Cheadle and Sampson, 2003)]. This autosomal recessive disorder 
has been termed MUTYH associated polyposis (MAP). MUTYH functions as a base 
excision repair (BER) DNA glycosylase and is responsible for removing adenines mis-
incorporated opposite 8 -oxo-7,8-dihydro-2’-deoxyguanosine (8-oxoG), one of the 
most stable products of oxidative DNA damage (Slupska et al., 1999). The highly 
conserved BER system plays a major role in the protection against oxidative DNA 
damage and is particularly important in the colon where high levels of reactive 
oxygen species are generated by commensal bacteria and dietary carcinogens 
[(Ames and Gold, 1991) (Bartsch et al., 2002) (Huycke and Gaskins, 2004)]. A number 
of additional BER enzymes also protect against oxidative DNA damage (Wood et al., 
2005). OGG1 and NTH1 remove the damaged base from 8-oxoG:C (Roldan-Arjona et 
al., 1997) and 8-oxoG:G base-pairs (Matsumoto et al., 2001) respectively, and a 
recently discovered family of enzymes called NEIL1-3 have overlapping substrate 
specificities with OGG1 and NTH1 (Hazra et al., 2003). In addition, MTH1 functions as 
an 8-oxoGTPase that hydrolyses oxidised guanine triphosphates in the nucleotide 
pool, thereby preventing their incorporation into the nascent strand (Sakumi et al., 
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1993). Here, we determined whether germline variants in OGG1, NEIL1, NEIL2, 
NEIL3, MTH1 and NTH1, may, like MUTYH, predispose to multiple CRA and 
carcinoma. 
Data in this chapter was presented in the manuscript “Inherited 
predisposition to colorectal adenomas caused by multiple rare alleles of MUTYH but 
not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3” (Dallosso et al., 2008) of which James 
Colley was an author who helped write the manuscript and as a consequence there 
are some overlaps in parts of the text. 
 
4.2 Materials and Methods 
4.2.1 Samples 
One hundred and thirty four unrelated index cases with multiple CRA with or 
without carcinoma were recruited from regional UK polyposis registers in 
Birmingham, Cambridge, Cardiff, Liverpool, Manchester, Southampton and Surrey. 
Given the pattern of inheritance observed in MAP, patients were selected for a 
family history consistent with autosomal recessive transmission of the disease. No 
cases carried biallelic MUTYH mutations, nor a truncating mutation in APC 
(associated with familial adenomatous polyposis). Patients were categorised 
according to the number of CRAs recorded at colonoscopy or colectomy in order to 
identify a set that closely resembled a MAP like phenotype (Group B). Group A 
consisted of 55 patients with 3-10 CRAs and presented at a mean age of 48 years, 
Group B consisted of 53 patients with 11-100 CRAs and presented at a mean age of 
48 years, Group C consisted of 26 patients with more than 100 CRAs presenting at a 
mean age of 44 years. DNA was prepared from venous blood samples using standard 
methods. As is expected where the cause of disease severity is genetic variation, 
adenoma frequency was greater in younger patients (p = 0.005; linear regression). 
396 British Caucasian control blood DNA samples were obtained from the 
European Collection of Animal Cell Cultures (ECACC) (Dallosso et al., 2008). 47 Dutch 
patients with 11-100 CRAs and a family history consistent with recessive inheritance 
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and 262 matched control samples were obtained from Dr F.J Hes in Leiden 
University. 
 
4.2.2 PCR 
We amplified exons 1-8 of OGG1 and 2 -5 of MTH1 as previously described 
(Al-Tassan et al., 2002). The open reading frames (ORFs) of NEIL1, NEIL2, NEIL3 and 
NTH1 were amplified as 9, 6, 11 and 5 fragments, respectively. We amplified exons 2 
to 4 of NEIL2 (spanning the variants p.R103Q and p.R257L) as a 6.5kb long distance 
PCR fragment (Appendix C). 
 
4.2.3  Denaturing High Performance Liquid Chromatography (dHPLC)  
dHPLC was carried out as described in Section 2.4.7 at the melting 
temperatures predicted by Navigator (Version 1.54) software (Appendix C). Samples 
with aberrant elution profiles were identified using Navigator assisted trace calling 
(Colley et al., 2005) and were sequenced directly. 
 
4.2.4 Sequencing 
PCR products were purified as described in Section 2.4.3 and sequenced as 
described in Section 2.4.4. Purification of sequencing products was carried as 
described in Section 2.4.5. All mutations were confirmed by sequencing at least two 
independent PCR products. 
 
4.2.5 Assays for Sequence Variants 
We used ARMS assays (2.4.9) or restriction digests (2.4.8) to genotype the 
common variants in the patient samples and to determine the frequency of the 
missense, nonsense and splice site variants in at least 650 British Caucasian control 
chromosomes (ECACC, Salisbury, UK). Primer sequences and conditions are available 
in Appendix B. 
91 
 
4.2.6 Statistical Analysis 
Variants were assessed for departure from the Hardy-Weinberg equilibrium 
using the chi-square test or, when the number of genotypes was <5, by using the 
Monte-Carlo permutation test with 10,000 permutations (HWSIM software). 
Differences between the proportion of cases and controls with each variant were 
analysed using the chi-square or Fisher's exact tests. Corrections for multiple testing 
were performed by a permutation test, randomly reshuffling case-control status 
(when individual genotypes of cases and controls were available). When individual 
genotypes for controls were unavailable, correction for multiple testing was 
performed using spectral decomposition of matrix of pair-wise r2 measures of 
linkage disequilibrium (Nyholt, 2004). 
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4.2.7 Author’s Contribution 
 
Figure 4.1: Authors Contribution to Chapter 4.
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4.3 Results 
We screened the entire ORFs of OGG1, NEIL1, NEIL2, NEIL3, MTH1 and NTH1 
for germline variants in 134 patients with multiple CRA, by using a combination of 
dHPLC and direct DNA sequencing. In total, we identified 65 variants, 41 of which 
were silent or intronic changes (Table 4.1) and 24 were coding sequence alterations 
(22 missense changes, a nonsense change and a splice site alteration) (Table 4.2). Of 
the 22 missense changes, 5 were identified in OGG1 (p.R46Q, p.A85S, p.A288V, 
p.I321T and p.S326C), 2 in NEIL1 (p.P208S and p.R339Q), 3 in NEIL2 (p.R103Q, 
p.R164T and p.R257L), 10 in NEIL3 (p.R38C, p.P117R, p.D132V, p.Q172H, p.H286R, 
p.R315Q, p.L443P, p.H471Q, p.R520G and p.A547S) and 2 in MTH1 (p.V106M and 
p.K155I). In total, 11 of these missense variants were novel at the time. All patients 
with missense variants with MAFs <15% were sequenced for the entire ORF of the 
corresponding gene to search for biallelic mutations (as found in MAP).  
We also designed assays for each of the missense variants and screened for 
their presence in a panel of 396 British Caucasian control blood DNA samples. Four 
patients carried both p.R103Q and p.R257L in NEIL2; however, these variants were 
also identified together in control samples and cloning and sequencing of an NEIL2 
genomic region encompassing exons 2 and 4 revealed that both variants were 
present on the same allele. Three patients carried the missense changes p.Q172H 
and p.R38Cin NEIL3; however, these variants were detected together in three 
control samples. Five patients carried the relatively common variant p.P117R (minor 
allele frequency [MAF]~12%) in NEIL3 in combination with rare missense changes 
(with both p.R38C and p.Q172H in 1 case, with p.R38C in 1 case, with p.R315Q in 1 
case, and with p.R520G in 2 cases); however, four control samples also harboured 
p.P117R in combination with these rare variants (with p.R38C in 1 sample, with 
p.R315Q in 2 samples, and with p.R520G in 1 sample) and p.P117R was also 
identified in a homozygous state in five (out of 384) control samples. No other 
patients carried biallelic missense variants (apart from those harbouring the 
common variants p.S326C in OGG1 and p.H286R, p.L443P and p.H471Q in NEIL3). 
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We determined whether any missense variants were over-represented in 
cases (analysed by polyp number and as a whole) versus controls. All except four of 
the missense variants (p.I321T in OGG1, p.P208S in NEIL1, p.R164T in NEIL2 and 
p.D132V in NEIL3) were detected in control samples. No variants showed evidence 
for departure from the Hardy-Weinberg equilibrium amongst the cases. A single 
variant, p.P117R in NEIL3, was over-represented in patients with 11-100 CRAs 
(P=0.01) (Table 4.2). This apparent over-representation was re-assessed in an 
independent cohort. An analysis of 47 Dutch patients with 11-100 CRAs (and with a 
family history consistent with recessive inheritance) and 262 matched control 
samples failed to demonstrate a significant association, either alone or in 
combination with the original data. Indeed, after correcting the original data for 
multiple testing, p.P117R was no longer found to be significantly over-represented 
(P=0.13 by the permutation test and 0.21 by the spectral decomposition of LD 
matrix).  
A single sporadic case harboured a novel nonsense mutation (p.Q90X) in 
NTH1. Complete sequencing of the NTH1 ORF failed to identify a second mutation in 
this case and extended family members were not available to determine the 
segregation of this variant. Furthermore, no tumour samples were available to assay 
for somatic inactivation of the wild type NTH1 allele. p.Q90X was screened for and 
found in a heterozygous state in two (out of 359) control samples. We identified five 
cases that harboured the previously reported splice site variant c.434+2 T>C in NEIL1 
(dbSNP reference rs5745908). Sequencing of the NEIL1 ORF in these cases failed to 
reveal any second mutations and fresh tissue samples were not available to 
determine the effect of this variant on RNA splicing. Eight out of 360 control samples 
were also found to be heterozygous for this variant.
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Table 4.1: Intronic and silent variants identified. 
Gene / 
location 
Nucleotide 
change 
Amino 
acid 
Minor allele 
freq. 
Reference 
OGG1     
IVS2 c.389-111 T>G - <1% - 
IVS3 c.5659 G>C - <1% - 
IVS3 c.566-4 G>A - 1% (Al-Tassan et al., 
2002) 
IVS4 c.748-15 C>G - 17% rs2072668 
3' UTR c.1038 + 279 A>G - 14% - 
     
NEIL1     
5' UTR c.1-50 C>G - <1% - 
IVS1 c.434+34 G>A - <1% - 
Exon 8 c.1071 G>A p.K357 <1% - 
IVS8 c.1103-17 G>T - <1% - 
IVS8 c.1103-45A>T - <1% - 
     
NEIL2     
Exon c.1+114 A>G p.Q38 <1% - 
IVS1 c.138+25 T>C - ND - 
IVS1 c.138+35 C>T - ND - 
IVS2 c.492-8C>T - <1% rs8191641 
IVS2 c.492-50 G>C - 3% rs8191640 
Exon 3 c.564 A>G p.P188 21% rs8191642 
IVS3 c.689-13 C>T - 22% rs8191663 
3' UTR c.999+21 C>T - 22% rs1534862 
3' UTR c.999+34 delC - 22% rs8191667 
     
NEIL3     
Exon 1 c.45 C>A p.R15 24% rs10013040 
5'UTR c.1-37 G>A - 4% - 
IVS1 c.157-18 A>G - 5% rs3792606 
IVS2 c.278+50 G>A - <1% - 
IVS5 c.627+13 A>T - 12% - 
IVS5 c.627+41 A>G - 42% rs2271102 
IVS6 c.701+34 del 7bp - 7% - 
Exon 6 c.756 T>C  18% rs17676249 
IVS7 c.869+9 T>C - 19% - 
IVS7 c.1040-85 T>D - 49% - 
IVS7 c.1040-107 A>G - <1% - 
IVS7 c.1080-181 A>G - <1% - 
Exon 8 c.1143 G>T p.R381 <1% rs2048074 
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Exon 8 c.1272 C>T p.V424 29% rs10007075 
IVS9 c.1636-73 A>G - 2% rs6820069 
     
MTH1     
IVS3 c.221+7 A>T -  - 
Exon 4 c.366 C>T p.D122  - 
Exon 5 c.426 C>T p.D142  rs1799832 
3' UTR c.540+32 C>T -  - 
     
NTH1     
IVS2 c.378+67 C>T -  rs2233519 
Exon 4 c.600 C>T p.Y200  - 
IVS5 c.939+30 C>T -  - 
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Table 4.2: Coding region SNP statistics. 
Gene / 
exon 
AA 
change 
Nucleotide 
change 
Type of 
Evolut1 
change 
Allele Freq in cases 
Freq in 
controls2 
P-
value3 
Reference / 
dbSNP4 A 
(110) 
B 
(106) 
C 
(52) 
OGG1               
1 p.R46Q c.137 G>A SC > C 1 0 1 3/1044 0.16 
(Kohno et al., 
1998)  
2 p.A85S c.253 G>T C > NC 0 1 0 7/688 0.75 
(Chevillard et 
al., 1998) 
5 p.A288V c.863 C>T C > NC 2 0 0 3/716 0.33 rs3219012 (1%) 
7 p.S326C c.977 T>C SC > NC 23 21 7 79/362 0.17 
(Shinmura et 
al., 1998)  
rs1052133 
(28%) 
7b p. I321T 
c.962 T>C 
Transcript 
2d 
NC >n/a 0 0 1 0/720 0.07 
 
          
NEIL1          
1 N/A c.434 +2 T>C n/a>n/a 1 2 5 8/720 0.13 rs5745908 (1%) 
4 p.P208S c.622 C>G SC > SC 1 0 0 0/624 0.15  
8 p.R339Q c.1016 G>A NC > NC 1 0 0 1/704 0.24  
          
NEIL2          
2 p.R103Q c.308 G>A SC > NC 2 2 0 7/649 0.31 rs8191613 (7%) 
2 p.R164T c.491 G>C SC > SC 1 0 0 0/710 0.13  
4 p.R257L c.770 G>T NC > NC 2 2 0 7/553 0.43  
          
NEIL3          
1 p.R38C c.112 C>T SC > NC 3 1 2 10/706 0.16  
3 p.P117R c.349 C>G NC > SC 8 19 3 75/724 0.01 rs7689099 (7%) 
     6/94* 60/524* 0.09*  
3 p.D132V c.395 AC>TG NC > SC 1 0 0 0/580 0.13  
4 p.Q172H c.516 G>C SC > SC 2 0 1 4/462 0.2 
rs17064658 
(4%) 
6 p.H286R c.857 A>G C > NC 22 17 7 113/724 0.07  
7 p.R315Q c.944 G>A SC > SC 0 1 0 2/586 0.38  
8 p.L443P c.1328 T>C NC > NC 23 28 13 185/726 0.03 
rs13112358 
(40%) 
8 p.H471Q c.1413 C>A SC > SC 20 23 10 154/718 0.67 rs13112390 
9 p.R520G c.1558 A>G NC > SC 0 4 1 18/622 0.29 rs1876268 (5%) 
10 P.A547S c.1639 G>T SC > SC 1 0 0 5/722 0.5  
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MTH1          
4 p.V106M c.316 G>A C > SC 1 1 0 6/718 0.62 
(Yoshimura et 
al., 2003) 
rs4866 (1%) 
5 p.K155I c.464 A>T SC > NC 0 1 0 2/702 0.34  
          
NTH1                 
2 p.Q90X c.268 C>T n/a >NC 0 1 0 2/718 0.34   
 
Allele frequencies of coding region sequence variants in OGG1, NEIL1, NEIL2, NEIL3, 
MTH1 and NTH1 in patients with multiple CRAs and controls. 
1Alignment of human (NP_002533; NP_078884; NP_659480; NP_060718; NP_002443), 
mouse (NP_035087; PAB28790; XP356749; NP_666320; NP_32663), Drosophila 
(NP_572499, OGG1 only), Arabidopsis (GI25349383; NP_564608; NP_849798; 
NP_565965), S. cerevisiae (NP_013651; S49801, OGG1 and NEIL2 only) and E. coli 
(NP_418092- formamidopyrimidine DNA glycosylase; NP_415242- endonuclease VIII; 
BAB33526 - 7,8-dihydro-8-oxoguanine-triphosphatase) OGG1, NEIL1, NEIL2, NEIL3 and 
MTH1 homologues was carried out using ClustalW (v.1.82). Residues were determined to 
be conserved (C), semi-conserved (SC) or non-conserved (NC) through evolution based 
on the retention of identical or similar amino acids in prokaryote, vertebrates or neither, 
respectively. The allele frequencies of each variant in patients with 3-10 CRAs (Group A - 
55 patients), 11-100 CRAs (Group B - 53 patients) and more than 100 CRAs (Group C - 26 
patients), is shown (over 95% of samples were successfully genotyped).  
2Variants were typed in British Caucasian control samples (supplied by ECACC); 
3P-values were determined for each cohort of patients vs. controls.  
4dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) reference numbers and published minor 
allele frequencies are shown.  
*The NEIL3 missense variant p.P117R was assayed in an independent cohort of Dutch 
patients with 11-100 CRAs and matched controls - no significant association was 
identified. AA, amino acid; n/a, not applicable.
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4.4 Discussion 
We have sought pathogenic mutations in six genes that function in concert 
with MUTYH to protect against oxidative DNA damage. Although it is difficult to 
ascertain the likely pathogenic effect of novel variants without performing functional 
assays, we have used three complimentary genetic approaches to help determine 
pathogenicity: (i) since MAP is an autosomal recessive disease and since five out of 
the six genes analysed function as BER glycosylases (like MUTYH), we sought biallelic 
mutations in MAP-like cases, (ii) we looked for the presence of both single and 
combinations of variants in normal control samples, and, (iii) we sought over-
representation of variants in cases versus control samples. No patients harboured 
clearly pathogenic biallelic sequence variants, nor was there evidence that any single 
variant was disease causing. Although we initially found that p.P117R in NEIL3 was 
over-represented in a sub-group of cases, this finding was not replicated in an 
independent cohort and became insignificant upon correcting for multiple testing 
and therefore probably represents a chance observation. Furthermore, despite 
finding CRA patients carrying the nonsense mutation p.Q90X in NTH1 and the splice 
site variant c.434+2 T> C in NEIL1, no biallelic mutations were identified in these 
cases and these variants were also identified in control samples suggesting that they 
are not associated with a CRA phenotype. Interestingly, p.Q90X lies in an N-terminal 
domain of NTH1 that is not present in the E. coli homolog endonuclease III (Aspinwall 
et al., 1997) and is closely followed by an in frame methionine at codon 102 that 
fulfils the criteria of a Kozak translation initiation signal (Pedersen and Nielsen, 
1997). Therefore, it is possible that partially truncated, but functional, NTH1 is 
produced from this allele. Indeed, Liu and Roy (Liu and Roy, 2002) have shown that 
truncation of this N-terminal domain of NTH1 actually stimulates its activity.  
Four rare missense variants were not identified in control samples although 
we found no supporting evidence for their pathogenicity: p.I321T (only present in a 
rare alternatively spliced transcript of OGG1) and p.D132V in NEIL3 are non-
conservative amino acid substitutions, and, p.P208S in NEIL1 and p.R164T in NEIL2 
are semi-conservative amino acid substitutions.  
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This study demonstrates that mutations of likely functional significance in 
OGG1, NEIL1, NEIL2, NEIL3, MTH1 and NTH1 are not common in patients with CRA 
and these findings support those of a smaller study (Sieber et al., 2003b), that failed 
to identify pathogenic mutations in OGG1 and MTH1 in patients with a similar 
phenotype. Not only do the substrate ranges of the BER glycosylases overlap, but the 
mismatch repair complex MSH2/MSH6, the CSB protein and BRCA1 and BRCA2 have 
all been implicated in the repair of 8-oxoG (reviewed (Cheadle and Sampson, 2003)). 
Further studies are therefore warranted to determine whether it is a specific, and as 
yet undetermined, facet of MUTYH function that underlies its apparently unique 
(amongst BER enzymes) association with CRA. 
Since the completion of this work in 2008 the OGG1 variant p.R46Q has been 
identified as a pathogenic mutation (Morak et al., 2011) affecting the last nucleotide 
of exon 1 and altering splicing in vitro. Morak did not find p.R46Q in 70 control 
samples however in our set of 1,044 it occurred with a 0.14% MAF leading us to 
assume it was benign.
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5 Chapter five 
 
Investigating sequence analysis software for high throughput variant 
detection and their application to study the ‘rare variant hypothesis’ of 
multifactorial inherited predisposition 
 
5.1 Introduction 
With the arrival of multi-capillary platforms and robust sequencing chemistry, 
the cost of a sequencing reaction is coming to level where single direction 
sequencing reads are an option for SNP discovery projects. However, the data 
production capacity of these systems has risen to a level where manual checking of 
chromatograms is often impractical. We aimed to evaluate four sequence analysis 
programs for automated identification of SNPs from ABI sequence data files. We 
used Sequencher (Gene Codes version 4.5), InSNP (Christian-Albrechts-University 
Kiel), Mutation Surveyor (SoftGenetics, version 3.0), and the Staden package (MRC 
LMB Cambridge, version 1.6) to search for inherited sequence variants in the APEX1, 
MBD4, MPG, NEIL3, NUDT5, PCNA, POL λ and TDG genes (a collection that was 
relevant to several on-going projects at the time) in 67 patients with multiple 
colorectal adenomas. In total, 64 PCR amplicons were designed to span the open 
reading frames of these 8 genes, and over 4,000 chromatograms were generated by 
ABI 3100 and ABI 3730 Genetic Analysers. 77 SNPs were identified by manual 
analysis of the chromatograms and this was considered the ‘gold-standard’ to which 
the software packages were compared.  
We also compared the performance of an optimised version of the Staden 
package (through Agencourt, Beckman Coulter) against manual assessment by 
Sequencher in another large scale variant detection project. We analysed a 2,555bp 
region of the adenomatous polyposis coli (APC) gene (encompassed by 6 PCR 
amplicons) in a large cohort of 969 healthy controls (a total of >5,800 .ab1 files).  
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It has been proposed that multiple rare variants in numerous genes 
collectively account for a substantial proportion of multifactorial inherited 
predisposition to a variety of diseases including CRAs. We have studied this 
hypothesis by comparing the frequency of rare inherited non-synonymous variants 
identified by sequence analyses of the β-catenin down-regulating domain of APC in 
patients who did not carry conventional pathogenic mutations in APC or MUTYH 
(‘non-FAP non-MAP patients’) as compared to healthy controls using In silico 
analyses to predict function. 
Data in this chapter was presented in the manuscript “Multiple rare 
nonsynonymous variants in the adenomatous polyposis coli gene predispose to 
colorectal adenomas” (Azzopardi et al., 2008) of which James Colley was an author 
who helped write the manuscript and as a consequence there are some overlaps in 
parts of the text. 
 
5.1.1 Sequencing as a tool for SNP-discovery 
Access to multi-capillary sequencers is now common place for many 
molecular biology groups. The platforms and chemistry are robust and the cost of a 
single sequencing reaction is relatively low. Sequencing is therefore likely to replace 
the more traditional techniques such as single-stranded conformational 
polymorphism analysis (1.2.1.2), denaturing gradient gel electrophoresis (1.2.1.1), 
chemical or enzymatic cleavage (1.2.2.1, 1.2.2.2) and dHPLC (1.2.2.3); all of these 
techniques identify samples that contain novel SNPs but DNA sequencing is required 
for subsequent characterisation. 
Where sequencing is chosen as the SNP Discovery method, the throughput 
demands of research and clinical diagnostic laboratories have meant that large 
amounts of data are generated very quickly making sequence analysis a significant 
bottleneck in the discovery process. A large proportion of time is spent manually 
checking each chromatogram by eye, a problem which can be reduced by relying on 
automated analysis to identify SNPs. Numerous software packages are available for 
the analysis of the raw data files generated by ABI sequencers, including the 
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commercially available Mutation Surveyor software (SoftGenetics) and the freely 
available Staden package (Medical Research Council Laboratory of Molecular 
Biology, Cambridge, UK). Both of these programmes can be set up to provide SNP 
reports based on automated calling but also provide a list of ‘potential SNPs’ for user 
review, and by focusing on these two sets of identified SNPs (and not the rest of the 
chromatogram), the amount of user time can be greatly reduced. In addition, 
Sequencher V4.6 (GeneCodes) has a SNP calling feature that calls a variant base 
which differs from the reference trace or consensus sequence and the stringency of 
this feature can be altered by the ‘Call Secondary Peak’ function. Here, we evaluated 
the utility of these three programs plus the freely available InSNP software 
(Manaster et al., 2005) (Christian-Albrechts-University Keil, Germany) to identify 
inherited variants in the APEX1, MBD4, MPG, NEIL3, NUDT5, PCNA, POL λ and TDG 
genes.  
 
5.1.2 The ‘rare variant hypothesis’ of multifactorial inherited predisposition 
In support of the ‘rare variant hypothesis’ of multifactorial inherited 
predisposition to common diseases (Fearnhead et al., 2005), it has recently been 
shown that rare non-synonymous variants in the genes encoding apolipoprotein A1, 
the adenosine triphosphate binding cassette transporter A1 and lecithin cholesterol 
acyltransferase, are over-represented in individuals with low plasma levels of high-
density lipoprotein cholesterol, a major risk factor for coronary atherosclerosis 
(Cohen et al., 2004). It is likely that rare non-synonymous variants in numerous 
genes also predispose to colorectal tumours since epidemiological studies predict 
that inherited factors play a role in 15-30% of colorectal cancers (CRCs), but only a 
minority of these can be accounted for by established CRC predisposition alleles 
(Fearnhead et al., 2005, Kinzler and Vogelstein, 1996). Germline truncating 
mutations in the APC gene cause familial adenomatous polyposis (FAP [MIM 
175100]), an autosomal dominant disorder characterised by hundreds or thousands 
of colorectal adenomas (CRA), some of which progress to cancer (Fearnhead et al., 
2001) and inherited mutations in the human MutY homologue (MUTYH) gene cause 
MUTYH-associated polyposis (MAP [MIM 608456]), an autosomal recessive disorder 
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with a multiple CRA and CRC phenotype (Al-Tassan et al., 2002, Sampson et al., 
2003). Whether rare inherited non-synonymous variants in APC might act as low 
penetrance alleles remains highly speculative; however, the variant p.I1307K has 
been shown to create a hypermutable tract that predisposes to somatic mutations 
(Laken et al., 1997) and p.E1317Q has been shown to be over-represented in the 
germline of patients with multiple CRAs (Lamlum et al., 2000) and has also been 
identified as a somatic change in sporadic CRC (Frayling et al., 1998). APC encodes a 
large protein which plays a role in signal transduction in the wnt-signalling pathway 
and it has been proposed that a specific level of β-catenin signalling, mediated by 
selection for APC genotypes that retain some 20 amino acid β-catenin down-
regulating repeats, is required for colorectal tumour formation (Albuquerque et al., 
2002). 
To address the potential role of rare non-synonymous variants of APC in 
inherited predisposition to CRAs, we sequenced and compared the frequency of 
these variants in the β-catenin down-regulating domain in 691 unrelated North 
American patients with CRAs and 969 matched healthy controls. We also assessed 
the performance of an optimised Staden package in these genomic analyses. 
 
5.2 Materials and Methods 
5.2.1 Samples 
To assess the four software packages DNA was extracted from the venous 
blood samples of 67 patients with multiple CRAs with or without cancer recruited 
from regional UK polyposis registers in Birmingham, Cambridge, Cardiff, Liverpool, 
Manchester, Southampton and Surrey 
 
5.2.2 PCR 
We analysed fragments spanning the coding region of APEX1 (Accession 
number NC_003076.4), MBD4 (NC_000003.10), MPG (NC_000016.8), NEIL3 
(NC_000004.10), NUDT5 (NC_000010.9, PCNA (NC_000020.9), POL λ (NC_000010.9) 
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and TDG (NC_000012.10). For NUDT5, the fragment covering exon 4 was not 
included due to poor amplification.  
Reaction and thermal cycling conditions are described in Section 2.4.2, 
primers and annealing temperatures for APEX1, MBD4, MPG, NEIL3, NUDT5, PCNA, 
POL λ and TDG genes are in Appendix D. 
 
5.2.3 Sequencing 
PCR products were purified as described in Section 2.4.3 and sequenced as 
described in Section 2.4.4. Purification of sequencing products was carried as 
described in Section 2.4.5. Mutations were described according to the established 
nomenclature system (Antonarakis, 1998). 
 
5.2.4 Base Calling 
All four programs used the base calls from the ABI software, so any call errors 
were carried through to the software analysis. Sequencher’s ‘call secondary peak’ 
function over rides the base calls and provides its own call. Mutation Surveyor has a 
similar function. Staden creates its own confidence calls for variant identification - if 
a variant has been missed by the ABI calling it will retain the wrong base call in the 
‘Contig view’ but it can still be highlighted by the software as a high or low 
confidence variant. Where the ABI base caller has introduced a false positive call, 
Staden does not necessarily highlight them for checking as it makes its own 
assessment. InSNP retains the ABI base calls throughout. To identify SNPs not called 
by the ABI software, it provides a SNP plot from which SNPs can be picked out by the 
user. 
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Table 5.1: PCR Primers. 
Primers for the APC β-catenin down regulation domain. 
Gene/primer 
name 
Primer Sequence (5' to 3') Product 
Size (bp) 
Annealing 
Temp. (ºC) 
APC 01 For CAGTGAGAATACGTCCACACC 513 60 
APC 01 Rev CTAAACATGAGTGGGGTCTCC   
APC 02 For TCAGCTGAAGATCCTGTGAGC 574 60 
APC 02 Rev GGCTGGATGAACAAGAAAATCC   
APC 03 For CTCCTCAAACAGCTCAAACC 564 60 
APC 03 Rev CATGCTTTTGGGGTTGCAACC   
APC 04 For TCTGCCATGCCAACAAAGTC 490 62 
APC 04 Rev TCACACGGAAAGGCTTGTGAC   
APC 05 For TACAGATGAGGCTCAAGGAG 598 60 
APC 05 Rev GGTAACTTTAGCCTCTGATTCC   
APC 06 For CATCATTACACGCCTATTGAAGG 667 60 
APC 06 Rev TGGGACTATGTTTTTCATTATCACC   
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5.2.5 Sequencher 
Manual - For a single fragment, all the .ab1 files were imported from the ‘File’ 
menu into a Sequencher file containing the consensus sequence of the gene. Using 
the ‘Contig’ menu, traces were aligned manually and poor sequence and trailing ‘N’s 
at the 3’ and 5’ ends were trimmed. All chromatograms were scanned by eye and 
variants recorded.  
Automated - The .ab1 trace files were imported into a Sequencher file, 
trimmed according to the default parameters and assembled automatically. The 
‘compare to function’ was used to compare the traces to a pre-determined reference 
trace using six increments from 90 to 15% (calls a SNP when the secondary peak 
height is 90-15% of that of the primary peak) and the resulting variance table was 
analysed. 
 
5.2.6 InSNP 
The PCR fragment consensus sequence was imported together with the PCR 
oligonucleotide sequences. The .ab1 trace files were imported according to their 
direction (the software requires forward and reverse reads to be imported 
separately). Traces were ‘aligned’ to the reference sequence and ‘sorted’ by quality. 
InSNP provides 4 relevant options for analysis; the ‘Find Indels’ and ‘Trim’ functions 
were carried out, ‘Filtered’ to remove the low quality sequence and ‘find SNPs’ to 
generate a list of variations. 
 
5.2.7 Staden 
Automated - .ab1 files were imported into preGap4 which recalls bases and 
assigns quality values, detects point mutations and assembles multiple reads into a 
Contig, the output of preGap4 is a database that is suitable to use as input into Gap4. 
Gap4 is the Contig editor of the Staden suite, within Gap4 a reference trace was 
selected for each analysis and a “Mutation Report” containing all information on 
potential variants was exported to a file.  
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Manual - In Gap4 file, for each analysis all highlighted loci were reviewed and 
edited before the new Mutation Report was exported. This review included the user 
making an informed decision regarding low quality SNPs, this helped to identify 
indels that were incorrectly named or over looked in the mutation report. 
 
5.2.8 Mutation Surveyor 
The GenBank reference sequence was imported into the software together 
with the .ab1 trace files. The ‘R>S’ button was used to compare all files to each other 
and the ‘import’ function was selected to start the analysis. All variants (high and low 
confidence) were reviewed before the SNP report was exported. 
 
5.2.9 Analysis of the APC β-catenin down-regulating domain 
5.2.9.1 Sequencing and Staden-based analysis of healthy controls 
We sought sequence variants in 969 unrelated North American healthy 
controls that were matched to the unrelated North American non-FAP non-MAP 
patients (Table 5.2) for age (mean 41.6yrs for controls and 47.8yrs for patients), sex 
(~50% males/50% females in both groups) and self-reported ethnic backgrounds 
(data not shown). All control samples were anonymised. Peripheral blood DNA 
samples from healthy controls were sequenced over a ~2.5kb region of APC spanning 
the β-catenin down-regulating domain by Agencourt Biosciences using 6 overlapping 
PCR fragments (Table 5.1). 
Agencourt analysis was performed using an optimised version of the Staden 
package (details of the optimisation would not be disclosed) and compared to our 
manual analyses using Sequencher. 
 
5.2.9.2 Mutation detection of cases with CRAs 
Myriad Genetics undertook comprehensive mutation analysis of the APC and 
MUTYH genes in 691 unrelated North American patients that were referred by their 
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physicians for genetic testing because of a clinical diagnoses of either FAP or 
“multiple” colorectal polyps. Peripheral blood DNA samples from all patients were 
sequenced for the entire ORF and splice sites of APC and exons 7 and 13 of MUTYH 
(which harbour the two common MUTYH mutations, (Sampson et al., 2005)) and 
screened for deletions at the APC locus by MLPA and by Southern blot analysis 
(Eliason et al., 2005). Samples with a single MUTYH mutation were then sequenced 
for the ORF and splice sites of MUTYH to identify biallelic mutations. Comparisons of 
numbers of patients versus controls harbouring variants were performed using 
either the Chi-squared test or Fisher’s Exact test. 
 
5.2.9.3 In silico analyses 
Predictions using Polyphen, were based on Homo Sapiens APC and 
predictions using Align-GVGD, were based on a multiple sequence alignment 
(created using using t-coffee) of APC orthologues from Homo Sapiens, Echinops 
Telfairi, Pan Troglodytes, Macaca Mulatta, Oryctolagus Cuniculus, Bos Taurus, 
Xenopus Tropicalis, Monodelphis Domestica, Rattus Norvegicus, Mus Musculus, 
Dasypus Novemcinctus and Loxodonta Africans. 
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Table 5.2: Ethnicity. 
Self-reported ethnic backgrounds of the patients and healthy controls from North 
America. 
 Non_FAP Non-
MAP patients 
Healthy 
controls 
African 5% 5% 
Ashkenazi 4% 4% 
Asian 2% 2% 
Caucasian 61% 61% 
Latin American 4% 4% 
Native American 2% 2% 
Near Eastern 1% 1% 
None Specified 15% 15% 
Other 5% 5% 
 
  
 
111 
 
5.2.10 Author’s Contribution 
 
Figure 5.1: Author’s Contribution to Chapter 5. 
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5.3 Results 
5.3.1 Evaluating software for automated variant detection 
We sought germline variants in 67 patients with multiple CRAs with or 
without carcinoma by sequencing the ORFs of APEX1, MBD4, MPG, NEIL3, NUDT5, 
PCNA, POL λ and TDG. In total, 64 fragments were amplified and sequenced, which 
generated 4,046 out of a potential 4,288 chromatograms. 242 (5.6%) 
chromatograms were unavailable due to PCR failures or insufficient DNA. Each 
chromatogram was analysed using four different variant detection programs 
(Sequencher, InSNP, Staden and Mutation Surveyor), each with a variety of 
sensitivity settings to generated 14 data sets for analysis. In total therefore, 56,644 
analyses were carried out.  
A manual analysis of the sequencing traces observed using Sequencher (used 
solely as a chromatogram viewer), was considered the ‘gold-standard’ and a 
reference for the subsequent analyses of the four software packages. In total, 77 
SNPs were identified, 41 of which had MAFs <5% and 36 had MAFs >5%, thereby 
generating 878 samples with genotype calls heterozygous or homozygous for the 
rare allele. 
 
5.3.2 Sequencher 
We analysed the sensitivity of Sequencher for variant detection using the 
automated function together with six increments (from 90 to 15%) of the ‘Call 
Secondary Peak’ function. Using the automated function, 58/77 (75.3%) SNPs (Table 
5.3, Figure 5.2) and 626/878 (71.3%) genotypes (Table 5.4, Figure 5.3) were called 
correctly, but with 3,944 false positives (Table 5.5, Figure 5.4). 19 SNPs were not 
identified accounting for 73 of the missing genotypes. By reducing the ‘Call 
Secondary Peak’ function from 90% to 15%, we increased the detection rate of SNPs 
from 54/77 (70.1%) to 67/77 (87.0%) and the correct genotype calls from 464/878 
(52.8%) to 748/878 (85.2%), but at the expense of significantly increasing the 
number of false positives (from 4,450 to 44,903). 
113 
 
5.3.3 InSNP 
Under the automated analyses, we identified 26/77 (33.8%) SNPs. Upon 
manual review of the ‘Sequence Frequency’ chart, a further 25 SNPs were identified, 
thus allowing the correct identification of 51/77 (66.2%) SNPs and 594/878 (67.7%) 
genotypes, together with 4,249 false positives. In total, 26 SNPs were missed 
accounting for 134 missing genotypes. 
 
5.3.4 Staden 
The automated output correctly identified 70/77 (90.9%) SNPs and 752/878 
(85.6%) genotypes. User review identified a further 6 SNPs, generating a total of 
76/77 (98.7%) correctly called SNPs and 849/878 (96.7%) genotypes with 818 false 
positives. One SNP was not identified accounting for 28 of the missing genotypes. 
 
5.3.5 Mutation Surveyor 
73/77 (94.8%) SNPs were correctly identified as ‘high confidence’ (blue) with 
817/878 (93.1%) correctly called genotypes and 1,130 false positives. Three 
additional SNPs were identified as low confidence calls (red) together with 55/878 
(6.3%) correctly called genotypes and 1,838 false positives. By combining these data, 
we identified 76/77 (98.7%) SNPs and correctly called 872/878 (99.3%) genotypes, 
together with 2,968 false positives. 
 
5.3.6 Time Analyses 
The average time taken to complete the manual analysis of 67 samples for a 
single amplicon was 15.4 minutes (range of 6-32 minutes depending on the number 
of variants that had to be recorded, Figure 5.5). On average, 3.3 minutes was taken 
for Sequencher under the automated setting which included data import, auto trim 
and auto assembly plus generation, review and exporting of the SNP Report. In 11 
fragments, common polymorphisms were missed by the software but were detected 
by the manual review of the variation plot - in these cases the time taken 
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significantly increased as the names of the samples showing variation were recorded 
manually. InSNP provided a very fast analysis with data entry, analysis and output of 
a mutation report taking on average 1.3 minutes to perform. However, the reliability 
of SNP calling was acutely affected by the sequence quality - anything but high 
quality data caused significant analysis problems. The first stage of the Staden 
analysis procedure (Pregap4 and Gap4) took 2 minutes to perform. The average time 
taken for fragment analysis of the mutation report was 6.7 minutes including a 
manual review of all highlighted SNPs (high and low confidence calls); this package 
was not capable of fully automated SNP detection. Data entry, analysis and output of 
a mutation report in Mutation Surveyor took on average 10.8 minutes to perform. 
 
5.3.7 An analysis of an optimised version of Staden for the identification of non-
synonymous variants in the β-catenin down-regulating domain of APC 
Using a re-sequencing approach, we sought rare non-synonymous variants in 
the ~2.5kb β-catenin down-regulating domain of APC in 969 unrelated North 
American healthy controls (Section 5.2.9). Sequencing was carried out by Agencourt 
using 6 PCR fragments and 5,814 .ab1 files were analysed by two methods. 
Agencourt used an optimised version of the Staden package and we used a manual, 
Sequencher-based, analysis. 
In total, eighteen different rare (MAFs <2%) non-synonymous variants were 
identified in the β-catenin down-regulating domain in 37 healthy controls using both 
the Staden and manual Sequencher analyses (100% concordance). Thirty-six controls 
carried single heterozygous variants and one carried three heterozygous variants 
(p.T1633K, p.T1655A and N1761T) (Table 5.8, Figure 5.6). Five out of eighteen of 
these non-synonymous variants (p.I1307K, p.E1317Q, p.M1413V, p.K1454E and 
p.R1676G) were also identified in the patient cohort (details below), whereas the 
remaining thirteen variants were unique to the control group. 
In total, five common polymorphisms (MAFs >5%) were identified in the β-
catenin down-regulating domain using both the Staden and manual Sequencher 
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analyses. The genotype concordance rate was 100% (2,958/2,958 genotypes were 
identified correctly by both analyses). 
 
5.3.8 Identification of non-synonymous APC variants in cases with CRAs 
Myriad Genetics identified truncating mutations of APC in 178 patients and 
biallelic mutations of MUTYH in 33, confirming FAP and MAP, respectively. These 
patients with conventional CRA-predisposition alleles were excluded from the 
subsequent analyses. Amongst the 480 non-FAP non-MAP patients, 15.4% had ≤10 
CRAs, 33.5% had 11-99 CRAs, 9.2% had ≥100 CRAs and 41.9% had ‘multiple CRA, 
number unknown’, as recorded at colonoscopy or colectomy. 
In total, 81 of the 480 (16.9%) patients without FAP or MAP carried rare non-
synonymous variants in the APC ORF. When non-FAP non-MAP patients were 
classified according to the number of CRAs, the group with 11-99 CRAs had a higher 
frequency of rare non-synonymous variants (18.6% of patients) as compared to the 
groups with ≤10 CRAs (13.5% of patients) or ≥100 CRAs (13.6% of patients) (Table 
5.6). 
 
5.3.9 Comparison of rare non-synonymous variants in the β-catenin down-
regulating domain in non-FAP non-MAP cases versus controls 
We found that significantly more non-FAP non-MAP patients carried rare 
non-synonymous variants in the β-catenin down-regulating domain as compared to 
the healthy controls (32/480 vs. 37/969, 2=5.74, P=0.0166) and this over-
representation was highest in the non-FAP non-MAP patients with 11-99 CRAs 
(13/161 vs. 37/969, 2=5.914, P=0.015) (Table 5.6). In terms of individual variants, 
we did not observe an over-representation of p.I1307K in the non-FAP non-MAP 
patients versus controls (6/480 vs. 9/969, respectively). However, we did find that 
significantly more non-FAP non-MAP patients carried p.E1317Q as compared to 
healthy controls (13/480 vs. 11/969, 2=4.88, P=0.0272), although even when this 
variant was excluded from the analyses, significantly more non-FAP non-MAP 
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patients with 11-99 CRAs carried other rare non-synonymous variants in the β-
catenin down-regulating domain as compared to controls (9/161 vs. 26/969, 
2=3.887, P=0.0487). These data suggest that a proportion of non-synonymous 
variants in the β-catenin down-regulating domain of APC are likely to alter β-catenin 
signalling to promote tumourigenesis. 
In contrast, the frequencies of rare synonymous variants in this region and 
common polymorphisms were almost identical between the non-FAP non-MAP 
patients and controls (Table 5.7). Both groups of patients also had similar self-
reported ethnic backgrounds so it was highly unlikely that these findings could be 
attributed to population stratification. 
 
5.3.10 In silico predictions of likely pathogenicity of APC SNPs 
Non-synonymous variants could interfere with APC’s roles in β-catenin 
degradation, mediation of intercellular adhesion, stabilization of the cytoskeleton, 
chromosome stability or regulation of the cell cycle and apoptosis (Al-Tassan et al., 
2002, Fodde et al., 2001). We used the programs PolyPhen and Align-Grantham 
Variation/Grantham Deviation (Align-GVGD) (Mathe et al., 2006, Ng and Henikoff, 
2006) to help predict the functional consequences of all 18 different non-
synonymous variants that we identified in APC. In silico analyses using PolyPhen 
predicted that 9 non-synonymous variants were likely to be damaging whereas Align-
GVGD predicted that 6 variants, 4 of which were also called ‘damaging’ by PolyPhen, 
were likely to alter function (Table 5.8). Together, these analyses predicted that 
11/18 (61%) non-synonymous variants were likely to alter function. 
 
5.4 Discussion 
5.4.1 Comparison of Sequencher, Staden, InSNP and Mutation Surveyor for (semi-
) automated variant detection 
Here, we showed that Staden and Mutation Surveyor performed extremely 
well and correctly identified 76/77 (98.7%) SNPs and 96.7% and 99.3% of the 
genotypes, respectively. Both packages failed to identify a single SNP (c.444T>G, 
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p.D148E in APEX1); however this variant was in a region of poor signal intensity, but 
was accurately called by manual analysis (Figure 5.7). This illustrates the necessity of 
having high quality sequence data for accurate (semi-) automated mutation 
detection. Both of these packages also failed to fully genotype a SNP corresponding 
to c.117-32 delCAACA in POLλ. This variant occurs at the 5’ end of the exon 2 PCR 
product. Staden assessed some of these fragment to be poor sequence (as opposed 
to ‘heterozygous indels’) and removed a region of good sequence (approximately 20-
25 bases, with only 2 to 5 of these bases having a confidence value over 40) from the 
analysis. Mutation Surveyor detected this SNP but only in its heterozygous state and 
homozygotes were missed - the sequences 3’ to the deletion were aligned correctly 
but the 5’ sequences were misaligned and treated as poor sequence, and hence the 
gap was not identified. The relatively low specificity of Mutation Surveyor meant 
that 2,968 false positives were generated and needed to be checked manually 
causing the time taken for analysis to be the second longest. Staden, on the other 
hand, generated only 818 false positives. 
 
5.4.2 Assessment of an optimised Staden package for variant detection in a large 
cohort of healthy controls 
We have assessed an optimised Staden package for the analysis of >5,800 
ab1 chromatograms generated from Sanger sequencing of 6 PCR amplicons 
(spanning 2,555bp) in 969 healthy controls. Staden and manual Sequencher analyses 
correctly identified 18 nonsynonymous variants, 11 synonymous variants and 5 
common polymorphisms within this region and correctly genotyped 3,428/3,428 
(100%) variant samples. We conclude that this optimised Staden package offers 
extremely high performance in a large scale variant detection project. 
 
5.4.3 Role of non-synonymous variants in colorectal tumourigenesis 
The role of non-synonymous mutation in APC is not clear with various 
publications supporting (Frayling et al., 1998, Gryfe et al., 1999, Hahnloser et al., 
2003, Laken et al., 1997, Lamlum et al., 2000) and opposing (Gismondi et al., 2002, 
Popat et al., 2000, Sieber et al., 2003a) the claims the p.E1317q an p.I1317Q 
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predispose to CRA. In our population we found that significantly more non-FAP non-
MAP patients with CRAs carry p.E1317Q compared to controls, suggesting a role for 
this variant in predisposing to CRA, we did not find an over-representation of 
p.I1307K. Notably our study found that significantly more non-FAP non-MAP patients 
carried a variety of rare non-synonymous variants, even when p.E1317Q was 
excluded from the analysis indicating that numerous rare variants in APC act as low 
penetrance disease alleles. 
Recent studies (Fearnhead et al., 2004) have reported that rare variants in 
the Wnt signalling genes AXIN1 and CTNNB1 and the mismatch repair genes hMLH1 
and hMSH2 along with p.E1317Q in APC, are over-represented in patients with 
multiple CRAs. Here, we present genetic and in silico data that show rare, inherited 
non-synonymous variants in APC also play a significant role in inherited 
predisposition to CRA. In support of this, further work from our laboratory (by Dr 
Azzopardi and Dr Dallosso) has shown that seven out of sixteen non-synonymous 
variants (43.8%) showed a significantly reduced ability to suppress β-catenin-
regulated transcription in vitro, and both p.I1307K and p.E1317Q were found to be 
functionally compromised (Azzopardi et al., 2008). Further characterisation of these 
and other low penetrance alleles should therefore help contribute to our 
understanding of CRA and CRC-predisposition. 
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Table 5.3: SNP identification. 
Number of SNPs correctly identified by each software package (Figure 5.2). 
  Sequencher InSNP Staden Surveyor 
GENE Manual Auto 90% 75% 60% 45% 30% 15% Auto Manual Default Edited Blue Red 
APE1 4 2 1 3 3 3 3 3 1 2 4 4 4 4 
MBD4 7 6 3 4 6 6 6 6 0 5 7 7 6 7 
MPG 7 2 3 3 4 4 5 5 0 2 6 7 6 6 
NUDT5 7 5 4 5 5 5 5 5 1 2 7 7 6 7 
PCNA 5 5 5 5 5 5 5 5 3 4 5 5 5 5 
POLL 11 10 9 9 10 10 10 10 0 6 10 10 11 11 
TDG 15 8 9 10 11 13 13 13 5 9 12 15 15 15 
NEIL3 21 20 20 20 20 20 20 20 16 21 19 21 20 21 
Total 77 58 54 59 64 66 67 67 26 51 70 76 73 76 
 
‘Sequencher Manual’ gives the number of variant genotypes correctly identified using a manual review of the traces (the ‘gold-standard’). 
‘Sequencher Auto’ gives the number of correct variant genotypes identified by the “Compare to, Reference” function. ‘90%’ refers to those 
identified by adjusting the “Call Secondary Peak” function to 90% (likewise 75%, 60%, 45%, 30% and 15%). InSNP ‘Auto’ gives the numbers of 
correct variant genotypes identified in the InSNP report without any manual intervention. ‘InSNP Manual’ gives the number of correct variant 
genotypes identified by manual inspection of the base comparison images. ‘Staden Default’ gives the number of correct variant genotypes 
identified in the mutation report, ‘Edited’ are those added following a manual review of the putative SNPs. Surveyor Blue are the high 
confidence SNPs and Red are low confidence SNPs. 
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Table 5.4: Genotype identification. 
Number of genotypes correctly identified by each software package (Figure 5.3). 
  Sequencher InSNP Staden Surveyor 
GENE Manual Auto 90% 75% 60% 45% 30% 15% Auto Manual Default Edited Blue Red 
APE1 9 5 3 5 8 8 8 8 3 4 9 9 9 9 
MBD4 35 20 6 11 20 20 20 20 0 19 32 35 24 35 
MPG 16 4 7 7 8 8 10 10 0 3 11 16 11 16 
NUDT5 64 61 29 47 60 61 61 60 41 57 64 64 62 64 
PCNA 70 18 32 47 47 51 61 61 11 24 56 70 58 70 
POLL 204 135 105 126 133 135 144 153 0 102 174 176 191 198 
TDG 149 106 128 135 144 147 147 147 93 112 109 149 149 149 
NEIL3 331 277 154 223 252 288 291 289 249 273 297 330 313 331 
Total 878 626 464 601 672 718 742 748 397 594 752 849 817 872 
 
‘Sequencher Manual’ gives the number of variant genotypes correctly identified using a manual review of the traces (the ‘gold-standard’). 
‘Sequencher Auto’ gives the number of correct variant genotypes identified by the “Compare to, Reference” function. ‘90%’ refers to those 
identified by adjusting the “Call Secondary Peak” function to 90% (likewise 75%, 60%, 45%, 30% and 15%). InSNP ‘Auto’ gives the numbers of 
correct variant genotypes identified in the InSNP report without any manual intervention. ‘InSNP Manual’ gives the number of correct variant 
genotypes identified by manual inspection of the base comparison images. ‘Staden Default’ gives the number of correct variant genotypes 
identified in the mutation report, ‘Edited’ are those added following a manual review of the putative SNPs. Surveyor Blue are the high 
confidence SNPs and Red are low confidence SNPs. 
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Table 5.5: False Positives identified. 
False Positives identified by each software package (Figure 5.4). 
  Sequencher InSNP Staden Surveyor 
GENE Manual Auto 90% 75% 60% 45% 30% 15% Auto   Blue Red 
APE1 0 372 560 609 782 1,104 2,572 12,101 326 39 40 95 
MBD4 0 332 140 147 159 229 849 8,035 1,092 15 84 234 
MPG 0 285 482 533 621 741 963 1,957 401 50 87 212 
NUDT5 0 65 91 80 78 93 150 2,747 300 59 63 118 
PCNA 0 538 670 693 729 768 928 2,256 69 43 93 148 
POLL 0 153 151 124 138 177 476 4,818 441 71 302 832 
TDG 0 1,258 1,344 1,400 1,466 1,759 2,472 7,508 1,129 26 108 166 
NEIL3 0 941 1,012 1,093 1,274 1,562 2,400 5,481 491 515 353 1,163 
Total 0 3,944 4,450 4,679 5,247 6,433 10,810 44,903 4,249 818 1,130 2,968 
 
‘Sequencher Manual’ gives the number of variant genotypes correctly identified using a manual review of the traces (the ‘gold-standard’). 
‘Sequencher Auto’ gives the number of correct variant genotypes identified by the “Compare to, Reference” function. ‘90%’ refers to those 
identified by adjusting the “Call Secondary Peak” function to 90% (likewise 75%, 60%, 45%, 30% and 15%). InSNP ‘Auto’ gives the numbers of 
correct variant genotypes identified in the InSNP report without any manual intervention. ‘InSNP Manual’ gives the number of correct variant 
genotypes identified by manual inspection of the base comparison images. ‘Staden Default’ gives the number of correct variant genotypes 
identified in the mutation report, ‘Edited’ are those added following a manual review of the putative SNPs. Surveyor Blue are the high 
confidence SNPs and Red are low confidence SNPs. 
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Figure 5.2: SNP Count. 
Number of SNPs identified by the software packages under various sensitivity 
settings (Table 5.3). Shown are manual, automatic and ‘Call Secondary Peak’ 
increments for Sequencher (Seq.); automatic, manual and combined for InSNP; and 
high and low confidence calls plus a combined result for both. 
 
 
Figure 5.3: Genotypes. 
Number of correct genotypes identified using the different programmes (Table 5.4).  
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Figure 5.4: False Positives identified. 
Number of false positives identified using the different programmes (Table 5.5) 
 
 
Figure 5.5: Analysis Times.  
Average time taken (in minutes) to analyse a single exon for 67 samples for each 
programme. 
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Table 5.6: APC SNPs in Non-FAP non-MAP patients. 
Inherited non-synonymous variants spanning the APC ORF in 480 non-FAP non-MAP 
North American patients with CRAs (classified according to number of adenomas) 
and in the β-catenin down-regulating domain in 969 North American healthy 
controls. 
Category Non-synonymous variants Total (and frequency) 
SNPs in bold lie within the β-catenin down-regulating domain 
non-FAP non-MAP patients (spanning the entire APC ORF) 
≤10 CRAs p.P981R, p.I1307K (2), p.E1317Q (2), p.T1445A, 
p.G2502S, p.R2505Q, p.N2593S, p.S2621C 
10/74 (13.5%) 
11-99 CRAs p.R216Q, p.P981R, p.V1125A, p.L1129S, 
p.T1160K, p.I1307K (3), p.E1317Q (4), 
p.V1352A, p.M1413V, p.C1578G, p.I1579V, 
p.D1714N, p.G1921S, p.P2158R, p.H2232D, 
p.A2274V, p.G2502S (5), p.R2505Q, p.I2573V, 
p.S2621C, p.A2795T 
30/161 (18.6%) 
≥100 CRAs p.K150R, p.S643P, p.R653K, p.G2502S (3) 6/44 (13.6%) 
Multiple 
CRAs, 
number 
unknown 
p.K150R, p.E538V, p.P870S, p.C947S, 
p.P870S+p.M949I, p.L1129S, p.T1160K, 
p.I1307K, p.E1317Q (7), p.A1446T, p.K1454E, 
p.P1467S, p.A1474T, p.I1572T, p.P1934L, 
p.R2066G, p.I2329V, p.G2502S (10), p.I2541V, 
p.I2756V 
35/201 (17.4%) 
Total 81/480 (16.9%) 
 
32/480 (6.7%)* in the β-
catenin down-regulating 
domain 
 
Healthy controls (β-catenin down-regulating domain) 
 p.A1247T, p.I1307K (9), p.E1317Q (11), 
p.K1363I, p.M1413V (3), p.K1454E (2), 
p.P1458S, p.T1493M, p.P1584S, R1589G, 
p.R1589C, p.T1633K+p.T1655A+p.N1761T, 
p.R1676G, p.S1730F, p.Q1916K, p.I1975F 
37/969 (3.8%)* 
*2=5.74, P=0.0166 
 
In total, 54 different rare non-synonymous variants in APC were identified in this 
study. Each non-synonymous variant was identified in a single patient/control within 
each group unless otherwise indicated in parentheses. 
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Table 5.7: Frequency of rare synonymous variants in patients and healthy controls. 
Eleven different rare synonymous variants were found spanning the β-catenin down-
regulating domain in 55 (5.7%) healthy controls. 
 
 non-FAP non-
MAP patients 
Healthy 
controls 
β-catenin down-regulating 
domain 
6.0% 5.7% 
 
 
Table 5.8: In silico predictions. 
In silico predictions of the likely functional consequences of the non-synonymous 
variants identified in APC. 
Non-synonymous 
variant 
PolyPhen prediction Align-GVGD prediction 
p.A1247T benign neutral 1 
p.I1307K possibly damaging neutral 2 
p.E1317Q benign neutral 1 
p.K1363I probably damaging deleterious 1 
p.M1413V possibly damaging deleterious 2 
p.K1454E benign deleterious 2 
p.P1458S benign neutral 2 
p.T1493M possibly damaging deleterious 1 
p.P1584S probably damaging deleterious 1 
p.R1589G probably damaging neutral 2 
p.R1589C benign neutral 2 
p.T1633K possibly damaging neutral 1 
p.T1655A benign deleterious 2 
p.R1676G benign neutral 1 
p.S1730F possibly damaging neutral 1 
p.N1761T possibly damaging unclassified 
p.Q1916K benign neutral 2 
p.I1975F benign unclassified 
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Figure 5.6: APC β-catenin down-regulating domain SNPs. 
Distribution of inherited APC non-synonymous variants in 480 non-FAP non-MAP 
patients with CRAs and in 969 healthy controls (spanning the β-catenin down-
regulating domain). 36 patients carried a single variant and 1 patienta carried three 
variants. Functional domains are coloured: ■ oligomerisation domain (codons 6-57), 
■ armadillo region (codons 453-767), ■ 15 amino acid repeat β-catenin binding 
domain (codons 1020-1169), ■ 20 amino acid repeat β-catenin down-regulating 
domain (codons 1262-2033), ■ SAMP repeats/axin binding domain (codons 1562-
2056), ■ basic domain (codons 2200-2400), ■ EB1 binding domain (codons 2559-
2771), and, ■ HDLG binding domain (codons 2771-2843) (domains not drawn to 
scale). Non-synonymous variants are plotted as stars, coloured according to the 
domains in which they lie (black stars denote non-synonymous variants that do not 
lie within known functional domains). 
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Figure 5.7: APEX1 p.D148E. 
The variant c.444T>G, p.D148E in APEX1 occured in a region of poor quality 
sequence. The left hand side shows the defualt view, the right hand side has been 
enhanced. Only manual analysis was able to identfy this variant. 
XXXX XXXX 
 
XXXX XXXX 
 
yXXX 
 
XXXX XXXX 
 
XXXX XXXX 
 
XXXX XXXX 
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6 Chapter six 
 
Identification and characterisation of common nonsynonymous 
variants in every DNA repair gene in the human genome 
 
6.1 Introduction 
The ever increasing pool of on-line SNP data means that ‘in house’ laboratory 
analyses may be unnecessary when identifying common variations. Though 
numerous databases exist (1000Genomes, HapMap, Ensembl, GeneSNPs, CGAP, 
MutationDiscovery.com), the majority refer to the dbSNP ‘refSNP cluster ID number’ 
(rs) number as the definitive identifier. dbSNP is a central repository for genetic 
variation covering an array of species which is only limited by the data that is 
submitted (Sherry et al., 2001). The database was established in 1998 and all 
laboratories are encouraged to contribute their own data. Despite the name, the 
database is not exclusive to SNPs as it also contains entries for variations such as 
indels and microsatellite markers, but the majority of records do refer to SNPs as 
they are the most common source of genetic variation. SNPs are considered to be 
validated within dbSNP if they fulfil any one of five criteria: (i) it has been submitted 
more than once by independent investigators, (ii) it has been submitted with 
genotype data showing the minor allele in at least two chromosomes, (iii) it has been 
confirmed as validated by the submitter, (iv) all alleles have been observed in at least 
two chromosomes each, or, (v) it has been genotyped by HapMap. 
 
6.1.1 Utility of dbSNP (build 129) as a resource for common ORF variation 
In 2003, Carlson et al.(2003) showed that build 104 of dbSNP was not 
sufficient to create a panel of SNPs for whole genome association studies despite 
containing information on 2.7 million human SNPs. However, there has since been 
an explosion of data deposited into this database. Build 127 (March 2007) of dbSNP 
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contained nearly 12 million human SNPs, 5.7 million (47.5%) of which had been 
validated and build 129 contained 18 million human SNPs, 7 million (41.7%) of which 
had been validated (Figure 6.1). Between builds 130 and 131 the number of human 
SNPs more than doubled for validated and un-validated entries largely due to the 
submission of SNPs from a number of samples which have undergone whole genome 
sequencing (i.e. the Watson and Venter genomes). The current build of dbSNP at the 
time of writing (build 132, April 2011) contains information on nearly 20 million 
validated human SNPs. Here, we evaluated the data held in dbSNP for common 
variants in the Caucasian population within the open reading frames of ten DNA 
repair genes. 
 
6.1.2 Automated searching of dbSNP 
Manually mining SNPs from dbSNP is a laborious process with each SNP page 
requiring individual scrutiny to identify frequency information for specific 
populations. Several programmes have been designed to automate this process 
(PolyMAPr, SNPselector, SNPper, SNPHunter, and Pupasuite); however, all of these 
have significant pitfalls. PolyMAPr (Freimuth et al., 2005) was unavailable at the time 
of analysis, SNPselector (Xu et al., 2005) used only dbSNP v126, SNPper (Riva and 
Kohane, 2002) and SNP Hunter (Wang et al., 2005) were limited to the analysis of a 
single gene at a time and Pupasuite (Conde et al., 2005) returned only a limited 
amount of frequency data in ‘single gene mode’ and none for the ‘gene lists’ mode. 
We therefore designed our own software to extract selected information from the 
database in an automated fashion. 
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Figure 6.1: Human SNPs in dbSNP from build 106 to the present build (135). 
Since July 2009 there has been a sudden and profound increase in both the number 
of validated and un-validated SNPs in the dbSNP database. 
The process that determines the validated SNPs in build 134 was affected by a 
software bug (communicated by e-mail) so the data point is not plotted here, data 
points for build 133 to 135 have been joined with a dotted line. 
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6.1.3 Creating a functional resource 
Damage to DNA is caused during replication, by environmental and dietary 
mutagens and by endogenous products of intercellular processes. Lodish et. al. 
(2000) estimated that up to a million lesions could occur per cell per day. As a 
consequence, the human genome is constantly undergoing repair and cells have 
developed several repair mechanisms to deal with the different forms of damage 
that may occur. Although it is well documented that rare high penetrance mutations 
in many of the genes from different DNA repair pathways predispose to cancers (e.g. 
BRCA1, BRCA2, MUTYH, PMS2, XPC.) the role of common nonsynonymous variants in 
these genes and their functional consequences are unclear. This is primarily due to a 
lack of sensitivity of the currently available DNA repair assays and a lack of 
appropriately profiled cell lines on which the assays can then be performed. Here, 
we aimed to profile 480 normal human lymphoblastoid cell lines for every common 
nonsynonymous SNP in every DNA repair gene in the human genome and to provide 
this resource free of charge to researchers to facilitate their functional analyses. We 
have also carried out in silico assessments of the likely functional consequences of 
these SNPs. 
 
6.2 Materials and Methods 
6.2.1 PCR 
Reaction and thermal cycling conditions are described in Section 2.4.2, 
primers and annealing temperatures are in Appendix E. 
 
6.2.2 Initial assessment of dbSNP 
SNPs were initially sought in dbSNP with frequency information in the 
Caucasian population in a total of ten genes - ERCC5 (Accession number 
NC_000013.9), XPA (Accession number NC_000009.10), XPC (Accession number 
NC_000003.10), RPA1 (Accession number NC_000017.9), RPA2 (Accession number 
NC_000001.9), GTF2H1 (Accession number NC_000011.8), GTF2H2 (Accession 
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number NC_000005.8), GTF2H3 (Accession number NC_000012.10), GTF2H4 and 
GTF2H5 (Accession number NC_000006.10). We selected the ‘Gene Model’ and also 
BLAST aligned exons to dbSNP. In addition, we sequenced PCR fragments spanning 
the coding region of these ten genes in 23 Caucasian DNA samples from healthy 
controls, purchased from ECACC (Porton Down, Salisbury). SNPs were identified 
using the Mutation Surveyor package as described in Chapter 5 and described 
according to the established nomenclature system (Antonarakis, 1998). 
 
6.2.3 Development of novel software to search dbSNP  
We used the method of ‘stripping’ in which the source code for each html 
SNP page was filtered and processed to provide only the data that we specified. In 
this way any search returns the most recent data and a user can chose to rapidly 
repeat the process for subsequent builds if necessary. GeneID was found to be the 
only reliable method of searching dbSNP for two reasons; firstly, it limits the results 
instantly to human genes and secondly, searching by Gene names will return coding 
SNPs from a gene that shares the gene region but are actually intronic for the 
searched gene. Our PYTHON script was built to adhere to the dbSNP rules concerning 
automated query submission namely that individual queries were sent 2 seconds 
apart. Gene names were converted from their ‘official symbol’ to their Entrez 
GeneID using the US National Institutes of Health (NIH) Database for Annotation, 
Visualization and Integrated Discovery (DAVID) tool (release 2008). Our programme 
(Appendix F) was coded by Dr Jon Giddy in the School of Computer Science and 
Informatics, Cardiff University.
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6.2.4 Cell lines and SNP profiling 
We purchased DNA from 480 EBV-transformed lymphoblastoid cell lines from 
unrelated healthy individuals from ECACC. Fetch2.py was used to search dbSNP 
(build 129) for nonsynonymous SNPs from all 151 genes known to be involved in 
DNA repair (Wood et al., 2001) and that had a MAFs>4% in the Caucasian population 
(N.B. detailed discussion of the MAF selected is given in Section 7.2.3). SNPs were 
genotyped by the Illumina FAST-track service using Goldengate assays, by 
GeneService using Taqman assays or by KBiosciences using KASPar technology. 
 
6.2.5 In silico analyses 
In silico analyses were carried out using PolyPhen, AlignGVGD and SIFT, as 
described in Section 5.3.10. The three software packages attempt to predict the 
likely magnitude of a SNP on a protein sequence by examining basic biophysical 
properties and conservation of amino acid residues.   
The NCBI database Homologene was used to source the protein sequences 
for each gene and their homologues. In order to provide a degree of normalisation, 
only mammalian sequences were used. 
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6.2.6 Author’s Contribution 
 
Figure 6.2: Author’s Contribution of Chapter 6. 
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6.3 Results 
6.3.1 Assessment of dbSNP 
We evaluated the data held in dbSNP (build 129) for common variants in the 
Caucasian population within the ORFs of ten DNA repair genes (ERCC5, XPA, XPC, 
RPA1, RPA2, GTF2H1, GTF2H2, GTF2H3, GTF2H4 and GTF2H5). We compared the 
variants found in dbSNP to those found by sequencing the same genes in 23 DNA 
samples from healthy European controls. Using 23 control samples, we had >90% 
power to detect variants with MAFs >4%. 
Mining of dbSNP revealed no coding region SNPs (with frequency information 
in the Caucasian population) in four of the genes analysed (RPA2, GTF2H1, GTF2H3, 
GTF2H5). For the remaining six genes (ERCC5, GTF2H2, GTF2H4, RPA1, XPA and XPC) 
we identified a total of 23 coding SNPs of which 8 were synonymous variants and 15 
were nonsynonymous variants (Table 6.1). 19 variants were identified by reviewing 
the cSNP lists in the Gene Model section of the respective dbSNP page and the 
remaining 4 were found after BLAST analysis of the individual exons. Of the 23 SNPs, 
17 had MAFs >4% in the Caucasian population. 
In total, 105/115 (91.3%) fragments were successfully amplified and Sanger 
sequenced in a single direction with 92.65% coverage for the ERCC5 ORF, 95.70% for 
XPA, 94.26% for XPC, 95.87% for RPA1, 96.05% for RPA2, 91.35% for GTF2H1, 95.87% 
for GTF2H2, 94.95% for GTF2H3, 95.13% for GTF2H4 and 97.85% for GTF2H5. All 
common SNPs found by sequencing (in ≥2/23 samples; MAFs ~4%) were already 
present in dbSNP (Table 6.2) which suggests that this database is a comprehensive 
resource of common variation. As expected a small number of rare (MAFs<2%) SNPs 
(p.P19L in ERCC5, p.V147M and p.V147M in XPC) were identified by sequencing that 
we not present within dbSNP. 
 
6.3.2 Development of a new programme for extracting SNP information 
Nonsynonymous SNPs with a MAF of >4% in the Caucasian population were 
initially manually mined from dbSNP build 126 for 151 DNA repair genes (Wood et 
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al., 2001). When the build 127 was released, repeating the manual search was not 
practical, so an automated method was developed. Fetch2.py was developed and 
used on build 129, and returned results on 38 nonsynonymous SNPs across 85 DNA 
repair genes that had frequency information for Caucasian samples. 195 SNPs had 
MAFs >5%, 26 SNPs had MAFs of 4%, 16 SNPs had MAFs of 3%, 52 SNPs had MAFs of 
2%, 37 SNPs had MAFs of 1% and 54 SNPs had MAFs <1%. No variants were 
identified in 47 genes analysed. (4% and 5% SNPs combined in Appendix G). 
All SNPs identified by the manual review were also identified by our software. 
In addition, ten SNPs were identified by the software (in build 129) that were not 
present when manually reviewed (in build 127). These were rs45439799 MAF 0.010, 
rs2048074 MAF 0.210, rs5744857 MAF 0.436, rs5744944 MAF 0.436, rs5744990 MAF 
0.158, rs5745022 MAF 0.411, rs4987206 MAF 0.001, rs4987207 MAF 0.009, 
rs4987208 MAF 0.010 and rs4251691 MAF 0.460. Four of these SNPs were identified 
as synonymous upon manual inspection. Annotation error of the POLE gene within 
dbSNP had caused Fetch2.py to extract the data in error. 
Six of these new SNPs (including all 2 with high MAFs >5%) were verified as 
genuine by genotyping of 480 healthy control samples 4 SNPs were assayed by the 
Illumina assay, 2 by Taqman (Table 6.3). 
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Table 6.1: Result of searching 10 genes in dbSNP. 
Gene name rs# MAF 
ERCC5 p.H46H rs1047768 0.39 
ERCC5 p.M254V rs1047769 0.05 
ERCC5 p.E399K rs4150315 0.01 
ERCC5 p.C529S rs2227869 0.05 
ERCC5 p.D320D rs4150314 0.01 
ERCC5 p.N879S rs4150342 0.08 
ERCC5 p.D1104H rs17655 0.25 
GTF2H2 p.I151M rs2576895 0.4 
GTF2H2 p.K133E rs162961 0.36 
GTF2H2 p.I199T rs162959 0.08 
GTF2H2 p.V236L rs162956 0.26 
GTF2H4 p.T98T rs1419693 0.12 
GTF2H4 p.R337Q rs3218820 0.03 
GTF2H4 p.P385P rs1132408 0.11 
RPA1 p.S352S rs2230930 0.1 
RPA1 p.S535S rs2230931 0.16 
XPA p.R228R rs16923331 0.02 
XPC p.L16V rs1870134 0.01 
XPC p.L48F rs3731062 0.03 
XPC p.R492H rs2227999 0.1 
XPC p.A499V rs2228000 0.3 
XPC p.R687R rs3731151 0.25 
XPC p.K939Q rs2228001 0.37 
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Table 6.2: Discovered SNPs. 
Shading indicates the 10 common variants (MAFs ~4%) also identified by Sanger 
sequencing, all of which were already present in dbSNP and thereby validating this 
database as a comprehensive resource of common SNPs. 
 
Gene exon c.Name p.Name rs. no Freq. in 
dbSNP 
Freq. by 
sequencing 
ERCC5 1 c.56 C>T p.P19L not found - 1/46 
ERCC5 7 c.760 A>G p.M254V rs1047769 0.05 1/44 
ERCC5 8 c.1195 G>A p.E399K rs4150315 0.01 0/46 
ERCC5 8 c.1586 G>C p.C529S rs2227869 0.05 1/19 
ERCC5 8 c.960 C>T p.D320D rs4150314 0.01 1/46 
ERCC5 12 c.2636 A>G p.N879S rs4150342 0.08 0/46 
ERCC5 15 c.3310 G>C p.D1104H rs17655 0.25 9/46 
GTF2H2 4 c.135_136delAG frameshift not found - 11/46 
GTF2H2 8 c.453 A>G p.I151M rs2576895 0.4 23/46 
GTF2H2 8 c.397A>G p.K133E rs162961 0.36 23/46 
GTF2H2 10 c.596 T>C p.I199T rs162959 0.08 4/46 
GTF2H2 11 c.706G>C p.V236L rs162956 0.26 2/46 
GTF2H4 4 c.294 A>C p.T98T rs1419693 0.12 6/46 
GTF2H4 11 c.1010 G>A p.R337Q rs3218820 0.03 0/46 
GTF2H4 13 c.1155 C>A p.P385P rs1132408 0.11 1/42 
RPA1 15 c.1605T>C p.S535S rs2230931 0.16 1/46 
XPA 6 c.684A>G p.R228R rs16923331 0.02 0/46 
XPC 1 c.46C>G p.L16V rs1870134 0.01 0/46 
XPC 2 c.142 C>T p.L48F rs3731062 0.03 1/44 
XPC 4 c.439 G>A p.V147M not found - 1/46 
XPC 9 c.1475G>A p.R492H rs2227999 0.10 4/46 
XPC 9 c.1496C>T p.A499V rs2228000 0.30 11/46 
XPC 11 c.2061 A>G p.R687R rs3731151 0.25 9/44 
XPC 16 c.2815A>C p.K939Q rs2228001 0.37 23/46 
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Table 6.3: Genotype Assays. 
SNP Name MAF Assay 
rs45439799 0.01 Illumina 
rs2048074 0.21 Taqman 
rs5744857 0.436 Not assayed* 
rs5744944 0.436 Not assayed* 
rs5744990 0.158 Not assayed* 
rs5745022 0.411 Not assayed* 
rs4987206 0.001 Illumina 
rs4987207 0.009 Illumina 
rs4987208 0.01 Taqman 
rs4251691 0.46 Illumina 
* Synonymous  
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6.3.3 Generating a resource of cell lines profiled for every common 
nonsynonymous SNP in every DNA repair gene in the human genome 
221 SNPs with (according to dbSNP) MAFs >4% were submitted for ‘in silico 
locus conversion’ on the Goldengate platform (Illumina). 46 SNPs failed locus 
conversion either because of their proximity to other known SNPs (within 60bp of 
the SNP loci) or because Illumina’s assay prediction software gave them a low chance 
of success. 175 SNPs were subsequently genotyped in DNA samples from 480 EBV-
transformed lymphoblastoid cell lines from unrelated healthy individuals by Illumina. 
33 of the ‘locus conversion failed’ SNPs were subsequently genotyped via ABI 
TaqMan assays and 6 were genotyped with KBioscience’s KASPAR assays. Only 1 SNP 
could not be genotyped by any assay due to the presence of several common SNPs in 
the immediate adjacent sequence. 
In total, 135 of the SNPs (Appendix H were found to have MAFs ≥4% in the 
cell lines described herein and in our population of 2,200 European control DNAs 
(Section 7.2.1) that were genotyped at the same time. 80 SNPs had a lower than the 
expected MAFs 26 of which were monomorphic.  
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6.3.4 In silico analyses predicting the functional effect of SNPs 
134/135 SNPs underwent in silico analysis with the 3 most commonly used programmes, 
NEIL3 p.R381-/R was not suitable for analysis as the recessive allele creates either a 
synonymous change or a deletion of the loci, both options are not analysed by the software. 
Polyphen predicted that 38/134 (28.4%) of the nonsynonymous variants with MAFs>4% 
(Appendix I) were damaging or possibly damaging, with the remainder being classified as 
benign. AlignGVGD predicted that 22/134 (16.4%) of the nonsynonymous variants were 
likely to have a functional effect (C45, C55 or C65) 23 (17.2%) were possibly functional (C35, 
C25 C15) and 89 (66.4%) were classified as neutral variations (C0). SIFT predicted 39/134 
(29.1%) of the variants as damaging and 95 (70.9%) were ‘tolerated’. 
Overall, 72/134 (53.7%) of the variants were predicted by one or more of the 
algorithms to be alter protein function. 19/134 (14.2%) of the variants were predicted by 
two algorithms to be damaging and 15 (11.2%) SNPs were predicted by all three algorithms 
to be damaging. 62/134 (46.3%) SNPs returned results of ‘no functional effect’ with all 
algorithms. 
 
6.4 Discussion 
6.4.1 Assessment of dbSNP 
We showed that from a pilot study of ten genes, dbSNP contained a comprehensive 
amount of data for common sequence variation. Furthermore, by exploiting our novel 
software, we are able to rapid search this resource and download lists of relevant SNPs. 
However, it is clear that there are still limitations to this database: 
(i) False Positive Rate 
A number of groups have investigated potential false positive data within dbSNP and 
found that a significant proportion of entries were unreliable. Mitchell (2004) reviewed four 
of the publications (Carlson et al., 2003, Cutler et al., 2001, Gabriel et al., 2002, Reich et al., 
2003) and estimated that 15-17% of SNPs were false positives caused by the submission of 
sequencing errors or paralogous sequences (Dvornyk et al., 2004, Musumeci et al., 2010). 
142 
 
(ii) False Negative Rate 
Three SNPs were not found in dbSNP that were present in our population (Table 6.2). 
Two of these had low MAF (both 2%) but the third has a MAF of 24% (GTF3H2 c.135_136 del 
AG) - this variant does exist in dbSNP but the frequency information for the Caucasian 
population was absent. 
(iii) Full model vs. abbreviate lists 
Five SNPs were listed on the XPC full ‘Gene Model’ list and labelled as exonic but did 
not appear on the abbreviated cSNP list; this is attributed to a known annotation error that 
dbSNP is trying to resolve. 
(iv) Validation 
In our study, we only assessed those SNPs within dbSNP that had frequency 
information in the Caucasian population. However, if we considered all SNPs (regardless of 
whether frequency data was present) we found 117 coding SNPs (build 129) 85 of which 
were nonsynonymous or frameshift variants. Only 40 of these were considered validated by 
dbSNP and this includes five which were also validated by the criteria in HapMap; however, 
further analyses of HapMap revealed these five SNPs are, in fact, monomorphic in all 
populations tested (rs4150295, rs3731140, rs3731126, rs3731063 and rs4150665). HapMart 
(an application for performing bulk downloads from the HapMap database (Smith, 2008) 
shows that out of 3.9 million Caucasian SNPs, 1.2 million are apparently ‘monomorphic’ 
including 28,279 cSNPs, 53% of which are nonsynonymous. Therefore, it is clear than many 
SNPs in dbSNP are very rare/private and will have limited utility in association studies. 
 
6.4.2 Functional assessment of common nonsynonymous SNPs in DNA repair genes 
Xi et al (2004) found that the scores observed from SIFT and Polyphen were highly 
associated with concordance between 298/478 (62.3%) of their variants. In using their 
approach we found 87/134 (64.9%) of variants to be concordant, using the same approach 
we found concordance of 64.2% between SIFT and Align GVGD and 58.2% between Align 
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GVGD and Polyphen. In combining all three programmes 67/134 (50.0%) SNPs are 
concordant. 
In comparing the number of SNPs called Benign, Class C0 and Tolerated (in Polyphen, 
Align GVGD and SIFT respectively) we identified 62 SNPs. In comparing the number of SNPs 
called C65, Probably Damaging and Damaging we identified 5 SNPs, over all the 
concordance of the three programmes in this respect is 50.0% leaving 72 ambiguous results. 
By allowing some broader definitions (Possible/C0/Tolerated, Possible/C15-65/Damaging) 
concordance raises to 61.2% but still leaves 52 ambiguous calls. 
It is important to note that when Align-GVGD analyses were undertaken with all 
homologous sequences from the Homologene database, all SNPs initially listed as C25 or 
greater (derived from an alignment of only mammalian species) were reduced to C0. 
Therefore, sequence variation introduced by non-mammalian sequences makes it very 
difficult for any residue change to be considered significant. So, although species diversity is 
required to identify conserved residues, use of all homologous sequences may limit the 
usefulness of these programmes. 
As a consequence of the poor performance of in silico analyses and the lack of 
sensitive in vitro assays, the functional consequences of common nonsynonymous variants 
in DNA repair genes remains unclear. Most studies carried out to-date are either based on 
‘artificial’ over-expression systems, knockdown human cell lines or genetically manipulated 
yeast or E-coli cells. We aimed to provide a resource of human cells lines which would 
provide a better and more natural environment for studying these nonsynonymous variants 
and, hopefully, would avoid the need to carry out transfections with artificial constructs. We 
profiled 480 normal human cell lines for every common nonsynonymous SNP in every DNA 
repair gene in the human genome. This resource will be made available free of charge to 
researchers to facilitate their analyses. Investigators can now select cell lines that only 
harbour their variant of interest and avoid those cells that harbour additional common 
variants within the same gene or pathway. By investigating ‘purer’ populations of ‘variant’ 
cells, researchers may be able to determine which variants have genuine functional effects. 
  
144 
 
7 Chapter seven 
 
Investigating the role of common nonsynonymous variants in DNA repair 
genes in CRC-susceptibility and response to treatment 
 
7.1 Introduction 
7.1.1 Inherited predisposition to CRC and role of DNA repair 
Inherited factors are thought to play a significant role in up to one third of CRCs 
(Section 1.6) but only a minority of these can be accounted for by established CRC 
predisposition genes (Kinzler and Vogelstein, 1996). <6% of cases carry high-penetrance 
germline mutations (Aaltonen et al., 2007) such as those found in the APC gene, mismatch 
repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2) and the BER gene MUTYH. It has been 
proposed that a substantial proportion of the remaining inherited predisposition is caused 
by either rare or common low penetrance variants (reviewed (Bodmer and Bonilla, 2008)). 
In support of the ‘rare variant hypothesis’, we have recently shown that individually rare, 
but collectively common, inherited nonsynonymous variants in APC (the gatekeeper of 
colonic proliferation) play a significant role in multifactorial inherited predisposition to CRAs, 
which can develop into CRCs if left untreated (Chapter 5 (Azzopardi et al., 2008)). Other 
investigators have also reported that rare variants in the Wnt signalling genes AXIN1 and 
CTNNB1 and the MMR genes MLH1 and MSH2 contribute to colorectal tumourigenesis 
(Fearnhead et al., 2004). 
In the 'common-disease common-variant' model, the risk associated with the 
individual variants is small; however, they make a significant contribution to the overall 
disease burden by virtue of their high frequencies in the population. Moreover, by acting in 
concert with each other, they have the potential to significantly affect an individual's risk of 
developing CRC. The availability of comprehensive sets of tagSNPs that capture most of the 
common sequence variation has allowed genome-wide association studies (GWAS) for 
disease associations to be efficiently conducted. Several studies have conducted multistage 
GWA for CRC and, to-date, identified fourteen susceptibility loci mapping to 8q24 
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(Tomlinson et al., 2007), 18q21 (Broderick et al., 2007), 15q13 (Jaeger et al., 2008), 11q23 
(Tenesa et al., 2008), 10p14 and 8q23.3 (Tomlinson et al., 2008), 14q22, 16q22, 19q13 and 
20p12 (Houlston et al., 2008), 1q41, 3q26.2, 12q13.13 and 20q13.33 (Houlston et al., 2010).  
We hypothesized that rare inherited variants in the MMR and BER pathways may 
predispose to CRAs and/or CRC, we also hypothesized that common nonsynonymous 
variants in these and other DNA repair pathways may also act as susceptibility alleles 
(Chapter 6). Here, we studied patients with aCRC from the UK-national, multi-centre, 
randomised controlled trials (RCTs) COIN and COIN-B. The COIN trial is a comparison 
between “COntinuous chemotherapy plus cetuximab, or INtermittent chemotherapy with 
standard continuous palliative combination chemotherapy with oxaliplatin and a 
fluoropyrimidine in first line treatment of metastatic colorectal cancer”. All patients had 
either previous or current histologically confirmed primary adenocarcinomas of colon or 
rectum, together with clinical or radiological evidence of advanced and/or metastatic 
disease, or had histologically/cytologically confirmed metastatic adenocarcinomas, together 
with clinical and/or radiological evidence of a colorectal primary tumour. (See Section 7.2.2 
and Table 7.1 for more details on these patients).
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Table 7.1: Clinicopathological data for patients in COIN and COIN-B. 
    COIN (%) COIN-B (%) 
n = 
 
2070 113 
Age at diagnosis 
Mean (S.D.) 62.6 (9.7) 61.9 (10.5) 
<20 1 (0.1) 0 (0.0) 
20-49 207 (10.0) 12 (10.6) 
50-59 476 (23.0) 25 (22.1) 
60-69 852 (41.2) 50 (44.3) 
70-79 521 (25.2) 24 (21.2) 
80-89 13 (0.6) 2 (1.8) 
    
Sex 
Female 696 (33.6) 48 (42.5) 
Male 1374 (66.4) 65 (57.5) 
    
WHO-PS 
0 969 (46.8) 58 (51.3) 
1 948 (45.8) 46 (40.7) 
2 153 (7.4) 9 (8.0) 
    
Primary Site 
Colon  1116 (53.9) 69 (61.1) 
Rectum 653 (31.6) 32 (28.3) 
Rectosigmoid junction 297 (14.4) 12 (10.6) 
Other 3 (0.1) 0 (0.0) 
Missing 1 (0.1) 0 (0.0 
    
Number of 
metastatic sites 
0 14 (0.7) 1 (0.9) 
1 736 (35.6) 43 (38.1) 
2 813 (39.3) 50 (44.3) 
≥3 507 (24.5) 19 (16.8) 
    
Metastatic sites 
Liver only 458 (22.1) 24 (21.2) 
Liver + others 1,094 (52.9) 56 (49.6) 
No Liver 518 (25.0) 33 (29.2) 
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7.1.2 Pharmacogenetics of CRC and role of DNA repair 
The treatment of metastatic CRC (mCRC) is rapidly improving. Average survival has 
increased from around 6 months with best supportive care (BSC) alone, through 10-12 
months with single agent Fluorouracil (5FU) regimens (Maughan et al., 2002) and up to 16-
20 months in randomised trials including irinotecan and/or oxaliplatin as well as 5FU 
(Douillard, 2000, Saltz et al., 2000). International results have shown increased response 
rates (RR) (31-56%) median progression-free survival (PFS) (6.5-9.0 months) and median 
overall survival (OS) (14.5-21.4 months) with combination chemotherapy in first line 
treatment. In addition, cetuximab, a chimeric monoclonal antibody targeted against 
epidermal growth factor receptor (EGFR) has been shown to improve OS (6.1 months in the 
cetuximab group compared to 4.6 months in the best supportive care group) and PFS in 
patients with CRC in whom other treatments have failed (Jonker et al., 2007). Despite these 
advances, it is clear that although some people respond well to chemotherapy and 
monoclonal antibody treatment, others do not (~50% fail to respond to first line treatment).  
There are also considerable side effects associated with chemotherapy. For 5FU, 
these include gastrointestinal (diarrhoea in 50% of patients, nausea 43%, vomiting 28%, 
stomatitis 25%, and abdominal pain 12%), cutaneous (hand-foot syndrome 53%, dermatitis 
10%), general (fatigue 24%), neurologic (headache 5%, paraesthesia 5%, dizziness 5%), 
cardiovascular (lower limb oedema 4%), haematologic (grade 3/4 neutropenia 4% and 
thrombocytopenia 2%) and biochemical (grade 3/4 bilirubin elevation 17%) problems. 
Oxaliplatin is administered together with 5FU (or capecitabine) and, in general, the adverse 
events with this combination are more frequent and more severe than with 5FU treatment 
alone. 
Inherited genetic variations can affect a patient’s response to chemotherapy and 
pharmacogenetics aims to use knowledge of these variations to ‘tailor’ therapy for 
improved response and reduced toxicity. To-date, most research has focused on single 
polymorphisms; however, a more comprehensive approach to predict treatment response is 
to consider genetic variation in entire biological and pharmacological pathways. Damage to 
cellular DNA is believed to determine the antiproliferative properties of platinum drugs. 
Oxaliplatin targets DNA forming platinum-DNA adducts which produce 1,2-GG intrastrand 
cross-links and the removal of this damage is mediated by the nucleotide excision repair 
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(NER) and homologous recombination repair pathways (Reardon et al., 1999). 
Fluoropyrimidines (FPs) have three possible mechanisms of action that are exerted by 
different metabolites. Two of these mechanisms of FP-mediated cytotoxicity act at the level 
of DNA (disruption of dNTP pools and the direct incorporation of FPs into DNA) and the 
most important consequences are the mutagenic effects of base analogues/mispairs in DNA 
and the fragmentation of DNA created in the cell’s attempts to repair these lesions. The 
BER, MMR and double strand break (DSB) repair pathways have all been suggested to 
modify FP response (Meyers et al., 2003). 
Given that numerous repair pathways have been implicated in removing the damage 
caused by these chemotherapeutic agents, we assayed germline DNA from patients in the 
COIN and COIN-B clinical trials for every nonsynonymous SNP with a MAF of >4%, in every 
repair gene characterised in the human genome (Chapter 6). In this way, we intend to 
generate ‘DNA repair SNP profiles’ which can then be related to response to and side effects 
from, the different chemotherapy regimens being used. 
 
7.2 Materials and Methods 
7.2.1 Samples 
We analysed 2,186 samples from unrelated patients with aCRC from COIN (2,073 
samples) and COIN-B (113 samples). All patients gave fully informed consent for their 
samples to be used for bowel cancer research (approved by REC [04/MRE06/60]). COIN 
patients were randomised 1:1:1 to receive continuous oxaliplatin and fluoropyrimidine 
chemotherapy (Arm A), continuous chemotherapy plus cetuximab (Arm B), or intermittent 
chemotherapy (Arm C). COIN-B patients were randomised 1:1 to receive intermittent 
chemotherapy and cetuximab (Arm D) or intermittent chemotherapy and continuous 
cetuximab (Arm E). In all patients, treatment was identical for the first 12-weeks apart from 
the choice of fluoropyrimidine together with the randomisation of ± cetuximab. 
We also analysed 2,176 blood DNA samples from healthy controls from the UK Blood 
Services collection of Common Controls (UKBS collection) (Wellcome Trust Case Control 
Consortium 2007, Wellcome Trust Case Control Consortium and Australo-Anglo-American 
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Spondylitis Consortium 2007). This collection was funded by the Wellcome Trust grant 
076113/C/04/Z, by the Juvenile Diabetes Research Foundation grant WT061858, and by the 
National Institute of Health Research of England. These samples were selected from a total 
of 3,092 samples within the UKBS collection that best matched the patients with aCRC in 
terms of place of residence within the UK. The UKBS samples had appropriate ethical 
approval (REC 05/Q0106/74). 
 
7.2.2 Genotyping 
We attempted to assay every nonsynonymous SNP with a MAF >4% in the Caucasian 
population in every DNA repair gene in the human genome (Wood et al., 2001). We 
identified relevant SNPs by searching dbSNP (Chapter 6). In total, we catalogued 221 DNA 
repair SNPs with MAFs >4% of which 46 failed in silico locus conversion on the Illumina 
BeadArray™ platform. The 4% figure was chosen to increase our chance of finding SNPs with 
a 5% or greater MAF in our population. Using Illumina's Fast-Track Genotyping Services (San 
Diego, CA) (Section 1.3.20) we assayed 175 nonsynonymous SNPs in 80 DNA repair genes 
(Section 6.3.3) of which 39 were from genes within the BER, MMR and their associated 
response pathways and 136 were from other genes known to function in DNA repair.  
 
7.2.3 Statistical analyses (susceptibility alleles) 
Genotypes for each variant were tested for deviation from the Hardy Weinberg 
Equilibrium (HWE) using a chi-squared test. Single marker association analyses were 
performed using the PLINK version 1.07 software (Purcell et al., 2007). To correct for 
multiple testing, we carried out Bonferroni correction. 
 
7.2.4 Statistical analyses (pharmacogenetics) 
The primary efficacy endpoint was; 12-week response, defined as complete response 
(CR) or partial response (PR) at 12-weeks, versus stable disease (SD) or progressive disease 
(PD). The primary endpoints for toxicity were: (i) a dose reduction or delay in chemotherapy 
in the first 12-weeks of treatment due to any toxicity except peripheral neuropathy (PN) and 
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(ii) grade ≥2 PN or dose reduction or delay due to PN versus grade 0 or 1 PN and no 
oxaliplatin dose modification in the first 12-weeks. Since neurotoxicity is a cumulative event, 
patients who received <12 weeks of treatment for reasons other than neurotoxicity were 
excluded. 
Pharmacogenetic analyses were carried out using a co-dominant model with two 
degrees of freedom, tested using the likelihood-ratio chi-squared statistic. Analyses were 
adjusted for cetuximab use and type of fluoropyrimidine. 
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7.2.5 Author’s Contribution 
 
Figure 7.1: Author’s contribution to Chapter 7. 
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7.3 Results 
7.3.1 Identifying novel low penetrance susceptibility alleles 
Our cohort (Section 7.2.2) has recently been used to validate four novel CRC-
susceptibility loci (Houlston et al., 2010). Using ~2,200 cases and 2,200 controls and with a 
MAF>4%, we had over 95% power to detect alleles with odds ratio of 1.3 or greater. To 
further demonstrate the utility of this cohort to identify CRC-susceptibility alleles, we 
assayed a SNP from each of the ten other known loci identified from GWAS. aCRC cases 
identified as being of non-Caucasian origin (n=38) were excluded from the analyses and 3 
samples failed genotyping. We independently validated five SNPs/loci using these samples 
(rs4939827 at 18q21, P=1.14x10-4; rs16892766 at 8q23, P=1.83x10-4; rs4779584 at 15q13, 
P=2.86x10-4; rs10795668 at 10p14, P=3.34x10-3 and rs6983267 at 8q24, P=5.65x10-3). 
In an attempt to identify novel CRC-susceptibility alleles, we assayed 175 
nonsynonymous SNPs, representing 80 DNA repair genes, in our case-control series. 
Genotyping concordance rates for duplicate samples was 100% (9,216/9,216 genotypes 
were concordant) GenTrain scores ranged from 0.466 to 0.966 (Figures 7.2 and 7.3) and the 
overall genotyping success rate was 99.999% (724,695/725,760 genotypes were called 
successfully). We found that nine SNPs, representing seven genes, were significantly over-
represented at the 4% level (all nine SNPs conformed to the Hardy Weinberg equilibrium) 
(Table 7.2). Only rs1805327, corresponding to p.E281G in RAD1 (X2=13.60, P=2.4x10-4) 
remained significant after rigorous correction for multiple testing (P=0.024). Genotype-
specific ORs (OR=0.73, 95% CI 0.62 - 0.87) were most compatible with an over dominant 
model of disease susceptibility. The minor allele was associated with a decreased risk of CRC 
(ORACvsAA= 0.697, CI 0.58 - 0.83; ORACvsCC = 0.649, CI 0.26 – 1.62). 
p.E281 in RAD1 is conserved in; Pan Troglodytes, Canis Lupus Familiaries, Mus 
Musculus, Ratus norvegicus, Gallus gallus and Danio rerio (Figure 7.4) and in silico analyses 
suggest that p.E281G has a likely functional effect with a PolyPhen score of 1.586 (possibly 
damaging) an align-GVGD score of class C65 (GD 97.85) (likely to interfere with function) 
and a SIFT score of 0.03 (affect protein function).
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Figure 7.2: rs12768894, GenTrain 0.466. 
The lowest GenTrain score from the Illumina genotyping of 175 SNPs shows clear separation 
between the three genotype groups. 
 
Figure 7.3: rs2228527, GenTrain 0.966. 
The highest GenTrain score from the Illumina genotyping of 175 SNPs. 
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T-COFFEE, Version_9.02.r1228 (2012-02-16 18:15:12 - Revision 1228 -
 Build 336) 
Cedric Notredame  
CPU TIME:1 sec. 
SCORE=97 
* 
 BAD AVG GOOD 
* 
H.sapiens        :  97 
P.troglodytes    :  97 
C.lupus          :  97 
B.taurus         :  97 
M.musculus       :  97 
R.norvegicus     :  97 
G.gallus         :  97 
D.rerio          :  97 
D.melanogaster   :  94 
cons             :  97 
 
H.sapiens       241 VSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESES  282  
P.troglodytes   241 VSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESES  282  
C.lupus         240 VSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVSESES  281  
B.taurus        240 VSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVP--DS  279  
M.musculus      241 VSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVP--ES  280  
R.norvegicus    241 VSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVP--ES  280  
G.gallus        240 VSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPNEEITEAEL  281  
D.rerio         240 VSVRTDSRGFLSLQYLVRNDDGQICFVEYYCCPDEEVE--EE  279  
D.melanogaster  237 VAIKTNSVGLLELHLVMQGDSQEEIFIQFFIIPLL--N--TD  274  
 
cons            245 *:::*:. *:*.*: :::.:. :  *::::  *           287 
 
Figure 7.4: p.E281G region of RAD1. 
3’ section of the RAD1 CLUSTALW analysis shows ‘GOOD’ conservation over most of the 
RAD1 sequence. p.E281G (marked with an arrow) has some homology with the included 
species but it is not completely conserved. 
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7.3.2 Identifying alleles that affect response to, and side effects from, chemotherapy 
We analysed all patients treated with chemotherapy, regardless of whether they 
also received cetuximab (all arms of COIN and COIN-B) for the 175 nonsynonymous variants 
in DNA repair genes. All three arms of COIN and the two arms of COIN-B had similar efficacy 
and toxicity outcomes at 12-weeks (Maughan et al., 2011) therefore these groups were 
combined to increase power. 
 The primary outcomes assessed were 12-week response, any toxicity (excluding 
PN) and PN. Overall, ~45% of patients responded after 12-weeks of treatment. Based on 
2186 patients, we had >85% power to detect an OR of 1.31, corresponding to a 7% 
difference in response, for a variant with a MAF >20% (and an OR of 1.56, corresponding to 
an 11% difference in response, for a variant with a MAF >5%). The incidence of dose 
reduction or delay in chemotherapy in the first 12-weeks of treatment due to any toxicity 
was 35%; we therefore had >85% power to detect an OR of 1.32, corresponding to a 7% 
difference in toxicity, for a variant with a MAF >20%. The incidence of grade ≥2 PN or dose 
reduction or delay due to PN in the first 12 weeks was 13%; therefore we had >85% power 
to detect an OR of 1.43, corresponding to a 5% difference in PN, for a variant with a MAF 
>20%. 
We found that 5 coding region variants in the DNA repair pathways were associated 
with 12-week response, 4 were associated with any toxicity and 5 were associated with PN 
at a 5% significance level, respectively (Table 7.3 for significant SNPs and Appendix J for all 
data). However, none remained significant after correction for multiple testing.  
Interestingly, the most significant variants for 12-week response (p.N279S in EXO1 
and p.R399Q in XRCC1) were in genes that function in base excision repair. The SNPs are 
reported as “Probably Damaging” by Polyphen; however, AlignGVGD assigns categories C0 
to both SNPs where a broad spectrum of species are aligned. Aligning only available 
vertebrate species re-assigns p.N279S as C45, p.R339Q remains a C0. 
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7.4 Discussion 
DNA damage triggers signal transduction pathways involving sensor, transducer and 
effector proteins. Rad9, Rad1 and Hus1 form the ‘9-1-1’ DNA damage sensor complex which 
is recruited to the site of damage by RAD17-RFC-2-5. The subsequent recruitment of 
specialised DNA polymerases and glycosylases by 9-1-1 is responsible for the repair of the 
lesions. 9-1-1 activates the transducers ataxia telangiectasia mutated (ATM) and ATM- and 
Rad3-related (ATR) which in turn activate the checkpoint effectors Chk2 (ATM) or Chk1 
(ATR) to initiate cell cycle arrest or apoptosis (Zhou et al. 2000). Disruption of the 9-1-1 
complex as a result of functional mutations in all three proteins has been shown to 
influence the cells ability to undergo cell cycle arrest as a result of DNA damage.  
Recent studies have shown that the proteins encoded by many of the known high 
penetrance CRC predisposition genes interact with, and are stimulated by, the 9-1-1 
complex. MUTYH interacts with Hus1 and Rad1, and co-localises to nuclear foci with Rad9 
following oxidative damage (Shi et al., 2006). Each subunit of the 9-1-1 complex interacts 
with MSH2, MSH3 and MSH6 and can stimulate the binding activity of MSH2/hMSH6 with 
G/T-containing DNA (Bai et al., 2010). Rad9 also interacts with MLH1 and disruption of the 
interaction by a single-point mutation in Rad9 leads to significantly reduced MMR activity 
(He et al., 2008). RAD1 consists of 282 amino acids and p.E281G results in the substitution of 
an acidic residue to a neutral amino acid. Given that residues in the C terminal domain of 
RAD1 bind to the N terminal domain of RAD9 in the formation of the ring complex, it is 
possible that p.E281G affects ring formation (Dore et al., 2009).  
Hannah West (a Ph.D. student in our laboratory) has carried out further analyses of 
RAD1. She has carried out direct sequencing of the RAD1 open reading frame and promoter 
region in 15 aCRC cases carrying the rs1805327 AG genotype in an attempt to identify any 
other potentially functional variants that may be in linkage disequilibrium with rs1805327. 
She did not find any other likely pathogenic variants, suggesting that p.E281G itself is 
directly responsible for the observed association. She has also tested whether p.E281G 
might affect the stability of RAD1 RNA and/or protein. Although RAD1 was expressed in 
most tumours, she did not observe any differences in the RNA expression levels in CRCs 
from patients with the p.E281 as compared to the p.G281 genotypes. Furthermore, she did 
not find any differences in the RAD1 protein levels as determined by immunohistochemical 
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analysis of CRCs from patients with a range of p.E281G genotypes. Further studies are 
therefore warranted to understand the functional effects of this variant. 
 
7.4.1 Pharmacogenetics 
Several previous studies have suggested that DNA repair variants effect response to 
therapy for aCRC. A study of 91 patients looked at a synonymous SNP in ERCC1 (p.N118) 
which was postulated to impair mRNA translation. The relative response to 5-FU/oxaliplatin 
was significantly higher in the T/T genotype group compared with those with C/T and C/C 
genotypes: 61.9%, 42.3%, and 21.4%, respectively (P=0.018) (Viguier et al., 2005). A study of 
71 patients treated with 5-FU/oxaliplatin looked at the effect of p.K751Q in ERCC2 - 24% of 
patients with the K/K genotype responded versus 10% of those with either K/Q or Q/Q 
genotypes (P=0.015). A study of 106 patients who received 5-FU/oxaliplatin showed that 
four alleles, including ERCC2 p.751Q, were associated with shorter OS (relative risk: 3.33, 
P=0.037) (Stoehlmacher et al., 2004). In the Federation Francophone de Cancerologie 
Digestive 2000-05 Trial (349 patients with DNA) ERCC2 p.K751Q was associated with an 
increased risk of OxFU induced G3+ hematologic toxicity (P=0.01) (Boige et al., 2010). In a 
study of 42 patients, who received 5-FU/oxaliplatin, two SNPs were shown to have a 
predictive value: a C to T change in ERCC5 leading to a synonymous SNP p.H46 and a T to C 
change in the 5’UTR of XPA. Patients with the ERCC5 C/C genotype had a PFS of 9.8 
compared with 7.8 month for those with T/C or C/C genotypes (P=0.009). Also, patients with 
a combination of ERCC5 C/C and XPA C/C or T/C had a better PFS in comparison to the rest 
of the group: 13.7 versus 7.8 months (P=0.0001) (Monzo et al., 2007). A study of 61 patients 
who received 5-FU/oxaliplatin has looked at the predictive value of p.R399Q in XRCC1 - 66% 
of non-responders had at least one Q allele compared to only 27% of the responder group 
(P=0.038) (Stoehlmacher et al., 2001). 
In our study, we did find modest effects for p.N279S in EXO1, p.R399Q in XRCC1, 
p.N372H in BRCA2, p.F63L in EME and p.T9I in LIG4 on response to therapy (Table 7.3); 
however, none of these findings were close to being statistically significant after rigorous 
correction for multiple testing. Our data therefore suggest that some of the aforementioned 
studies are likely to have identified false-positive associations due to the use of small under-
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powered sample sets however the field of pharmacogenetics remains a high research 
priority.  
The successful identification of a relationship between K-ras mutation and 
cetuximab (Karapetis et al., 2008) has the potential to bring a level of stratification to CRC 
treatment and other similar relationships are sure to be identified in the coming years. 
CRUK has also launched a stratified medicine project with the aim of establishing a national 
genetic testing service as they expect treatments to become increasingly targeted to groups 
of patients with the ultimate goal of personalised medicine.
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Table 7.2: Nonsynonymous SNPs in DNA repair genes over-represented at the 4% level. 
      CASE Control 
Allele freq. 
in cases 
Allele freq. 
in controls 
  
X2 P value 
Corrected 
P value 
SNP Gene 
Amino 
acid 
AA AB BB fail AA AB BB fail A B A B OR 
rs1805327* RAD1 p.E281G 1889 245 10 1 1825 340 9 1 4023 265 3990 358 0.7342 13.6 0.00023 0.038 
rs3087374 POLG p.Q1236H 13 286 1846 
 
15 350 1810 
 
312 3978 380 3970 1.2204 6.27 0.01225 1 
rs3087403 REV1 p.V138M 152 843 1149 1 172 918 1085 
 
1147 3141 1262 3088 1.1191 5.5 0.01906 1 
rs2228527‡ ERCC6 p.R1213G 1385 668 92 
 
1470 624 81 
 
3438 852 3564 786 1.1237 4.51 0.03369 1 
rs799917† BRCA1 p.L871P 243 975 927 
 
237 917 1021 
 
1461 2829 1391 2959 0.9103 4.22 0.03992 1 
rs12360068 MMS19L p.A579V 
 
164 1981 
 
2 201 1971 1 164 4126 205 4143 1.2449 4.2 0.04039 1 
rs1800282 FANCA p.V6D 10 353 1781 1 25 384 1766 
 
373 3915 434 3916 1.1632 4.17 0.04124 1 
rs2228529‡ ERCC6 p.Q1413R 1386 666 92 1 1468 626 81 
 
3438 850 3562 788 1.1176 4.1 0.04292 1 
rs16942† BRCA1 p.K1183R 947 968 228 2 1040 913 222   2862 1424 2993 1357 1.0934 4.07 0.04362 1 
 
AA = Wildtype, AB= Heterozygote = BB = homozygous recessive 
Note: rs1805327 in RAD1 remained significant after correction for multiple testing (P=0.025). The BRCA1 variants p.L871P†, p.K1183R† and 
p.S1613G† and the ERCC6 (CSB) variants p.Q1413R‡ and p.R1213G‡ were in complete linkage disequilibrium. 
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Table 7.3: Variants with P<0.05 for the primary outcomes in patients treated with chemotherapy ± cetuximab. 
Outcome rs no. Gene Variant n AA AB BB Χ2 (df) 
P-
value 
Corrected 
P-value 
12-week 
response 
rs4149909 EXO1 N279S 1847 1741 106 0 8.67 (1) 0.0032 0.538 
rs25487 XRCC1 R399Q 1847 246 847 754 9.56 (2) 0.0084 1.000 
rs144848 BRCA2 N372H 1848 958 732 158 7.21 (2) 0.027 1.000 
rs17714854 EME1 F63L 1847 1800 47 0 4.74 (1) 0.029 1.000 
rs1805388 LIG4 T9I 1846 47 515 1284 6.32 (2) 0.042 1.000 
          
 
Any Toxicity 
(except 
peripheral 
neuropathy) 
rs4986850 BRCA1 ‡D397N 2167 19 282 1866 7.30 (2) 0.026 1.000 
rs5745459 MSH4 Y589C 2167 2124 43 0 4.06(1) 0.044 1.000 
rs12022378 DCLRE1B H61Y 2167 60 620 1487 6.18 (2) 0.046 1.000 
rs1799966 BRCA1 ‡S430G 2167 962 976 229 6.13 (2) 0.047 1.000 
          
 
peripheral 
neuropathy 
rs3750898 DCLRE1A H317D 2019 132 722 1165 8.55 (2) 0.014 1.000 
rs1800058 ATM L72F 2017 0 70 1947 5.50 (1) 0.019 1.000 
rs3093921 PARP2 D222G 2019 1945 74 0 4.86 (1) 0.027 1.000 
rs13181 ERCC2 K751Q 2018 829 905 284 6.66 (2) 0.036 1.000 
rs9352 CHAF1A V923A 2019 594 984 441 6.06 (2) 0.048 1.000 
 
‡The BRCA1 variants D397N and S430G variants were in LD (r2=0.16, D’=1) so likely to be associated with the same signal. 
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8 Chapter Eight 
 
Using exome re-sequencing to identify the cause of severe peripheral 
neuropathy after oxaliplatin-based chemotherapy 
 
8.1 Introduction 
Oxaliplatin, a third-generation platinum drug, is the standard of treatment in 
combination with 5-fluorouracil/leucovorin for locally advanced and metastatic cancer of 
the colon or rectum. It improves survival in the adjuvant setting amongst stage III patients 
compared with 5-fluorouracil/leucovorin treatment, as well as in the first-line treatment of 
metastatic disease as compared with 5-fluorouracil/irinotecan therapy (Goldberg et al., 
2004). In addition, oxaliplatin has shown promising activity against rectal, pancreatic and 
gastric malignancies (Becouarn et al., 2001). Oxaliplatin and other platinum agents exert 
their effects by forming inter-strand and intra-strand cross-links on DNA (Brabec and 
Kasparkova, 2005) which stall the cell cycle, inhibit DNA synthesis (Johnson et al., 1980) and 
triggers apoptosis (Faivre et al., 2003). 
Peripheral neuropathy is a well-recognised dose-limiting toxicity of oxaliplatin 
(Hartmann and Lipp, 2003). Oxaliplatin induces two clinically distinct forms of peripheral 
neuropathy (Ocean and Vahdat, 2004). The acute syndrome, consisting of distal or perioral 
paresthesias and pharyngolaryngeal dysethesias, appears soon after the administration of 
oxaliplatin and is usually transient and reversible within hours or days. The chronic form is a 
pure sensory, axonal neuronopathy, closely resembling cisplatin-induced peripheral 
neuropathy (Pasetto et al., 2006). High cumulative doses of oxaliplatin are associated with 
occurrence of chronic peripheral nerve damage (Quasthoff and Hartung, 2002) and chronic 
sensory neuropathy has been observed in ∼50% of patients who received oxaliplatin with 
infusional 5-fluorouracil/leucovorin. Most importantly, it is neurotoxicity, rather than 
tumour progression, which is often the cause of treatment discontinuation (McWhinney et 
al., 2009). 
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Since neurotoxicity is not correlated with response to treatment (McWhinney et al., 
2009) it is likely that this is an avoidable side effect. However, the mechanism underlying 
oxaliplatin induced peripheral neuropathy has not been defined. Here, we sought to 
delineate the underlying mechanism by exome re-sequencing patients with severe 
peripheral neuropathy after treatment with oxaliplatin-based chemotherapy who were 
negative for known peripheral neuropathy mutations. 
 
8.2 Materials and Methods 
8.2.1 Patients 
We analysed blood DNA samples from unrelated patients with advanced CRC from 
the UK national trial COIN (Maughan et al., 2011) (Sections 7.1.1 and 7.2.2). In all patients, 
treatment was identical for the first 12 weeks apart from the choice of fluoropyrimidine 
together with the randomisation of ± cetuximab. 
We obtained the maximum grade of peripheral neuropathy observed in each patient 
after 12 weeks of oxaliplatin-based chemotherapy. Patients with Grade 3/4 peripheral 
neuropathy or that had had oxaliplatin-dose reduction due to severe peripheral neuropathy 
were classified as suffering from peripheral neuropathy associated with oxaliplatin (PNAO). 
 
8.2.2 Molecular analyses and exome re-sequencing 
PMP22 gene dosage analysis was carried out at the Bristol Genetics Laboratory, 
Southmead Hospital, North Bristol NHS Trust. Library fragments containing exomic DNA 
were collected using the Roche Nimblegen SeqCap EZ Exome (version 2) Library solution-
based method. Massively parallel sequencing was performed on the Illumina Genome 
Analyser at the University of North Carolina. FASTQ files were processed through a 
sequence analysis pipeline using BWA (version 0.5.1) (Li and Durbin, 2009) for sequence 
alignment and modules from the Broad Institute’s Genome Analysis Toolkit (GATK) (version 
2.0) (McKenna et al., 2010) to recalibrate quality scores, refine alignments around potential 
indels, eliminate duplicate reads, call indel and SNP genotypes, generate QC metrics, and 
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apply quality filters to the genotype calls. SNP calls were annotated using the analysis 
package ANNOVAR (subversion 322) (Wang et al., 2010). 
 
8.2.3 PCR and Sanger sequencing 
PCR reaction and thermal cycling conditions are described in Section 2.4.2, primers 
and annealing temperatures are in Table 8.3. Sanger sequencing was carried out as 
described in Section 2.4.3, 2.4.4 and 2.4.5. Samples were run on an ABI 3100 genetic 
analyser (Applied Biosystems) and sequence data viewed using Sequencher v4.6. 
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8.2.4 Author’s Contribution 
 
Figure 8.1: Author’s Contribution to Chapter 8. 
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8.3 Results 
8.3.1 Patient selection 
Patients were selected from a total of 2,445 patients with advanced CRC undergoing 
treatment with oxaliplatin and a fluoropyrimidine (and sometimes cetuximab) as part of the 
COIN trial (Section 7.1.1). Severe peripheral neuropathy was observed in 23% of patients 
receiving oxaliplatin and fluorouracil-based therapy and 16% of those receiving oxaliplatin 
and capecitabine-based therapy, over the entire treatment period (Maughan et al., 2011). 
We selected ten patients that suffered from severe PNAO; these were considered the most 
severe sufferers in terms of peripheral neuropathy so as to enrich for potential inherited 
genetic defects. 
 
8.3.2 Exome re-sequencing 10 patients with PNAO 
We used the Roche Nimblegen SeqCap EZ Exome capture (version 2) kit together 
with the Illumina Genome Analyser to carry out exome re-sequencing of 10 patients with 
PNAO to help elucidate any underlying genetic defect. Coverage of the whole exome for 
each patient ranged from 23 to 39 fold. We identified on average 68.6 (range 59-81) stop-
gains and 187.5 (range 158-209) indels predicted to result in frameshift mutations per 
patient exome. We reasoned that those rare variants not present in dbSNP v.129 (‘novel’) or 
with MAFs <1% were the most likely to cause PNAO and warranted further investigation. 
We identified on average 9.7 (range 3-15) and 27.7 (range 14-56) novel stop-gains and 
truncating indels, respectively, per patient and 17.3 (range 14-21) and 60 (range 55-69) 
stop-gains and truncating indels with MAFs <1%, respectively (Table 8.1).
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Table 8.1: Oxaliplatin transport, metabolism and associated repair pathway SNPs. 
Numbers of stop-gains and truncating indels identified in the whole exome or the oxaliplatin 
transport, metabolism and associated repair pathways in ten patients with PNAO. 
  
Patient No. 
  
1 2 3 4 5 6 7 8 9 10 
Stop-gains                     
Whole 
exome 
Total 67 85 86 76 83 86 81 79 73 96 
Novel 3 10 8 10 12 12 12 8 7 15 
(MAF <1%) (15) (19) (21) (14) (20) (18) (14) (18) (16) (18) 
In Ox 
transport / 
metabolism 
/ repair 
pathway 
Total 1 1 1 2 1 1 1 2 1 2 
Novel 0 0 0 0 0 0 0 1 0 0 
(MAF <1%) (1) (1) (1) (2) (1) (1) (1) (1) (1) (2) 
Truncating indels                     
Whole 
exome 
Total 73 111 81 87 83 100 90 78 94 81 
Novel 16 56 21 20 14 41 27 18 39 25 
(MAF <1%) (57) (55) (60) (66) (69) (59) (63) (60) (55) (56) 
In Ox 
transport / 
metabolism 
/ repair 
pathway 
Total 2 2 1 1 1 0 3 0 0 0 
Novel 0 0 0 0 0 0 0 0 0 0 
(MAF <1%) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
 
We considered that variants absent from dbSNP v.129 (termed novel) or with MAFs <1% (in 
parenthesis) were the most likely to affect function and warranted further investigation. 
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8.3.3 Excluding known inherited neuropathies 
The hereditary neuropathies are a clinically and genetically heterogeneous 
group of disorders with overall prevalence of 1 in 2,500. Although there are over 30 known 
genes associated with inherited peripheral neuropathies, approximately 75% of patients 
with Charcot Marie Tooth disease and 85% of patients with hereditary neuropathy with 
liability to pressure palsies have a duplication or deletion of PMP22 at 17p11.2, respectively. 
The Bristol Genetics Laboratory therefore carried out multiplex ligation-dependent probe 
amplification (MLPA) analysis of PMP22 in all ten patients with PNAO and excluded any 
abnormalities in PMP22 gene dosage. 
We also examined the exome re-sequencing data for PMP22 and other genes 
associated with rare inherited neuropathies such as MPZ, LITAF, EGR2, NEFL, GJB1, PRPS1, 
DNM2, YARS, MFN2, RAB7, GARS, HSPB1, HSPB8, GDAP1, LMNA, MED25, MTMR2, 
SBF2/MTMR13, SH3TC2, NDRG1, PRX, FGD4, FIG4, BSCL2, DCTN1 and IGHMBP2. On 
average, we had >10x coverage for 79.6% of each of the respective ORFs in each patient 
(Table 8.2). 
We failed to find any stop-gain mutations or truncating insertions or deletions 
(indels) in these genes in our 10 patients with PNAO. Although we did find a several 
nonsynonymous variants these were also found in dbSNP at a similar frequencies and were 
therefore considered to be benign polymorphisms. Therefore, we excluded all known genes 
associated with inherited neuropathies as the likely cause of PNAO. 
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Table 8.2: 10X coverage of selected genes. 
 Patient 
1 
Patient 
2 
Patient 
3 
Patient 
4 
Patient 
5 
Patient 
6 
Patient 
7 
Patient 
8 
Patient 
9 
Patient 
10 
BSCL2 86.2 75.0 86.2 86.2 86.2 80.6 79.8 86.2 81.8 83.2 
DCTN1 97.9 78.8 94.9 97.9 99.8 88.9 98.3 97.0 92.8 99.7 
DNM2 86.8 79.9 86.6 90.7 92.7 88.1 91.7 86.9 93.0 91.8 
EGR2 89.3 85.5 99.0 97.9 96.8 92.2 99.7 93.7 87.6 100.0 
FGD4 99.2 97.9 99.1 100.0 99.7 97.3 100.0 100.0 100.0 99.6 
FIG4 99.9 96.3 93.4 100.0 100.0 95.0 99.9 99.9 98.0 100.0 
GARS 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
GDAP1 100.0 100.0 99.4 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
GJB1 97.4 90.7 96.2 93.3 100.0 91.2 95.0 89.8 94.1 100.0 
HSPB1 10.4 4.7 15.9 29.9 29.3 0.0 20.6 26.9 17.6 25.2 
HSPB8 67.5 66.8 80.0 71.1 100.0 90.4 75.5 68.5 82.7 81.4 
IGHMBP2 95.8 87.0 96.3 96.2 96.5 92.2 97.9 95.4 95.8 96.6 
LITAF 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
LMNA 92.6 73.5 99.9 86.6 95.4 92.9 99.9 83.9 88.6 99.5 
MED25 62.8 47.1 67.5 71.3 73.9 60.2 69.8 64.2 60.7 72.1 
MFN2 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
MPZ 98.7 86.2 96.8 100.0 94.2 89.0 100.0 98.3 86.1 100.0 
MTMR2 95.9 95.3 95.8 95.9 96.5 95.9 99.0 95.9 95.9 97.9 
NDRG1 100.0 96.3 100.0 100.0 96.2 97.1 100.0 99.1 97.2 100.0 
NEFL 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PRPS1 100.0 100.0 90.5 100.0 100.0 91.1 94.9 100.0 100.0 100.0 
PRX 5.2 4.9 5.1 5.1 6.7 5.1 5.1 5.1 6.4 5.1 
SBF2 99.0 98.1 97.4 98.9 99.0 98.5 98.7 99.0 98.8 98.9 
SH3TC2 98.1 88.6 96.8 99.5 100.0 98.1 99.0 98.2 92.7 99.8 
YARS 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
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8.3.4 Identification of truncating mutations in the oxaliplatin transport, metabolism and 
associated DNA repair pathways 
We hypothesized that rare germline truncating mutations in genes involved in 
oxaliplatin transport, metabolism or the repair of its associated damage might be 
responsible for the phenotype of PNAO. We identified genes potentially involved in the 
pharmacokinetics and mechanism of action of platinum compounds via literature reviews. 
In total we identified eighty-one genes that may play a role including four genes involved in 
drug influx (SLC22A1, SLC22A2, SLC31A1 and SLC47A1), eight genes involved in 
detoxification (CCS, SOD1, MT1A, MT2A, NQO1, GSTT1, GSTP1 and GSTM1), two genes 
involved in oxalate metabolism (AGXT and GRHPR), three genes involved in sequestration 
(ATOX1, ATP7A and ATP7B), twenty-five genes involved in apoptosis due to DNA damage 
(SUPT16H, SSRP1, HMGB1, p53, COX17, AURKA, RB1, ABL1, p73, MAP2K3, MAP2K6, 
MAP3K1, MAPK8, MAPK14, RPS6KA5, EHMT2, DUSP1,2,4,8,10 and 16, CASP3, CASP8 and 
CASP9), thirty-three genes involved in DNA repair and the associated response pathways 
(POLH, POLM, REV3L, POLB, ATM, ATR, CHK1, CHK2, CDC25C, CDC2, BRCA1, BRCA2, MLH1, 
MSH2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, MSH6, PMS2, MPO, ERCC1-6, XPA, 
XRCC1, XRCC3 and MGMT), and six genes involved in drug efflux (ABCC1-5 and ABCG2).  
We sought stop-gain and truncating indels in these 81 genes in all ten patients with 
PNAO. We identified p.Q73X in MAP2K3 in multiple patients which was also shown to be 
common in dbSNP; therefore it was considered likely to be a common benign 
polymorphism. c.1275delTGGTAAGT SLC22A1 was predicted to be present in multiple 
patients (rs113569197, no frequency data) but Sanger sequencing of independent PCR 
products failed to confirm the presence of this deletion suggesting that it was an exome 
sequencing or bioinformatic artefact. 
We also identified a stop-gain in BRCA2 (p.K3326X) in two patient samples which was 
verified by Sanger sequencing independent PCR products. Although this is a well-studied 
rare variant (rs11571833, MAF 0.8%) shown not to play a role in breast cancer susceptibility 
(Mazoyer et al., 1996) it has been shown to be over represented in patients with inherited 
pancreatic cancer (Martin et al., 2005) we considered whether it could play a role in PNAO. 
We therefore assayed for p.K3326X in all other available cases from COIN. Overall, we found 
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similar proportions of cases with (2/63, 3.17% of patients) and without (37/1753, 2.1% of 
patients) PNAO harbouring this variant, thereby failing to support a causal role (P=0.395). 
 
We identified a single patient (Patient 8) who carried the novel stop gain p.S613X in 
exon 9 of ERCC4 (XPF) which was verified by Sanger sequencing of an independent PCR 
product. ERCC4 plays a role in nucleotide excision repair (NER) the main DNA repair pathway 
involved in the removal of bulky and DNA-distorting adducts, such as those formed by 
oxaliplatin (Scheeff et al., 1999). Patients carrying biallelic ERCC4 mutations are known to 
suffer from the UV sensitivity disorder xeroderma pigmentosum group F (XPF) characterised 
by an elevated risk of cancer, in particular skin and oral cancers (Lehmann et al., 2011, 
Matsumura et al., 1998). Interestingly, XP patients with mutations in other 
complementation groups (XPA, XPC and XPG) have been reported to suffer from peripheral 
neuropathy prior to treatment (Anttinen et al., 2008, Kanda et al., 1990, Robbins et al., 
2002, Thrush et al., 1974). We therefore looked for a mutation in the second ERCC4 allele in 
Patient 8 by direct sequence analysis of their entire ORF and flanking intronic sequences. 
We failed to find any other coding region variants. 
 
8.3.5 Phenotype of Patient 8 
Retrospective review of notes and clinical trials data indicate that this patient was a 79 year 
old lady at the time of oxaliplatin therapy and was diagnosed with metastatic CRC after an 
Ultrasound scan of her liver in March 2006. Her presenting symptoms to the primary care 
physician were of right upper quadrant pain and a 2 month history of intermittent 
diarrhoea. Her carcinoembryonic antigen (CEA) on presentation was 130. She went on to 
have a CT which demonstrated multiple metastases throughout both lobes of the liver. 
There was also a large caecal mass consistent with caecal tumour. Tru-cut biopsy of liver 
provided histological diagnosis of adenocarcinoma from a synchronous colonic primary 
cancer. 
Past medical history included tubular adenoma excised 2001, peri-orbital rosacea 
diagnosed in 2003, and a seborrhoeic wart excised. Allergy skin tests at this time had 
suggested nickel sensitivity, she had moderate macular degeneration consistent with her 
age group and mild osteoarthritis. She was allergic to lidocaine. Of particular note in this 
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case, there was no past medical history of skin cancers, no immunodeficiency disorders or 
related diseases, no ataxia, memory loss or muscle weakness. It is evident that this lady did 
not have xeroderma pigmentosum. 
 
8.3.6 Analysis of ERCC4 in other cases with PNAO 
We investigated whether other cases with PNAO were caused by variants in ERCC4 
by Sanger sequencing the ORF and flanking intronic sequences in the nine remaining 
patients (Patients 1-7, 9 & 10) in the original cohort (to search for variants missed via exome 
re-sequencing) together with 54 other cases with PNAO from COIN. We did not identify any 
additional cases with truncating mutations. In total, we identified five nonsynonymous 
variants: p.P379S was found in 3 patients (MAF = 2.34%) and was previously documented in 
dbSNP (rs1799802, MAF=1.8%); p.R415Q in 9 patients (MAF = 7.03%) and in dbSNP 
(rs1800067, MAF=4.9%) p.R576T in 1 (MAF = 0.78%) patient and in dbSNP (rs1800068, 
MAF=0.00%) p.E875G in 4 patients (MAF = 3.13%) and in dbSNP (rs1800124, MAF=1.3%) and 
p.H466Q in a single patient and not in dbSNP, this SNP is part of on-going an investigation. 
Apart from one case that carried both p.R576Tand p.E875G, all other cases carried a single 
ERCC4 nonsynonymous variant in a heterozygous state. p.P379S, p.R576T and p.E875G were 
all predicted to interfere with function by in silico analyses using Align-GVGD, whereas the 
variant p.R415Q was predicted as less likely to interfere with function. We also identified 3 
synonymous variants (p.A11 [rs3136042], p.S835 [rs1799801] and p.T885 [rs16963255]) and 
three variants in the 5’ un-translated region (UTR) (c.1-30A>T [rs1799797], c.1-356C>A 
[rs6498486] and c.1-69G>C [Novel]) all of which were unlikely to affect function. 
 
Since ERCC4 and ERCC1 function together to form a 5’ incision complex in NER 
(Sijbers et al., 1996) we also sought likely causal variants in ERCC1 via direct sequence 
analysis of the ORF and intronic boundaries in all 64 patients with PNAO. We did not identify 
any cases with ERCC1 truncating mutations. We found three synonymous variants (p.T75 
[rs3212947], p.N118 [rs11615], p.P128 [rs139827427]) and five variants in the promoter 
region/5’UTR (c.1-230C>A [rs41559012], c.1-96T>G [rs2298881], c.1-303C>T [rs41540513], 
c.1-495C>A [rs3212931], c.1-790T>C [rs3212930]). None of the variants in the promoter 
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region/5’UTR lay within potential transcription factor binding sites, so none were 
considered likely to affect function. 
 
8.3.7 Identification of truncating mutations in other genes potentially involved in 
neuropathy 
We also considered whether rare germline truncating mutations in genes involved in 
nerve function might also be responsible for PNAO. Therefore, we filtered our data against 
the HapMap CEU population data and manually reviewed dbSNP where necessary to 
identify every gene predicted to carry a novel or rare (MAF<1%) stop-gain or truncating 
indel (n=59 genes) from the whole exome analyses. These genes were assessed in the 
literature for a potential role in neuronal function. 51 genes were identified as potentially 
relevant; however, the variants p.Y54X in ANXA7, c.188_191del in NEFM, 
c.2711_2714deland c.188_191del in NRP2, c.1416_1417insG in APPL1, c.1944_1945insG in 
SEMA4C and c.1684_1685insGin PPP1R13L were not confirmed upon sequencing an 
independent PCR product from the relevant patient, so were excluded. A stop-gain variant 
in STOML3 (p.R155X) identified in a single patient and absent from dbSNP, was confirmed in 
an independent PCR product. STOML3 encodes stomatin like protein, a mechanosensory 
channel, deletion of which leads to loss of mechanoreceptor function and loss of 
mechanosensitive currents in isolated neurons from mice (Wetzel et al., 2007). We 
therefore sequenced the entire ORF, flanking intronic sequences and promoter region of 
STOML3 in 54 other patients with PNAO. No additional coding region variants were found 
and only a single intronic variant (rs9548577) was identified in one patient and was 
considered unlikely to affect function.
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Table 8.3: PCR Primers. 
Gene/ 
region 
Forward primer (5’-3’) Reverse primer (5’-3’) Product 
Size (bp) 
ERCC1    
Promoter A GCTGTCGTTGGTCACTGCT AGACTGCAGAGGGATCGAG 463 
Promoter B CCTGCTCTATGCTCTACTCTCC AGAGCTCCATAGCGTCAGGT 482 
Exon 1 TGCGGGATGAGAACGTAGAC CCCCATCCTATCCTCTTCGT 237 
Exon 2 AAAGGGGAGAGGAACTCACA GGAGAACAAAGTGGCTGGAA 405 
Exon 3 GTGCAAGAAGAGGTGGAGGA TCCAGAACACTGGGACATGA 263 
Exon 4 ATTCCAGTGAGAGGGAAAAGG CTGCATTTCCTCTTGGAAGG 265 
Exon 5 CCACCACGCCTGGCTAAT ACAGGAAGGAGAAGGGAAGG 241 
Exon 6 GGCAATTCTTATGACTGACCA TGGAACTGAAGCTCAACCAC 255 
Exon 7 CAGGCAGTCTGGGGACAC CAGGGAGATGGAAGGAAATG 260 
Exon 8 CCCTGGGGAATATCTGAGG AGGCTGGTCTCCAACTTCTG  
Exon 9 TAAAGAACCAAAACCCCACTC CAGAATCCCTCCCCAGAGAC 238 
Alt. Exon 3 AAGTGATCCTCCTGCCTCAG CTGGCTACAGGCCAGCTCTT 169 
    
ERCC4    
Promoter A AGCCTGGGCAACATATCAAC TTCATGGAGTCACCTGTAGGG 332 
Promoter B AGGGGATGTGGAAACTCAAA TAGCCGAGGAGAGCTGAGA 238 
Exon 1A CTCTCGGACTCGGCTCTCT GTGCAGCTGGAGAAAGTGG  
Exon 1B CCGCTGCTGGAGTACGAG TGTCATCGCGTAGTGTCAGG 433 
Exon 2 TCAGAGAAAGACAGCACATTATTT TGGAGAAAAATAAAATGGAAATTG 357 
Exon 3 CTCTGTTCTGTGCGTGGCTA CCATCAAATTGCTCTCGACTT 547 
Exon 4 TTTGTTGTTTTGCTTTTCGTG GCTATGTTTTTAAGTGACCTCCA 425 
Exon 5 GATACACAGGAAATAATCCTTTTGA CACACCTGATTCCCCCTAAA 354 
Exon 6 CGGTGTGGTTGGTAGGAAGA TTTCACATGGCCAAAGAAGAC 348 
Exon 7 TGATGCTCGTGTTATCTGTTG AAATAGAGACAGGGTTTCACCA 327 
Exon 8A ATGTCTTCCCTTCGGGTGA AGCCCGTTCTTTGTTTTGG 314 
Exon 8B GAGCGGAGGCCTTCTTATTG AGTGAGGGGTTCTTTCAGGA 377 
Exon 8C AAGGAGATGTCGAGGAAGGA AAGCAGCATCGTAACGGATA 401 
Exon 9 GCGCTCTAGGTTGCTGATTT CTTCCTTGCCCTATCCTTCC 287 
Exon 10 TCCTTGTTTTTGTTTTTGTTTTTC CCAACCCCCATTTTTAAGAG 361 
Exon 11A CCATCCATCAGAGTTAACAACA CCTCGGGAAGTGAGAGAGAA 403 
Exon 11B TGGAGCGCAAGAGTATCAGT ATCAAGGAGCGGCAGTTTTT 430 
Exon 11C CTGAAACAAAGCAAGCCACA TCTGGTCCACCGTACAATCA 442 
    
STOML3    
Exon 1A TTTCAAAAGCTCACTCACTGC TGTGAAGAACAGGCAGCAAC 419 
Exon 1B CTTCCCTCACCAGGGTAACT TGCTACAACTCCTGCTTTGC 293 
Exon 2 TTCTATGCAGCCACATCAGG CCAGACGGAATACAACAGCA 342 
Exon 3 CATTACCTTCCCCATCTCCA AATAGGCACCACCAGGAAAA 281 
Exon 4 CATGTATCGCCCCATGTAAA GCGGGTACTCAGCTCATCTT 302 
Exon 5 GCCAGGACAGGTTTTAGGTG GTGGGGGATGCTTTGAACT 441 
Exon 6 TCACTCCAAATGCTGTAAATGC AACCCCTTTCTCATGCAAAT 381 
Exon 7 CTGGGGAGAGGGGTATCAA GTGTTGGAATTCTCACCGTTT 410 
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8.4 Discussion 
To our knowledge, our data provide the first definite insight into the mechanism 
underlying oxaliplatin induced peripheral neuropathy in humans. Interestingly, several other 
studies help support our findings: (i) Patients with XP and with mutations in other 
complementation groups suffer from peripheral neuropathy prior to treatment (Anttinen et 
al., 2008, Kanda et al., 1990, Robbins et al., 2002, Thrush et al., 1974). Importantly, the 
patient with PNAO and the truncating mutation in ERCC4 described herein, carried a single 
mutant allele and was not reported as suffering from XP. These data may suggest that 
haploinsufficiency for a mutant ERCC4 allele is sufficient to induce peripheral neuropathy 
upon exposure to oxaliplatin. (ii) An Ercc1-/Δ murine model, which has reduced expression 
of the ERCC1-ERCC4 complex, develops accelerated spontaneous peripheral 
neurodegeneration with significant alterations of the sciatic nerves upon morphologic and 
ultrastructural analysis (Goss et al. 2011). (iii) In Xpa-/- and Xpc-/- mice, chronic exposure to 
cisplatin resulted in an accelerated accumulation of unrepaired intrastrand cross-links in 
neuronal cells. Furthermore, the augmented adduct levels in dorsal root ganglion cells of 
these mice coincided with an earlier onset of peripheral neuropathy-like functional 
disturbance of their sensory nervous system (Dzagnidze et al., 2007). (iv) Multiple myeloma 
patients carrying the variants rs1799800 and p.S835 (in linkage disequilibrium) in ERCC4, 
were at a 2.74 and 2.48-fold greater risk, respectively, of developing late onset peripheral 
neuropathy after treatment with bortezimab (Broyl at el. 2010). 
Biallelic mutations in ERCC4 or ERCC1 have been shown to cause XP, XPF-ERCC1 (XFE) 
progeroid syndrome or cerebro-oculo-facio-skeletal syndrome, characterised by increased 
risk of cancer, accelerated aging and severe developmental abnormalities, respectively 
(Gregg et al., 2011). Interestingly, the variant p.P379S, which we identified in 1 patient with 
PNAO in a heterozygous state, has previously been identified as a pathogenic mutation 
causing XFE progeroid syndrome (when it co-occurs with another mutation) (Gregg et al., 
2011). It has recently been shown that mutations in ERCC4 associated with XFE progeroid 
syndrome cause mislocalisation of XPF-ERCC1 into the cytoplasm probably due to protein 
mis-folding (Ahmad et al., 2010) analogous to the ∆F508 mutation in CFTR. Further studies 
are therefore warranted to determine whether rare nonsynonymous variants in ERCC4, 
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together with truncating mutations, contribute to PNAO. These studies are on-going in our 
laboratory. 
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9 Chapter nine 
 
General Discussion 
 
At the commencement of this study ‘Large Scale’ or ‘High Throughput’ genomic 
technology could generally be thought of as any instrumentation that was capable of 
utilising 96 well plates for automated or parallel processing. In reality the capacity of any 
instrument can only be described as ‘Large Scale’ relative to the other technology available 
at the time. A 96 capillary automated sequencer was once considered to be a significant 
improvement over slab gels hence providing ‘high-throughput’; however, when comparing 
that change to the difference between the capillary and NGS instruments the increase in 
throughput from gel to capillary seems marginal. Over the period of study much of the 
technology that was assessed has been effectively replaced by the massively parallel 
processing NGS techniques. SNP discovery on an exome or genome wide scale is becoming 
relatively common amongst research groups and NGS is poised to revolutionise clinical 
genetics as it has research by identifying disease genes for both Mendelian and 
multifactorial disease (Table 9.1). 
 
9.1 dHPLC 
In 2005 dHPLC was a commonly used technology in SNP discovery projects. 
Automated sampling of 96 well plates provided a high throughput method of screening for 
the presence of heteroduplexes (and recessive alleles where sample spiking was used). By 
screening samples in this way a researcher could avoid costly sequencing of homozygous 
fragments that would were uninformative. Furthermore being able to cross reference 
dHPLC and Sanger sequence chromatograms aided the identification of SNPs where 
chromatograms alone might not have been conclusive. 
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As the number of samples and fragments that were required for analysis grew, 
manually testing dHPLC traces became a bottle neck and automated software was 
introduced to solve the problem. Here we have demonstrated that the Transgenomic 
Navigator software is effective in identifying rare variants on their own or from fragments 
that also contain common variation. While many research groups have moved onto new 
technology recent publications demonstrate that the technique is still well used for SNP 
discovery (Zahary et al., 2012). 
Optimum Navigator analysis conditions were applied to a Glycosylase project where 
MAP like 134 samples were screened for the ORF of 5 glycosylase genes to investigate the 
relationship between rare variation and common disease. None of the SNPs discovered 
where found to be in association with CRC however, recent publications have found OGG1 
p.R46Q to be pathogenic (Anderson and Daggett, 2009, Morak et al., 2011) . Within our 
study this variant was excluded from further analysis due to its presence in our control 
population however, redundancy in the repair pathway may allow low penetrance variation 
such as this to exist in healthy individuals. 
 
9.2 Sequence Analysis Software 
As the cost of capillary sequencing dropped (Figure 9.1: The falling cost of Sanger 
Sequencing reactions) and the availability of 96 capillary machines increased, researchers 
have been able to afford large scale projects using sequencing as the method for SNP 
discovery. Though SNP detection by Sanger sequencing alone may not be as effective as 
using a combined dHPLC/Sequencing approach the improved throughput was considered to 
compensate for the loss in sensitivity. Here the bottleneck quickly became the analysis of 
chromatograms and as with dHPLC (Section 9.1) automated calling software was introduced 
to streamline the SNP discovery process. Here we have assessed various chromatogram 
analysis programmes and while excellent results were obtained from the Staden and 
Mutation Surveyor programmes Sequencher remained the primary sequence analysis 
software in our institute due to the wealth of additional sequence analysis features beyond 
chromatogram analysis. 
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In analysing a large quantity of data we were able to show a significant over 
representation of non-synonymous SNPs were found in the β catenin down regulating 
domain of APC therefore supporting hypothesis that  the unexplained proportion of 
hereditary CRC is caused by numerous rare variants in multiple genes each conferring a 
small increase in risk. 
 
9.3 dbSNP 
The number of validated SNPs in dbSNP continues to rise rapidly making the resource 
more valuable with each build. Extracting data can be laborious when researchers wish to 
obtain information that fulfils a strict set of criteria. Several programmes had been designed 
that accessed dbSNPs database directly but subsequent changes to that database left each 
programme in need of editing. Here we developed a piece of software to ‘strip’ html pages 
(rather than access the database directly) with the thought that this would avoid the pitfalls 
of database updates by dealing only with the user interface. Though the programme would 
have survived the previous updates changes in build 133 have prevented the script form 
running, changes have yet to be written into the code as we have not since required the 
function.  
In genotyping all common non-synonymous in every human DNA repair gene for 480 
normal human lymphoblastoid cell lines we have generated a resource of cell lines with DNA 
repair profiles. Our intention was to select cell lines with specific SNP profiles and test the 
variation in repair capacity within a set of control cell lines however, we were not able to 
reproducibly show the variation between cells response to oxidative damage, possibly due 
to the sensitivity of available assays. 
 
9.4 Pharmacogenetics 
It is though that an individual’s genetic variation plays a significant role in determining 
the success of any given therapeutic agent and we now have the technology to rapidly 
identify that variation and select or tailor treatments based on this knowledge. 
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Several recent studies with relatively small cohorts of samples have attempted to 
show association between genotypes and drug response (Section 7.4.1) however these 
associations were not reproduced in our set of over 2,000 samples. It is likely that the 
effects of SNPs on drug response will have a similar pattern to the effects of SNPs on 
disease, with a broad range of penetrance. Though a proportion of SNPs will be detectable 
from small studies with tightly controlled ‘phenotype’ a large number will be part of 
complex multi-gene systems and identification will require large studies to identify those 
variants with small ORs. 
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Table 9.1: Examples of NGS enabled discovery. 
 
Miller syndrome 
Kabuki 
syndrome 
Autism 
Autosomal 
recessive 
intellectual 
disability 
MIM # MIM263750 MIM147920 MIM209850 none 
     
Type Monogenic Monogenic Complex Complex 
Method 
 
Exome 
Sequencing 
Exome 
Sequencing 
Exome 
Sequencing 
Targeted 
Sequencing 
     
Gene 
 
DHODH 
 
MLL2 
 
FOXP1, GRIN2B, 
SCN1A, LAMC3 
50 genes 
identified 
 
Reference 
 
(Ng et al., 2010b) (Ng et al., 2010a) 
(O'Roak et al., 
2011) 
(Najmabadi et 
al., 2011) 
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Figure 9.1: The falling cost of Sanger Sequencing reactions 
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9.5 Next Generation Sequencing   
9.5.1 NGS in research 
In essence NGS technology can provide a view of the entire genome, multiple 
exomes, deep coverage targeted regions and more recently the epigenome. NGS is being 
applied to advance research into disease mechanisms, cancer biomarkers, diagnostics, drug 
development and any other discipline with an interest in genetics.  
By determining the sequence of an entire human exome it is now possible to apply 
an increasingly ‘hypothesis-neutral’ approach to mutation discovery making NGS an ideal 
tool for rare disease research. Before NGS was available, searching for a causative mutation 
in a monogenic disorder would require either a strong hypothesis suggesting a causative 
gene or vast resources such that numerous genes could be screened. Biochemical 
information, Association studies and animal models may lead to a list of candidate genes for 
testing but with an exome sequence the hypothesis is not necessary. In a recent 
presentation at Hinxton (Genomic Disorders 2011 - The Genomics of Rare Diseases. 23–26 
March 2011) Han Brunner presented results from the exome sequencing of 200 patients 
representing 30 different rare diseases. For 15/30 diseases, new disease genes were 
discovered and a further 5/30 diseases had causative mutation identified in known disease 
genes demonstrating an unprecedented ability to discover a large proportion of rare disease 
genes. 
In one of the first ‘rare monogenic disease – NGS’ publications (Ng et al., 2010b) 
mutations causing disease were discovered by sequencing the exomes of just four 
individuals, 2 siblings and 2 unrelated cases. Common variations (dbSNP129 and 8 HapMap 
exomes) were excluded and the study focussed on nonsynonymous, splice-site and coding 
Indel variation. Shared variation between the siblings was compared to the unrelated 
individuals leading to the identifications of a single candidate gene DHODH. By limiting SNP 
searching to exomes this approach cannot be considered entirely hypothesis neutral; 
however, it represents a considerable move in that direction compared to the candidate 
gene approach. 
SNP discovery and genotyping can be expanded into non-exonic DNA by sequencing 
entire genomes hence moving closer to a truly hypothesis neutral approach. Currently there 
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are financial and practical limitations to genome sequencing on a large scale; however, 
when these obstacles are overcome NGS may enable researchers to return to analysing 
multi-case families as was seen in early positional cloning methods with linkage analysis. 
When using a limited set of markers this approach was surpassed by Association studies 
using large populations as a mechanism of finding disease gene loci. With a complete 
picture of variation supplied by genome sequencing it may become a realistic option in 
some cases to return to a Linkage analysis approach to identify co-segregating mutation in 
families affected by complex disease. 
By focusing on small sections of the genome (a few Megabases or less) to create 
libraries NGS can provide deep coverage of a targeted sequence. This approach has the 
potential to identify low level variation (e.g. mosaicism) or rare transcription products 
depending upon the starting material. “Targeted Deep Sequencing” of mRNA has recently 
exposed levels of complexity to the human transcriptome which were not previously 
detectable. Mercer et. al. (2011) have described the sequencing of 0.77Mb of DNA 
including; exons, introns, known non-coding RNA and intergenic regions extracted from a 
primary foot fibroblast cell line. NGS enabled the region to be covered with an average 
4,607-fold coverage, in doing so they describe 204 previously unknown isoforms of 55 
protein coding loci. This demonstrates the utility of the technology to expose a new level of 
detail to our knowledge of transcription. The numerous known GWAS loci that as yet have 
no relationship to causative mutation (NHGRI data http://www.genome.gov/26525384) may 
benefit from this understanding of low level products. Variation in non-coding RNA (such as 
micro RNA) and rare transcripts may come to explain a functional aspect to some of these 
‘orphan’ GWAS loci. 
Transcriptome sequencing demonstrates that NGS is not limited to analysis of DNA. 
RNA sequencing on this scale can give a more comprehensive overview of expression than 
microarrays. By studying the expression profiles of cells treated with drugs and contrasting 
them with profiles from cells in a disease state it may be possible to find new uses for 
existing drugs. This approach is known as 'drug repositioning’, compounds that have failed 
their original purpose are screened for alternative therapeutic effects (a classic example 
being Pfizer’s Viagra, a failed Angina treatment). Given the failure rate and cost of creating 
new drugs, approaches that will demonstrate a potential use for a ‘failed’ compound are an 
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attractive option especially where trials have already been completed showing the drug to 
be suitable for humans. 
 
9.5.2 NGS in clinics 
Recent reports from Life Technologies and Oxford Nanopore suggest that the current cost of 
NGS is likely to continue to fall dramatically over at least the next 12 months and, ultimately 
a point will be reached where it is more cost effective for clinical laboratories to undertake 
NGS rather than individual genetic tests. 
It has been demonstrated that through NGS it is possible to obtain a clinical 
diagnosis by identifying variation. In a patient with a “suspected diagnosis” of Bartter 
syndrome (MIM 607364) Choi et. al. sequenced the exome and identified a missense 
mutation in the highly conserved residue (p.D652N) of SLC26A3 a gene known to cause 
congenital chloride diarrhoea (Choi et al., 2009). A further five patients were found to have 
deleterious mutations in the same gene. 
In the case of Nicholas Volker (Worthey et al., 2011) NGS identified a mutation 
causing a previously undefined type of Inflammatory Bowel Disease (IBD). The patient 
presented with symptoms similar to Crohn disease at the age of 15 months. Before he had 
turned four he had undergone over one hundred surgeries relating to gastrointestinal 
inflammation including the removal of his colon. The patient’s exome was sequenced for 
coding region mutation. After filtering nonsynonymous variation and testing with Polyphen 
p.C203Y was discovered in the X-linked apoptosis gene XIAP, a gene not previously 
associated with the observed pathology. The diagnosis based on NGS data led to a bone 
marrow transplant that has led to an effectively normal life. These cases demonstrate that 
NGS is already a solution for diagnosis of rare disease in situations where traditional 
diagnosis techniques fail to uncover a cause. 
 
9.5.3 NGS Problems  
The sequencing of a human genome has dropped from a reported $4B to under 
$4,000 in ten years. Whilst this is empowering researchers to investigate DNA on a new 
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scale it has also brought problems. Technology providers are heavily promoting the concept 
that these instruments will soon be fast and cheap enough for routine clinical practice but 
analysis is not trivial and while the cost of generating the data may soon seem insignificant 
the cost and practicality of analysis and storage are not improving at the same rate. Moore’s 
Law (Moore, 1965) is used in computing to predict the improvement over time of functions 
such as processor capacity and memory speed. It has proven to be highly accurate in 
predicting a doubling in performance annually. Production of NGS data far outpaces 
Moore’s Law as demonstrated in Figure 9.1. 
 
9.5.3.1 Data Analysis 
Data analysis is an area that contains a mass of variables. Currently a single data set 
when analysed with two separate pipelines will show inconsistency between the reported 
SNPs. Between pipelines decisions are made on elements such as mapping algorithms, 
quality calling, accounting for phasing, aligning non-unique sequence. The combination of 
these variables will culminate in differences in mapping and hence differences in SNP calling 
from the same raw data. Broadly speaking there are NGS analysis packages that tend to be 
the most commonly used (BWA aligner, GATK, SAM Tools) but there is not yet a consensus 
on settings within these programmes even when the objectives are identical. 
 
9.5.3.2 In vitro variation 
In a laboratory experiment with the same; protocol, reagents, instruments and 
library you would not necessarily expect to see the same result following NGS analysis. Two 
aliquots from the same library will not be identical at a molecular level. Even if it were 
possible to provide identical library aliquots (molecule for molecule) the numerous 
processes of library preparation are likely to result in differing sequence success at each loci. 
At the level of an individual project (within a single analysis pipeline) thresholds are set that 
determine whether a SNP is called or not. If a locus has 30X coverage and 15 of those 
sequences identify a minor allele then heterozygote calling is straight forward; however, if 
that sample has 10X coverage with 4, 3 or 2 minor alleles then calling relates to the 
judgement of the user.  
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(http://www.genome.gov/sequencingcosts) 
Figure 9.2: Falling cost of DNA Sequencing. 
The cost of producing raw sequence (blue) fell steeply in 2008 when centres started to 
move away from Sanger sequencing technology. The decrease in cost continues to outpace 
Moore’s law which predicts improvements in computer technology.
187 
 
9.5.3.3 Potential for misuse 
Fears of misuse of information are well founded and far reaching. An inability to 
obtain health insurance, a mortgage or even employment could potentially occur if an 
individual is known to carry strong risk factors for disease. In reality genetic predisposition 
does not necessitate disease and it is likely that all individuals will carry several significant 
risk factors.  
 
9.5.3.4 External Perception 
The NGS revolution has not yet begun to slow its pace and while Research is reaping 
the rewards the gap in public understanding is likely to grow at an equally exponential rate 
unless there is a significant change in the teaching practice from schools to professional 
medical courses (Ware et al., 2012). 
 Understanding our own risk of disease and acting accordingly are not always closely 
aligned. The technology is now available to provide individuals with detailed information on 
their known risk factors for various diseases; however, providing appropriate advice does 
not necessarily result in appropriate behavioural/lifestyle changes (Bloss et al., 2011). 
Indeed it can be readily demonstrated by the fact that in the UK alone there are an 
estimated 10 million cigarette smokers (http://www.ash.org.uk) despite the well-publicised 
risks. 
 
9.5.4 The Future of NGS 
Current NGS projects tend to focus on exomic sequences ignoring the rest of the 
genome for reasons of cost and perhaps perceived irrelevance of non-coding variation.  
While the cost of sequencing an exome is lower than the cost of a genome the 
difference is not as great as might be expected. The exome capture kits represent a 
significant proportion of the total cost as well as adding a significant time to the library 
preparation procedure (3-4 days). By extending the library preparation procedure with 
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fragment capture we introduce opportunities for errors and necessitate a qPCR validation 
step to prove enrichment has occurred. 
Exomes provide the most readily interpretable SNPs. Our knowledge of non-coding 
variation is minute in comparison to the quantity of sequence it refers to and it is not likely 
to expand until genome sequencing becomes the standard. With the developments that are 
promised for faster, cheaper sequence generation whole genome NGS is likely to become a 
core approach in clinical diagnostics, simplify library preparation and analysis and enabling 
our knowledge of mutation to expand into further into non-coding DNA. 
 The Baylor College of Medicine has already announced its aims to routinely genome 
sequence all new patients at the Texas Children's Cancer Centre (Genome web August 03, 
2011 http://www.bcm.edu/news/packages/pediatricgenomecenter/) and eventually to 
sequence all new paediatric cancer cases in the state of Texas, approximately 1,000 per 
year. This demonstrates the perceived importance this technology has to health care and 
will create a vast resource in childhood cancer research. 
In the short term the most significant impact of NGS is that will underlie an improved 
understanding of heterogeneous disease and drug response/efficacy. In the long term there 
is likely to come a tipping point where all current genetic testing for mutation is replaced by 
genome sequencing. This would simplify the work load of NHS diagnostic facilities and 
provide economies of scale whilst producing patient information that would be relevant for 
all subsequent medical considerations and treatments. 
In 2009-10 Welsh Assembly Government (WAG) budget for health care was £5.5B, or 
£1,781 per person 
(http://wales.gov.uk/topics/statistics/headlines/health2012/120328/?lang=en) when 
pharmacogenomics has developed to the point where Personalised Medicine is a reality, the 
proportion of this cost that is spent on individual genetic tests, treatment of Adverse Drug 
Reaction (ADR) and Cancer therapy will have to be balanced against the cost of nationwide 
sequencing programme. Should that information become available to the research 
community it would represent an invaluable resource. 
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9.5.5 Third Generation 
Third generation technology (Section 1.4.5) is set to provide the platforms with 
throughput and costs that will enable genome sequencing to surpass exome sequencing as 
the preferred approach. Oxford Nanopore announced two systems at the AGBT 2012 
conference that will require “minimal sample preparation“ and provide GBs of reads that 
are 10s of Gb in length for a total predicted cost of around US$1,000. However, the 4% error 
rate (presented at the conference) is a significant drawback in comparison to current Next 
Generation technology which operates with error rates that are a fraction of a per cent. 
While this third generation will undoubtedly provide improved de novo genome 
assembly, structural variant analysis, and Metagenomics a considerable improvement will 
be required before it is suitable for SNP related work. 
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Appendix 
 Appendix A: PCR primers for dHPLC. 
Gene/primer 
name 
Primer Sequence (5' to 3') Product 
Size (bp) 
Annealing 
Temp. (ºC) 
MSH6 (NG_007111.1)   
MSH6X2newF  GGTATGTATTTCCTTTTGGCAA  243 60 
MSH6X2newR CATGGCAGTAGTGACTCTT    
MSH6X3F  ACCCGGCCCTTATTGTTTAT  260 60 
MSH6X3R  CTTCCCCCATCACCCTAA    
MSH6X4.1F  AAATACTCTTTCCTTGCCTGGC  283 60 
MSH6X4.1R  CTTTGACAGGGCTGTTCAGG    
MSH6X4.2F  GCAGTGGAGTGGGGGATA G  293 54 
MSH6X4.2R  TTCCTCCTTAAGCCATTCTAAA    
MSH6X4.3F  GTCGCCCTACTGTTTGGTATC  277 60 
MSH6X4.3R  ATGAATTCCAGCCCCAGTTC    
MSH6X4.4F  GCTGTACCACATGGATGCTCT  289 60 
MSH6X4.4R  TCACCTTCCAGCACACTGTAA    
MSH6X4.6F  CGCCATTGTTCGAGATTTAG  286 60 
MSH6X4.6R  TGTCAACCCAATGGAATCAG    
MSH6X4.8F  CTGATTCCATTGGGTTGACA  268 60 
MSH6X4.8R  ACTGCATCTAGCACCATTCG    
MSH6X4.11F  CCAAAGCAGGCTTTGACTC  288 52 
MSH6X4.11R  TCCGTTCTTCAGCATTTATGA    
MSH6X5.1F  CCAAACGATGAAGCCTCACT  283 60 
MSH6X5.1R  CCCCCATATTTGGTCCAGTA    
MSH6X5.2F  GCCATCCTTGCATTACGAA  237 60 
MSH6X5.2R  TGTTTGGAAAATGATCACCTAAG    
MSH6X6F  TGCCTAGCTCTTACGTAAGGG  248 60 
MSH6X6R  CTGAATGAGAACTTAAGTGGGAA    
MSH6X9F  CTTGCTAGCACATGTATCGCT  294 60 
MSH6X9R  TTTCTTTGAAACTTAAGGTCAGTT    
    
NEIL2 (NM_001135746.1)   
NEIL2X1newF  TGCTTGGCACCTGTTAAAG 238 56 
NEIL2X1newR  CCTTCAGAGGAGTATTAC   
NEIL2X2.2F  GGCGAGGATGATTCTGAGTA 210 55 
NEIL2X2.2R  GGCCCTATGACTATGAGAGC   
NEIL2X3newF  ATGTGGGGATGTGTGTATGT 402 60 
NEIL2X3newR  AACAGCACTGGCACAACTAG   
NEIL2X4.1F  AGCTGATTTCTGCCTTGTTAA 275 60 
NEIL2X4.1R  GGCACTGTTCTTTCTGGTAGA   
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NEIL3 (NM_018248.2)   
NEIL3X1F  GCACAGCGGTATTCTCAC 315 60 
NEIL3X1R  GCCAGAGCAAAGAGATGAC   
NEIL3X2F  ACCTGGGCGTGAAGTAATA 348 55 
NEIL3X2R  GGAGCTCTCTTAAAAACACAGT   
NEIL3X5F  CAAGGCGTATTATTTCTTACAG 258 60 
NEIL3X5R  CTCCATGCTCTTTCCACTA   
NEIL3X8.1F  CATGTCTGGGTTTCTGTAAGT 428 55 
NEIL3X8.1R _new CTAGTATCTGGTTTGCTTTGT   
NEIL3X10F  TGATAACAGCAGTGAAGACTATA 351 60 
NEIL3X10R  GAGGAGGACCAAACATTATAC   
    
OGG1 (NM_002542.5)   
OGG1X5F  CCGGCTTTGGGGCTATA 466 60 
OGG1X5R  GTTTCTACCATCCCAGCCCA   
OGG1X7F  ACCTCCCAACACTGTCACTA 489 60 
OGG1X7R2 TGAACCGGGAGTTTCTCTGC   
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Appendix B: SNP genotyping Assays. 
Gene/variant Fragment Primer name Primer sequence (5' to 3') Product 
Size (bp) 
Anneal 
temp (oC) 
Assay 
OGG1 
(NM_002542.5) 
           
p.R46Q Exon 1 M1F CTTTGGGCGTCGACGAG 338 60 HphI digest 
(c.137 G>A)  OGG1_Ex1R1 CCCGTGCTTGTTTCCTCTT     G allele digested (130 + 
208bp) 
p.A85S Exon 2 OGG1_A85S_FG ACCGAGGAGACAAGAGCCCGG 150 56 ARMS1 
(c.253 G>T)  OGG1_A85S_FT ACCGAGGAGACAAGAGCCGGT       
   OGG1_A85S_R GGAATTTCTGAGCCACCTCTT       
c.748 -15 G>C Exon 5 OGG1_748-15_FN TCTTCCACAAGGGCTCAATC 205 57 ARMS3 
   OGG1_748-15_FM TCTTCCACAAGGGCTCAATG       
   OGG1_748-15_RCP CTGCAGCCCACTTTCCTCAC       
p.A288V Exon 5 OGG1_A288V_FC GCACCCTACCACGTCCCATGC 138 56 ARMS1 
(c.863 C>T)  OGG1_A288V_FT GCACCCTACCACGTCCCAAGT       
   OGG1_A288V_R GTCTGAGGGAGAGGTGACTA       
p.S326C Exon 7 OGG1_S326F_G TCAGTGCCGACCTGCGCCATTG 210 60 ARMS1 
(c.977 C>G)  OGG1_S326F_C TCAGTGCCGACCTGCGCCATTC       
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   OGG1_S326_R2 GTGCCTGGCCTTTGAGGTAGTC       
c.1037+ 279 A>G Exon 7 OGG1_Ex7_INTF  
OGG1_Ex7_INTRM 
CAGGCACCCCCAAATCAAGC 
CCTGTCCCCTCCTCACCTCCC 
179 55 ARMS3 
   OGG1_Ex7_INTRN CCTGTCCCCTCCTCACCTACT       
p.I321T Exon 7 OGG1_Ex7b_FNI CTGACAGCTCTGTCAGGTTAT 196 59 ARMS3 
(c.962 T>C)  OGG1_Ex7b_FMT CTGACAGCTCTGTCAGGTGAC       
   OGG1_Ex7b_RCP AGGGATCCTTACTGAAGGAC       
       
NEIL1 
(NM_001256552.1) 
           
c.434+2 T>C Exon 2 NEI1_434+2_F_T CAGGAGTACCAGCAGTTCAAGT 174 58 ARMS1 
   NEI1_434+2_F_C CAGGAGTACCAGCAGTTCATGC       
   NEI1_434+2_R AGCTGACCCAGGACAGGTATA       
p.P208S Exon 4 NEI1_Ex4F GGATGAACTGCCCAAGTCT 358 55 SacI digest 
(c.622 C>T)  NEI1_Ex4R AGCCTGGAAACACTATTGACA     T allele digested (102bp 
+ 256bp) 
p.R339Q Exon 9 NEI1_R339_F_G CTAAGAGGACTGCAACCCATCG 121 60 ARMS1 
(c.1016 G>A)  NEI1_R339_F_A CTAAGAGGACTGCAACCCAACA       
   NEI1_R339_R GAGGAAAGCCCACCAGAGG       
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NEIL2 
(NM_001135746.1) 
           
p.R103Q Exon2 NEI2_R103_Fnew GTCTGTAAGGCTTGGATCTCT 225 58 ARMS1 
(c.308 G>A) fragment 1 NEI2_R103_RA GGGGACGAGCTCTGCAGGCT       
   NEI2_R103_RG GGGGACGAGCTCTGCAGCCC       
p.R164T Exon 2 NEI2_R164_RG ATCAGATGGCCACACCATTCCC 181 56 ARMS1 
(c.491 G>C) Fragment 2 NEI2_R164_RC ATCAGATGGCCACACCATTCCG       
   NEI2_R164_F GCGAGGATGATTCTGAGTATT       
p.P188P Exon 3 NEI2_Ex3new_F ATGTGGGGATGTGTGTATGT 396 60 BsrI digest 
(c.564 A>G)  NEI2_Ex3new_R AACAGCACTGGCACAACTAG     A allele digested (174bp 
+ 222bp) 
c.689 -13 C>T Exon 4 NEI2_689-13_RC ATGATGTTCCCTGAAATAAATCG 169 56 ARMS1 
  fragment 1 NEI2_689-13_RT ATGATGTTCCCTGAAATAAAACA       
   NEI2_689-13_F GAATTGTCAACTCCATTTTACA       
p.R257L Exon 4 NEI2_R257_FG GTCCTGAGTGCCTCGCGGCG 482 61 ARMS2 
(c.770 G>T) fragment 1 NEI2_R257_FT GTCCTGAGTGCCTCGCGCCT       
   NEI2_R257_R CACGATGGTGCAATTCAACAG       
Exon 2 - Exon 4 n/a NEI2_LD_F 
NEI2_LD_R 
TAAGGCTTGGATCTCTGTTCAT 
TGCTCTGGCTCCTCTGACA 
6500 65 LD-PCR to clone region 
spanning R103Q and 
R257L 
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NEIL3 
(NM_018248.2) 
           
p.R15R Exon 1 NEI3_Ex1F GCACAGCGGTATTCTCAC 315 55 TaqI digest 
(c.45 C>A)  NEI3_Ex1R GCCAGAGCAAAGAGTGAC     A allele digested (100bp 
+ 215bp) 
p.R38C Exon 1 NEI3_Ex1F GCACAGCGGTATTCTCAC 315 55 BstUI digest 
(c.112 C>T)  NEI3_Ex1R GCCAGAGCAAAGAGTGAC     C allele digested (145bp 
+ 170bp) 
p.P117R Exon 3 NEI3_Ex3F GACTAACATTTGTTTGCTTATA 295 55 BssSI digest. 
(c.349 C>G)  NEI3_Ex3R AACCAAGCTCTGCAGTAT     G allele digested (116 + 
179bp) 
p.D132V Exon 3 NEI1_Ex3F GCGGGCAGAGATCCTGTA 289 60 HinFI digest. 
(c.395 AC>TG)  NEI1_Ex3R CCACCCCTGTTGTTGAGCTA     TG allele digested (109 + 
115 + 71bp) 
p.Q172H Exon 3 NEI1_Ex3R CCACCCCTGTTGTTGAGCTA 166 56 ARMS3 
(c.516 G>C)  Q172_NEWREV TCACCTAGCATCCGGCCTATC       
   H172_NEWREV2 TCACCTAGCATCCGGCCTATG       
c.627+41 A>G Exon 4 NEI3_Ex4F ATACCCTGATTAACATAAAGTG 453 55 ScaI digest. 
   627+41_DIG_REV GGTAGAAATGGGAAGCGGGAC     A allele digested (93 + 
360bp) 
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c.701+34 del 7bp Exon 5 NEI3_Ex5_FAM 
NEI3_Ex5R 
TTTCAGCATTCTCTTTTACAGG 
CTCCATGCTCTTTCCACT 
258 58 Fluorescent PCR 
products sized 
p.H286R Exon 6 H286R_FOR AGTGCCGTAAAGCAGGACTTGCT 180 52 ARMS3 
(c.857 A>G)  H286_REV CAATATCTTACCATATGTCAATAT       
   R286_REV CAATATCTTACCATATGTCAAGAC       
p.R315Q Exon 7 NEI3_Ex7F TGGGGTATTAATGGTTCTATA 307 55 DdeI digest 
(c.944 G>A)  NEI3_Ex7R CCCTCTTAGAAATGTAACAAA     A allele digested (8 + 60 
+ 75 + 164bp) 
c.1040 -85 T>C Exon 8 NEI3_Ex8F1new CATGTCTGGGTTTCTGTAAGT 428 55 ApoI digest 
   NEI3_Ex8R1new ACAAAGCAAAACCAGATACTAG     T allele digested (24 + 
111 + 118 + 175bp) 
p.V424V Exon 8 NEI3_Ex8F2new CTGCATTTGGAACTACAACTCT 245 52 ARMS3 
(c.1272 G>T)  V424V_NREV GGGTGCTGTATATCATTCAAATAC       
   V424V_MREV GGGTGCTGTATATCATTCAAAGAA       
p.R520G Exon 9 NEI3_Ex9F TGGGCTTTCCTCATCACTC 265 55 BslI digest 
(c.1558 A>G)  NEI3_Ex9R GCAGGGCAAGACAATAAGA     G allele digested (163+ 
165bp) 
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MTH1 
(NM_002452.3) 
           
p.V106M Exon 4 MTH1X4V106M_F TCCCTGGGCTGTGTGTAGAT 220 56 ARMS4 
(c.316 G>A)  MTH1X4V106M_RN TCTGTGCAGAAGACATGGAC       
   MTH1X4V106M_RM GTCTGTGCAGAAGACATGTAT       
p.D142D Exon 5 D142D_FCP ATGAAGTTTGGGTTGCACCTC 128 59 ARMS3 
(426 C>T)  D142D_RN AGTGGAAACCAGTAGCTGACG       
   D142D_RM AGTGGAAACCAGTAGCTGCCA       
p.K155I Exon 5 MTH1X5K155I_F TGAAGTTTGGGTTGCACCTC 164 57 ARMS3 
(c.464 A>T)  MTH1X5K155I_RN CTTGAAGTACCCGTGGACTT       
   MTH1X5K155I_RM CTTGAAGTACCCGTGGAGTA       
NTH1 
(NM_002528.5) 
           
p.Q90X Exon 2 NTH_2F ACCTGTGGCCCCACCAGAGG 373 58 BstNI digest. 
(c.268 C>T)  NTH_2R GGGAGGGTGCCAGCCAAAAG     C allele digested (170 + 
203bp) 
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MSH6 
(NG_007111.1) 
           
p.P92P Exon 2 normal CTTGGCCCAAACCAAATCTTCT 243     
(c.276A>G)   variant CTTGGCCCAAACCAAATCTTCC       
   common TAGAATTTCTGTGCTTCAATATTA       
p.D180D Exon 3 normal GAGAGCAATGCAACGTGCAAAT 260     
(c.540T>C)   variant GAGAGCAATGCAACGTGCATAC       
   common CCCCATCACCCTAACATAAAT       
p.Y214Y (c.642C>T) Exon 4 
fragment 1 
MSH6X4.1F  
MSH6X4.1R 
AAATACTCTTTCCTTGCCTGGC  
CTTTGACAGGGCTGTTCAGG 
366 60 SnaBI digest. C allele 
digested (122 + 244bp) 
c.3438+14A>T Exon 5 normal GACTTTCTGATAACAAAACCTT 237     
   variant GACTTTCTGATAACAAAACCTA       
   common ATCCTTGCATTACGAAGACT       
Internal control primers used to validated ARMS assays:  
1TSC2_Ex26F (5’-GAGCTTTGGCCCTTGGTGATA) and TSC2_Ex26R (5’-CTCGCCCACAGGAGACCTAGA), product size 338bp; 2TSC2_Ex38F 
(5’-ACCAGGCAGTAGCCGAGATC) and TSC2_Ex38R (5'-CCACAAGGCCCTCCATGTC), product size 275bp; 3AJ32 (5’-
TGGCACTGAGTTGACACTCT) and AJ31 (5'-CAAATAATGTTTTCCAGAGACA), product size 315bp; 4AJ54 (5’-CCCTGTCTGCCGTTAAATAC) 
and AJ55 (5'-GCTGTTTTGCACTCCTCAAT), product size 307bp. 
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Appendix C: Amplification and dHPLC conditions for glycosylase genes. 
Gene / primer 
name 
Primer sequence    
(5’ to 3’) 
Product 
Size (bp) 
Annealing 
Temp (ºC) 
dHPLC 
conditions 
    
Temp 
1 (ºC) 
Temp 
2 (ºC) 
OGG1 
(NM_002542.5)           
MIF CTTTGGGCGTCGACGAG 237 60 62.8 65.8 
M1R GAGGGGACAGGCTTCTCAG 
    M2F1 ATTGAGTGCCAGGGTTGTCA 245 52 62.1 63 
M2R1 CGGAACCCCAGTGGTGATAC 
    M2F2 TGTACTAGCGGATCAAGTAT 286 52 61 / 
M2R2 TGGCAAAACTGAGTCATAG 
    M3F1 GTCTGGTGTTGCTTTCTCTAAC 229 60 59.6 63 
M3R1 GTGATGCGGGCGATGTT 
    M3F2 TCTCCAGGTGTGCGACTGC 275 60 60 63.5 
M3R2 AGGAAGCCTTGAGAAGGTAACC 
    M4F GGAAGAACTTGAAGATGCCT 296 52 63.5 64 
M4R GCTCATTTCCTGCTCTCC 
    M5F CCGGCTTTGGGGCTATA 279 60 63 / 
M5R GTTTCTACCATCCCAGCCCA 
    M6F TACTTCTGTTGATGGGTCAC 153 60 59.3 61.5a 
M6R TGGAGGAGAGGAAACCTAG 
    OGG1_Ex7F ACCTCCCAACACTGTCACTA 489 60 55.5 61.5 
OGG1_Ex7R2 TGAACCGGGAGTTTCTCTGC 
    OGG1_Ex7bF AGGCTTAGCACTTGCACTTCC 267 60 58.7 / 
OGG1_Ex7bR AGGGATCCTTACTGAAGGAC 
    M8F1 CTGTGGCCCACGCACTTGTG 253 60 61.5 / 
M8R1 ACGTCCTTGGTCCAGCAGTGGT 
    M8F2 GAGAGGGGATTCACAAGGTG 287 60 60.5 62 
M8R2 GCCATTAGCTCCAGGCTTAC 
    
      NEIL1 
(NM_001256552.1) 
     NEI1_Ex1F1 AGCCGCTACCTCACAAAGTC 234 60 63.5 65 
NEI1_Ex1R1 CGGGCTGAAGCTGAGATG 
    NEI1_Ex1F2 GTGGAGAAGTCCTCTGTCAG 426 55 62.5 65 
NEI1_Ex1R2 CCAAGAAGGCACTAAGAGA 
    NEI1_Ex2F_NEW AGGGAGAAGAGGAACTGTAAC 352 60 62 / 
NEI1_Ex2R_NEW GGGATCTTCAGCCTGTAGT 
    NEI1_Ex3F GCGGGCAGAGATCCTGTA 289 60 64 / 
NEI1_Ex3R CCACCCCTGTTGTTGAGCTA 
    NEI1_Ex4F GGATGAACTGCCCAAGTCT 358 55 61 62 
NEI1_Ex4R AGCCTGGAAACACTATTGACA 
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NEI1_Ex5F GAGCCTGCCCTCTGATCTC 205 60 62.5 64.5 
NEI1_Ex5R TGGGGTCTCTGCCTGTGT 
    NEI1_Ex6/7F CCAGGCTGATTCCTGAATTA 411 60 58.5 62 
NEI1_Ex6/7R GGCTCAGAAAGCAGTTCAGA 
    NEI1_Ex8F GCCCTAACCAACCTCTGA 281 60 62.5 63.5 
NEI1_Ex8R CATCCCATCCTCTCCTGTAG 
    NEI1_Ex9F TGGGCTTTCCTCATCACTC 265 55 62 / 
NEI1_Ex9R GCAGGGCAAGACAATAAGA 
    
      NEIL2 
(NM_001135746.1) 
     NEI2_Ex1F_NEW TGCTTGGCACCTGTTAAAG 238 56 62 / 
NEI2_Ex1R_NEW CCTTCAGAGGAGTATTAC 
    NEI2_Ex2F1 TTCCCCTCTGGGTCTGT 330 55 56 62.5b 
NEI2_Ex2R1 CTGCCAAACAAACCAAAGC 
    NEI2_Ex2F2 GGCGAGGATGATTCTGAGTA 210 55 62 / 
NEI2_Ex2R2 GGCCCTATGACTATGAGAGC 
    NEI2_Ex3F_NEW ATGTGGGGATGTGTGTATGT 402 60 59 60.5 
NEI2_Ex3R_NEW AACAGCACTGGCACAACTAG 
    NEI2_Ex4F1 AGCTGATTTCTGCCTTGTTAA 275 60 59 62.5a 
NEI2_Ex4R1 GGCACTGTTCTTTCTGGTAGA 
    NEI2_Ex4F2 ACGTGGTGGAGTTCAGTA 328 60 63 / 
NEI2_Ex4R2 GCACCTCTGACCCACACTAT 
    
      NEIL3 
(NM_018248.2) 
     NEI3_Ex1F GCACAGCGGTATTCTCAC 315 60 62.5 64.5 
NEI3_Ex1R GCCAGAGCAAAGAGATGAC 
    NEI3_Ex2F ACCTGGGCGTGAAGTAATA 348 55 57 / 
NEI3_Ex2R GGAGCTCTCTTAAAAACACAGT 
    NEI3_Ex3F GACTAACATTTGTTTGCTTATA 354 55 55 / 
NEI3_Ex3R TTTCATCAATTACAAACTCTT 
    NEI3_Ex4F TACCCTGATTAACATAAAGTG 382 55c 53.5 56.5 
NEI3_Ex4R CGTTGGTTCCTTCACAGTA 
    NEI3_Ex5F CAAGGCGTATTATTTCTTACAG 258 60 57 / 
NEI3_Ex5R CTCCATGCTCTTTCCACTA 
    NEI3_Ex6F CTTGGCAGCACTGTTTGT 389 50c 55 57 
NEI3_Ex6R TCAGGTTCTTTGGTGACATTAT 
    NEI3_Ex7F TGGGGTATTAATGGTTCTATA 307 55 52.5 56 
NEI3_Ex7R CCCTCTTAGAAATGTAACAAA 
    NEI3_Ex8F1_NEW CATGTCTGGGTTTCTGTAAGT 428 55 53 55.5 
NEI3_Ex8R1_NEW CTAGTATCTGGTTTGCTTTGT 
    NEI3_Ex8F2 CTGCATTTGGAACTACAACTCT 349 55 55 56.5 
NEI3_Ex8R2 CAATTATCTTAAAGACCAAGGTT 
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NEI3_Ex9F GGGGTAAAGTGGTGTGAAT 328 50 53 57 
NEI3_Ex9R CTAGGAAAGTATTGCTATTTGTTA 
    NEI3_Ex10F TGATAACAGCAGTGAAGACTATA 351 60c 55.5 56.5 
NEI3_Ex10R GAGGAGGACCAAACATTATAC 
    
      MTH1 
(NM_002452.3) 
     T2F GCAAGGACAGAGGGCTTTCTG 249 60 60.5 61.5 
T2R CCAGCAGGCCATCAACTGAT 
    T3F GCACGTCATGGCTGACTCT 246 55 62 63.5 
T3R CTGGGAAAGCCGGTTCTAT 
    T4F TCCCTGGGCTGTGTGTAGAT 298 55 64.5 / 
T4R GAGATGGGACCCGCATAGT 
    T5F TGAAGTTTGGGTTGCACCTC 281 55 61.5 63.5 
T5R AGATGGTTTGCGGCTGTTC 
    
      NTH1 
(NM_002528.5) 
     NTH1F TGTAGTTCTGTGCCGCCCTCTG 273 55 65.5 66.5 
NTH1R TCCAGCCTGCAGCCCCTATC 
    NTH2F ACCTGTGGCCCCACCAGAGG 373 58 62 63.5 
NTH2R GGGAGGGTGCCAGCCAAAAG 
    NTH3F GCAACAAACCAGGGTGTGTC 323 58 64.5 / 
NTH3R GAGGTCTCTCTGAGGCCACTG 
    
      NTH4F GGGCTGCATCCTCCCAGGTT 287 58 61.5 64.5 
NTH4R GATGTGGGGAATCCCAAGAGC 
    NTH5F1 GGTGGAGTGTGCCCCTGTT 423 57c 63 64 
NTH6R1  CCTGAAGCGTAAAGCCACTTC         
 
Time shifts of +0.5 mina and +1.0 minb were applied for dHPLC analysis at this 
temperature; cPCR reaction included 4% DMSO.
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Appendix D: PCR Primers. 
Gene/primer 
name 
Primer Sequence (5' to 3') Product Size 
(bp) 
Annealing 
Temp. (ºC) 
APEX 
(NM_001244249.1) 
   
APE1X1F GGAGGCGGGGAAAGGATTTAGAG 366 60 
APE1X2R CTGCGACTTCTTCACAAACC   
APE1X3F GTGAAGAAGTCGCAGGAACCGTAGGCTT 381 60 
APE1X3R CCTGAAGGCTAAACGGAGAA   
APE1X4F GAATATTGTGCTGCTTGACTC 420 60 
APE1X4R GGGAAAGCAATCAAGAGGTG   
APE1X5F TTGCTAATTCTCTATCTCTG 673 56 
APE1X5R GAGTGTTTAAAGAAGGAATGG   
    
MBD4 
(NM_003925.1) 
   
MBD4_Ex1F CTTTCGCAACATTCAGACCTC 297 60 
MBD4_Ex1R ACTGTCCACTCTCCCGATACC   
MBD4_Ex2F TGAGTAGGCAGTGGAAGATAA 374 58 
MBD4_Ex2R AAGCTAAGATTCCTGCTATGC   
MBD4_Ex3F1 AATGTGGTCCAGTTCTTTTAA 399 56 
MBD4_Ex3R1 ATCAACACCCTCATCTTCTTT   
MBD4_Ex3F2 TTCAAACTGGAACCTCAGGAC 361 60 
MBD4_Ex3R2 AGCATCAGAAATGCAGACAGT   
MBD4_Ex3F3 GATGCTGAAAGTGAACCTGTT 496 58 
MBD4_Ex3F3 TCTTGGCTCTATTTTCACATC   
MBD4_Ex4F ATTATTTGCATCCCTCAATAT 214 56 
MBD4_Ex4R ATAGTGCATCAGAATTGAAAA   
MBD4_Ex5F AATCAGAACAGCAAATTCTAA 298 56 
MBD4_Ex5R TGACACACTCAAAATGGACT   
MBD4_Ex6F CCACCTGGAGTCTTGTAATCA 225 56 
MBD4_Ex6R TATGTTTTTCCTTTGGGTGTA   
MBD4_Ex7F ATTTTGGGAGGGTGTCTTTAG 205 58 
MBD4_Ex7R CAGAGACCAAATGTGCTGAAT   
MBD4_Ex8F GGTCTCTGCCTCTGTATCTTATGTTT 262 56 
MBD4_Ex8R TCTTAATGTGTGTGCCAATG   
    
MPG 
(NM_001015052.2) 
   
MPG_Ex1F TCGAGTGTGTCAGGGTGTT 185 58 
MPG_Ex1R CGTCGGCAAAACTGTAATG   
MPG_Ex2F CCTATTCGGATGCTTATTTA 378 60 
MPG_Ex2R GGGTTCAGGGACAACTG   
MPG_Ex3F GGGCACTGTTAGGGTGAG 357 60 
MPG_Ex3R CCACCTCAGTCCTCCTAG   
MPG_Ex4F1 GCTCCACTTCCAAACTGTC 242 60 
MPG_Ex4R1 CCAGCCATACAGCTTCATC   
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MPG_Ex4F2 CCAGCCGTGTCCTCAAG 311 58 
MPG_Ex4R2 AAAATCTTGTCTGGGCAGG   
    
NEIL3 
(NM_018248.2) 
   
NEI3_Ex1F GCACAGCGGTATTCTCAC 315 58 
NEI3_Ex1R GCCAGAGCAAAGAGATGAC   
NEI3_Ex2F ACCTGGGCGTGAAGTAATA 348 58 
NEI3_Ex2R GGAGCTCTCTTAAAAACACAGT   
NEI3_Ex3F GATATACTTTCTGCCACTCAAAAATGGT 289 56 
NEI3_Ex3R TTTCATCAATTACAAACTCTT   
NEI3_Ex4F TACCCTGATTAACATAAAGTG 381 56 
NEI3_Ex4R CGTTGGTTCCTTCACAGTA   
NEI3_Ex5F CAAGGCGTATTATTTCTTACAG 258 56 
NEI3_Ex5R CTCCATGCTCTTTCCACTA   
NEI3_Ex6F AGCACTGTTTTGTGGATAACAGAATT 383 58 
NEI3_Ex6R TCAGGTTCTTTGGTGACATTAT   
NEI3_Ex7F TGGGGTATTAATGGTTCTATA 307 58 
NEI3_Ex7R CCCTCTTAGAAATGTAACAAA   
NEI3_Ex8F1 CATGTCTGGGTTTCTGTAAGT 360 58 
NEI3_Ex8R1 TGAGGAGTTTCAAAACTCTCCTCCTG   
NEI3_Ex8F2 CTGCATTTGGAACTACAACTCT 349 58 
NEI3_Ex8R2 CAATTATCTTAAAGACCAAGGTT   
NEI3_Ex9F GGGGTAAAGTGGTGTGAAT 328 58 
NEI3_Ex9R CTAGGAAAGTATTGCTATTTGTTA   
NEI3_Ex10F TGATAACAGCAGTGAAGACTATA 351 58 
NEI3_Ex10R GAGGAGGACCAAACATTATAC   
    
NUDT5 
(NM_014142.2) 
   
NUDT5x1F GCGGCAGTTCCCTCACATAC 389 58 
NUDT5x1R CGAGCCCAAAAAAGGGAGTA   
NUDT5x2F AAACGTGCCCACAGATTATT 389 58 
NUDT5x2R CCCAATTTTATTCAGCAACTAT   
NUDT5x3F GGCAAGAGTTTTCGTTGTTA 527 58 
NUDT5x3R AGGTGTGGCTTCAAACTATAT   
NUDT5x4(1)F CTGTGGAAGGTCAGTGTAGTC 557 58 
NUDT5x4(1)R CTCGCTACGAAATGGTTTAG   
NUDT5x5F GATTTCCCGCTCCCATCAC 313 60 
NUDT5x5R AGGCCCTTCTGGCTCCAG   
NUDT5x6F CTACCAAATGTGAGAACTAGT 500 58 
NUDT5x6R GTGGGAATACACTTCATATAG   
NUDT5x7/8F GCTCGAGTTTGACAATGTAT 465 58 
NUDT5x7/8R CTAGGCATTTGACTTTAGTGA   
NUDT5x9F AGCATAGGAAGTGACATATA 319 60 
NUDT5x9R AGCTAATGGCAAATCTAC   
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PCNA 
(NM_002592.2) 
   
PCNAX1F ACGTTCGCCCGCTCGCTCTG 421 64 
PCNAX1R GATGGCCCACGCCAGCCAATGA   
PCNAX2F GAGAGTGGTAACCCCTTCTAA 501 60 
PCNAX3R CCCAGGAATCCCAGGTTAGA   
PCNAX4F AGTGAGGGTGCCAAATCATT 536 58 
PCNAX4R GGTAGGATTGGGAAGTTAGGC   
PCNAX5F TTGGCTGCTTATTAGAAAAACT 603 58 
PCNAX5R GAACTGCTTCTAAGATGCAAG   
    
POL λ 
(NM_001174084.1) 
   
POLLx1F CTACCCCCAAAGCCTGGTCAG 365 64 
POLLx1R AGGCCCTGGACAGGCAGAGT   
POLLx2F GGGGACTGTGAACACGTCAT 615 60 
POLLx2R CCTAAACCTCTTATAGCTGGGACTAC   
POLLx3F GCCTTGATCGTACCACTGTAC 492 58 
POLLx3R AGAGCTAAATGGCTTCACAATA   
POLLx4.1F GGCCTCACACCCAAGGAGA 446 60 
POLLx4.1R GCATTGATGGCCTTGGCATAG   
POLLx4.2F CCAGAAGGCGACCAATCAC 329 60 
POLLx4.2R CTCCCAGCTTCAACAACTATCAA   
POLLx5F TTACCCAGCCCTCATTCTATC 471 60 
POLLx5R CCCATCAGAGCACAGCATAG   
POLLx6F TTCCCAAGTCCTGCTGAGTAC 454 60 
POLLx6R GGCCTGGAGCTTCAGTCTTA   
POLLx7F GCTTGCCTCCTGCACAGT 482 60 
POLLx7R TGCCTCAGGACTGGAACTTC   
POLLx8.1F AAGGGCCCAGAGAGGGTAGT 466 64 
POLLx8.1R AGGCCTAAGAGCCTGAAGACAT   
POLLx8.2F GCCAAAACCAAGGGCATGAGTCT 300 64 
POLLx8.2R GGCCCTGCTCGCTGAGGAA   
POLLx2(1)F TTTCAGGGTAGGGGACTGT 569 60 
POLLx2(1)R CTCCCACCTAAACCTCTTATAG   
    
SMUG 
(NM_001243787.1) 
   
SMUG_Ex1F TGGATCCCTCCTACTCTG 420 58 
SMUG_Ex1R CCAAGCATCCACCTAGAA   
SMUG_Ex2F1 GGCCTCAGGTCTCCAGTT 314 60 
SMUG_Ex2R1 GGCAGCTCAGCAGGAGTA   
SMUG_Ex3F GAGGTCTTCTTCCATCACTGT 400 60 
SMUG_Ex3R CTTCGAGGTCTTGAATGTGTC   
    
    
TDG    
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(NM_003211.4) 
TDG_Ex1F CAGCCACTGTCTGGGTACTG 394 64 
TDG_Ex1R AGAGCAGCCCCGACCTC   
TDG_Ex2F CTCTCCTCTGTAATCCACTCTA 329 58 
TDG_Ex2R ATCCGATGTTGAACTTTCTAA   
TDG_Ex3F AGCTGCTAAAGTTTCTAAGTTAA 372 60 
TDG_Ex3R CAAGGACAACTGTTAAGTAAAG   
TDG_Ex4F TCCACCACTCCTCCATAGAA 360 60 
TDG_Ex4R ACATCCCTCCATTCTCATAGAC   
TDG_Ex5F GATCGTGCCACTACACTCTA 317 58 
TDG_Ex5R AGCTCAGCTTGAACTAGATACA   
TDG_Ex6_7F GCTGTCTGAATTTAGCATATTATA 409 58 
TDG_Ex6_7R TCACAATGGATAGGACAAATAA   
TDG_Ex8F ACAAATATTCTAATCTCAATGAGT 293 60 
TDG_Ex8R TATACACACACAAAATGAATAAA   
TDG_Ex9F CGGTTTTTACAGTTCTTATG 406 58 
TDG_Ex9R ATTCCCATTCTTCAATAATTT   
TDG_Ex10F CTGCAAAGAGCTGTGATCAT 343 58 
TDG_Ex10R AGCAAACTGAGGTTCTACTTGT   
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Appendix E: PCR Primers 
Amplicon Forward Primer (5' > 3') Reverse Primer (5' > 3') 
Size 
(bp) 
ERCC5 
(NM_000123.3) 
   
ERCC5_exon_1 GCCATCTTTGTTGTGTAGGAG CATCATCCTGCAGATGCCAC 308 
ERCC5_exon_2 TTTAGGTAGATCCCATGAGAGC TTGTACCCATGATGAACTCTC 538 
ERCC5_exon_3 ACAGCAATGTTTCTAGTGGTC AGAATCGCAGGAAATCAAGAC 253 
ERCC5_exon_4 AGGTTCCTTCCTTTCTCTCGG AGAGCATGCCTATTTCAGATGC 345 
ERCC5_exon_5 TGTAAGGGGTCCTTAAAAATC CTTTCACAGTTTGATATACCTC 208 
ERCC5_exon_6 CACTTTGTTGCCTGTCACAG CTGAGATATCGTGTAAGTATTGC 409 
ERCC5_exon_7 GGGAAAGGGTGGAAATATGG GTTTGGCACTATAGTAGTTAATCC 443 
ERCC5_exon_8.1 CTAGAAGCGTATTGTCACACTG TCTAACCACTGCACTCTCC 708 
ERCC5_exon_8.2 ACGTAGCCAGCACTAATGAG GATCTCTGAATTCCTACAGAGG 652 
ERCC5_exon_9 GCTCTTGATGATTGCAGGATC GCAACCACAAGATGTACTGC 435 
ERCC5_exon_10 CAGTCAGACTAAATGCAGGC TTAGGGACACACAGTGACC 346 
ERCC5_exon_11 AACTCTGCAGGAATGAATGC ATGCATCAAACTAGTTCCTTGG 417 
ERCC5_exon_12 AGAAGCTGAAACCCACCAGG CAGCATGACAGTTCATGCTG 748 
ERCC5_exon_13 GCCATCATTATACATTGTGGC AAAGAGTGAAAAGGAGAGCG 517 
ERCC5_exon_14 CAAGAATGGGTTCTTTGGACC GGTCTTTAACAGCTGTCAACC 237 
ERCC5_exon_15 CAAGGTTGAGCTTGTTGATTTGG ATACAAAGACCGTGCCACCAG 778 
    
XPA 
(NM_000380.3) 
  
 
XPA_exon_1 GGCGCTCTCACTCAGAAAG GCTTGCACGAGCCAGTCT 368 
XPA_exon_2 AGGTAACATACAGGCTTACC CATTTCCATATGCATGGCTG 366 
XPA_exon_3 TCAGGCATTGCATACATGCTG TTCTATGGCAGAACCATCGG 434 
XPA_exon_4 GTGCCCCTAAGTTGCTGG CCACACTCTGTAAGCAAAAGCCA 342 
XPA_exon_5 TCCTGTGACAATACAGTCAGAG CTTGAAGACCAACATACTGAGG 546 
XPA_exon_6 CATGTACATGGCTGAAAGCTTG ACAAGGGTTTCATTCATCTATGAAG 359 
    
XPC 
(NM_001145769.1) 
  
 
XPC_exon_1 TGACTAGGCCTCCAACGAAG TACGCAGGAGCTTGGATCG 453 
XPC_exon_2 ATAAGCTGCACTGCCTCCAC GATCCAATCTTCCATGGACC 371 
XPC_exon_3 GCTTGAATGGAACACTAGG TAGTGATCTGACTCCAAACAG 257 
XPC_exon_4 TGATTCTGTTCAGTACAGTAGC CAAAGTCCTCCTAAGCAGC 308 
XPC_exon_5 GAGGAGAAGGAATTGCCTG AGCACAAGCTCTTTGCACC 224 
XPC_exon_6 CATGTCTTGACTTTGGCAGC CTGTGGAAGTGACCTGAACC 325 
XPC_exon_7 CTTGGCTGGAAATGAAAATTCC GCACATGGCTGCCATTATC 257 
XPC_exon_8 TTCTTAGGATAACTATGTTCTTCC ACTCCGTGAATACCAGCTC 232 
XPC_exon_9.1 CTCTAGCTGGTGACTTAACC CTTGAAGAGCTTGAGGATGC 629 
XPC_exon_9.2 GCTCTGATTTTGAGCTCTCC CCTGACTGTGTCTTGGAGC 694 
XPC_exon_10 GTCTAAGGATCATCTCCCTC TGCTGTCCAGTCAGATGAGC 345 
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XPC_exon_11 ACGTTCAAGGCTGTTTGCC GCTCATCATCACTTCTCTGC 344 
XPC_exon_12&13 TGAGGAACTGGATGCCTTTG TGAAAATTGGAGCCACCAGG 558 
XPC_exon_14 CACTGTCTTCCACAAACTGG TGTATTCAGTGCTCGCTCC 333 
XPC_exon_15 ACTTGGTGTGAAGGAGAGGC CCTTTCTGAGCTGCATCTCC 291 
XPC_exon_16 GAACTTGCTGCCTCTTCATGG TGCCTTCTCAGCAGAGAAGC 416 
    
RPA1 
(NM_002945.3) 
  
 
RPA1_exon_1 AACTTCTCGGGCCAATAACTG CGATCGAAAGAATGCTTTGAGG 319 
RPA1_exon_2 ACTAGATGCTTCAGCTGACAG AGGGTTACAATGTAGACTGGC 339 
RPA1_exon_3 GCCACTTCGGTTTACGTATCC CGTAGCCAAGCAAGTACGG 266 
RPA1_exon_4 TAGCACAGGTATGAGTAGCTC GCCATGTGTTAGCTACCTGA 320 
RPA1_exon_5 GTTCATCACAATGATCATCGGG GAATCCAAAAGGTAGAACTCCG 262 
RPA1_exon_6 CGAATTCTAATCCATGGGAGTC CATGATTCCGAAGTCTGACAC 280 
RPA1_exon_7 ATTTCACTAGTGGCACCTCC TGGTGACCCTGAAGTTCAC 336 
RPA1_exon_8 TATGCGTAAGACGAGAAAGGC AGCTGAGCCTTCTGTTTCC 305 
RPA1_exon_9 TATCCCAGTGTCACTTGGG CCTGAGACTACCATCAAATCG 273 
RPA1_exon_10 TGGCAGACTAGGGGTTTCTG ACGCCAGCAAATGATGAACGG 364 
RPA1_exon_11 CCGTTCATCATTTGCTGGCGT CCAACTCCAGGAGCTCCT 322 
RPA1_exon_12 GTATGGATTCCATGTACGCTG TTCAAGAAACACGGAAGCTGC 406 
RPA1_exon_13 TAGCAGCAAGTTGCATGTGG AATTACGGCTCTGACAGCTG 310 
RPA1_exon_14 TAAGGGCAGGCTTTGAGCTG TTGTGACCACAGTGCCTGG 337 
RPA1_exon_15 TCTCCCCATCTTCTCAGTG GTGGGGTCAGTGTTATAGAATG 245 
RPA1_exon_16 TGAAACTACCCAGGAGATGC TGCCGTAGGTGACAAACAG 256 
RPA1_exon_17 TCACTGGAATGACTGAACTCTG GTAGCTAACATGGGATCGTC 332 
RPA2_exon_1&2 GTGCCAGAGAAAAGTAGCC GTCATAGATGACTCAGGGAC 556 
RPA2_exon_3 GGTGAATTCTCAGAGCAACATG CCCTGAAACCAAGGCTACAT 451 
RPA2_exon_4 AATGTAGCCTTGGTTTCAGGG GTTCAACATCTCCACAGTTCCA 236 
RPA2_exon_5 AAGAGGCTTTTACCAGCATC TCCAAAAGCCATGACATGAATC 207 
RPA2_exon_6 CCATATTTGGAATACCTCTGAGAG GAGCCAGAGAAAGACATCACTAA 382 
RPA2_exon_7 TGTCCACTCCAATGTAAGCAG CCAGGTACTTAAACAGTCGTAG 347 
RPA2_exon_8 GAGCTACGACTGTTTAAGTACC GTACCTATTTCACCTCACAAGG 269 
RPA2_exon_9 CTGTGAGAGCTTTCTATGTGC GAAACCTACTTCCTAGAAGCC 350 
    
GTF2H1 
(NM_001142307.1) 
  
 
GTF2H1_exon_2 TTGTAGAGGAATGATGCCGTG CAACTATGACATACAAATACATCAG 379 
GTF2H1_exon_3 AGGAATCCTGAATCATCTTGGG ACTAGGAGACTATAGAGAACCC 346 
GTF2H1_exon_4 GAACTGAAGGACCTCTGCTGC AATGGTCTTAAGACACATATTGGG 379 
GTF2H1_exon_5 CTTTGTCCAGTGTCCACTG TTGTGGGTTAGGAAGGTCAC 444 
GTF2H1_exon_6&7 GTAGAGTTGAGAGCTTTATGGTC CAAGTGGAATAGGTCTACTACGC 549 
GTF2H1_exon_8&9 GTTCGTGAGAAGTAATAAAAGTCCC GAACTGAGTCACAGGAAATAAGCG 546 
GTF2H1_exon_10 GAAGCTCATGGTGGGAAGAC TGTACTTTGATGGTGACGAACTG 316 
GTF2H1_exon_11 CTTATCGTTTCTTGCCTTGAGG ATGGTTCAATCTGCTTGTGCTC 312 
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GTF2H1_exon_12 AATGTTAAGAAAGAGAGGTGGC AACCAATAAAAGTTCAGCACTCC 250 
GTF2H1_exon_13 ATAGCACATCCTGGTTTGGC AGTCACTACCACAATTATCTGGC 288 
GTF2H1_exon_14 TCTGTTGGTCTCTACAGCTTG ACTACAAAGAGAAAGAAGATCAGGC 199 
GTF2H1_exon_15 AGCTCCGAAACTACACTCTG CAGGTCATAGTTCTCTCAATCTC 238 
    
GTF2H2 
(NM_001515.3) 
  
 
GTF2H2_exon_2 GAATAAGATGACCTGGCATTCC AGAAAAGACAGGGCAATAAAGCTC 242 
GTF2H2_exon_3 GGGCTAGTAATCATTTTAGCTTGTC GTCAGTTACCCTGAAACACAGC 242 
GTF2H2_exon_4 TGCACGTTATGACATTCTTACTC AGCAAGACAGAATGTTTCTCTAACC 236 
GTF2H2_exon_5 AGTACTTGAAATTGGCCCTTTC ATCCAGTGTTCTTCCCCAC 208 
GTF2H2_exon_6 GAGAAGTGATGCTTGATTAACAGG TGGGTAATTCACAAAATACATGTCC 252 
GTF2H2_exon_7 TCTGCTCCAATATCATCTACAGG TAAACAGGGCTACGAGGTTGG 220 
GTF2H2_exon_8 CAGTATGAAGTGAGAGTGTTTAC CCATATTAACACATCACTTCAGC 346 
GTF2H2_exon_9 CCTATGTTTACTGTTCTTTCTGGG ACCACAAAGATGAATCACACATAC 281 
GTF2H2_exon_10 CAGCCTTACAACTTGCGATCC GTAGCTCAGAACAGATTAAAACATCC 446 
GTF2H2_exon_11 CAGTTCGTTATGTCTATGAAGGTG TTGTGCAAATGAAAATGGAGAGC 219 
GTF2H2_exon_12 AGCTTGGAATTAGTCAGTTTCATC GATAGTCTTCATTGCCTATCTTTTG 331 
GTF2H2_exon_13 GTCAAGATAGCATGCTTTCCC TACGTGGAAGTGGAGTACTGG 341 
GTF2H2_exon_14 CAATCTTCTGTTATAGCCACAGG ATGGCATTCTTTATCTCATCTTCC 391 
GTF2H2_exon_15 TTCCTGAAAGTCATGTGTAAAGAC CCTGTTGAAAACTTATAGTACCATTG 240 
GTF2H2_exon_16 TTGAATGTCATCTAGCTGTGCTG AGAAGTCCTTTTATTCACAGTTGC 258 
    
GTF2H3 
(NM_001516.3) 
  
 
GTF2H3_exon_1 ACTCCACTTCCGCAGATTAGG TTCCATCTGGCCAGTCGTAG 228 
GTF2H3_exon_2 ACTGGGTCTTCTGTTAATCTC CTCAGTTAAACCAGAATTCTCC 279 
GTF2H3_exon_3 CTTAATTATGTCAAGACCTGACATGG CTTTTGCAACATGGAGTAGGAAC 279 
GTF2H3_exon_4 CATTCTGATCATGAGTGAGCC GTGAGAACGTGCAGGCATAC 345 
GTF2H3_exon_5 CATACTTAGTTCAATAAAGCACCC CTTCAGAGTACTCACATGTCC 263 
GTF2H3_exon_6 TTAGCTAGGTAGATGCTGG GATTTCATTTCCTGATTGTCTAC 307 
GTF2H3_exon_7 GAGCCTACGTTTTCCTATGAG CTCCCTGATATTCTGACTGAG 766 
GTF2H3_exon_8 TGTGACATTGGTGTGAGAGG CAGAATACCTCAGAGTAGAGC 227 
GTF2H3_exon_9 TCTCTGTTGTGGAGTGGC TCACTAATTGTCATAACCACCG 379 
GTF2H3_exon_10 TGAGAACCTCATTCCTCTGG CTTCCATTCCTTTCCCAGGAC 212 
GTF2H3_exon_11 AAATGGAGGCCTTGGAGTTCC GAAAAACAACACAGCTGAGAAACTG 314 
GTF2H3_exon_12 GTTTTTCAGCCACCCTATTGTTTC GTCTTCCCAACAAAGAATCTGC 305 
    
GTF2H4 
(NM_001517.4) 
  
 
GTF2H4_exon_2 GAATCAGTTAGAAAGGTCAGGG TCCAGGCTGCTACACTTTTACC 299 
GTF2H4_exon_3 GATGTTTGAGAGGTAATTGAGGG AGTGCTCCAAGGAACAGCAG 254 
GTF2H4_exon_4 GTTCAGAACAGGCAGAGATGG TGGAGACCACAAGGTTCTGG 334 
GTF2H4_exon_5&6 CAGGGTTCCTTACTCTTGGC CCCAGATACCATTTCTTAGGG 383 
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GTF2H4_exon_7&8 AAACGTGAGTGGACAAGTGGG TTCTCAGTCTACTCTACTGCC 489 
GTF2H4_exon_9 CAGAACGAACAGAGATGGAG AAAGGCAACACACCACCCTG 238 
GTF2H4_exon_10 CAGGCAGGAAGATGTAAGGC CATGAGAAATGTCAGAGAGCTC 303 
GTF2H4_exon_11 CTCATGACACTTGAAAGAAGGG AGCCTTCCATAATGTGACCC 292 
GTF2H4_exon_12 ACAGCTCAGATGGCTTTCCTG ATCATGTCATCACCAGCTGCC 164 
GTF2H4_exon_13 AGCTGGTGATGACATGATGG ATGCAGACTGAACTGTCTGCC 264 
GTF2H4_exon_14 CTTCACTTTCTCGTCTTCTCC AACACCTGAGTTCTGATGCC 293 
    
GTF2H5 
(NM_207118.2) 
  
 
GTF2H5_exon_1 CTCGTTTCAGAGGCAGATCC CTGTGCCACTTGTTAAAAGCG 281 
GTF2H5_exon_2 GCTCAAGTCTCTGTGATGTG CCTCTATGTCTAATCAGTCACC 336 
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Appendix F: Fetch2.py code. 
This python code takes an input file of GeneIDs and returns information on nonsynonymous 
SNPs including detailed population frequency data that may be included in the annotation. 
-------------------------------------------------------------------------------------------------------------------------- 
Fetch2.py 
C:\Python25 
 
import sys 
import EntrezServer 
 
from xml.etree import ElementTree 
 
fxnmap = { 
    'lr': 'locus-region', 
    'cn': 'coding-nonsynonymous', 
    'cs': 'coding-synonymous', 
    'ex': 'exception', 
    'in': 'intron', 
    'mu': 'mrna-utr', 
    're': 'reference', 
    'ss': 'splice-site' 
    } 
 
usage = """Usage: python %s <locus-id> [<fxnlist.>] 
where 
locus-id is a LocusID from NCBI database 
fxnlist is any number of the following 2-letter filters 
""" % sys.argv[0] 
 
if len(sys.argv) < 2: 
    sys.stderr.write(usage) 
    for key, val in fxnmap.items(): 
        sys.stderr.write("\t%s\t%s\n" % (key, val)) 
    sys.exit(0) 
locus = sys.argv[1] 
fc = sys.argv[2:] 
if len(fc) == 0: 
    fxnterm = '' 
    fxnlist = [] 
else: 
    fxnterm = ' AND (%s)' % ' OR '.join([fxnmap[x] + '[FXN_CLASS]' for x in fc]) 
    fxnlist = [fxnmap[x] for x in fc] 
 
snp = EntrezServer.ncbi.Database('snp') 
 
ctx = snp.Context() 
term = '%s[LOCUS_ID]' % locus 
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print 'Search term:', term 
sys.stdout.flush() 
ctx.Search(term = term) 
 
print 'Found', ctx.Count(), 'results' 
print 'Locus;RS;Tag(s);Study;Population;Class;A;C;G;T' 
 
ns_docsum = '{http://www.ncbi.nlm.nih.gov/SNP/docsum}(Morak et al., 2011)' 
ns_geno = '{http://www.ncbi.nlm.nih.gov/SNP/geno}' 
 
for i in range(ctx.Count()): 
    ExchangeSet = ctx.Fetch(retstart=i, retmax=1, mode='text', report='XML') 
    Rs = ExchangeSet.find(ns_docsum + 'Rs') 
    Rs_assembly = Rs.find(ns_docsum + 'Rs_assembly') 
    labels = {} 
    match = False 
    for Assembly in Rs_assembly.findall(ns_docsum + 'Assembly'): 
        Assembly_component =  Assembly.find(ns_docsum + 'Assembly_component') 
        Assembly_groupLabel \ 
            = Assembly.find(ns_docsum + 'Assembly_groupLabel').text 
        Component = Assembly_component.find(ns_docsum + 'Component') 
        Component_mapLoc = Component.find(ns_docsum + 'Component_mapLoc') 
        MapLoc = Component_mapLoc.find(ns_docsum + 'MapLoc') 
        MapLoc_fxnSet = MapLoc.find(ns_docsum + 'MapLoc_fxnSet') 
        if MapLoc_fxnSet is None: 
            continue 
        label = [None, None, None] 
        reflist = [] 
        aalist = [] 
        varlist = [] 
        vallist = [] 
        for FxnSet in MapLoc_fxnSet.findall(ns_docsum + 'FxnSet'): 
            geneId = FxnSet.find(ns_docsum + 'FxnSet_geneId').text 
            if geneId == locus: 
                fxnClass = FxnSet.find(ns_docsum + 'FxnSet_fxnClass') 
                value = fxnClass.attrib['value'] 
                if value == 'reference': 
                    ref = FxnSet.find(ns_docsum + 'FxnSet_residue').text 
                    if ref not in reflist: 
                        reflist.append(ref) 
                    aa = int(FxnSet.find(ns_docsum + 'FxnSet_aaPosition').text) + 1 
                    if aa not in aalist: 
                        aalist.append(aa) 
                else: 
                    residue = FxnSet.find(ns_docsum + 'FxnSet_residue') 
                    if residue is None: 
                        continue 
                    else: 
                        var = residue.text 
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                    if var not in varlist: 
                        varlist.append(var) 
                    aaPos = FxnSet.find(ns_docsum + 'FxnSet_aaPosition') 
                    if aaPos is None: 
                        continue 
                    else: 
                        aa = int(aaPos.text) + 1 
                    if aa not in aalist: 
                        aalist.append(aa) 
                    if value not in vallist: 
                        vallist.append(value) 
                        if value in fxnlist: 
                            match = True 
        if not reflist and not varlist: 
            # due to it being a different gene 
            continue 
        reflist.sort() 
        aalist.sort() 
        varlist.sort() 
        for val in vallist: 
            if val not in fxnlist: 
                break 
        else: 
            vallist = [] 
        vallist.sort() 
        label = ('%s%s%s %s'  
                 % ('/'.join(reflist), '/'.join([str(aa) for aa in aalist]), 
                    '/'.join(varlist), '/'.join(vallist))).strip() 
        if labels.has_key(label): 
            labels[label].append(Assembly_groupLabel) 
        else: 
            labels[label] = [Assembly_groupLabel] 
    if not match: 
        continue 
    tags = [] 
    if len(labels) == 1: 
        tag = labels.keys()[0] 
    else: 
        for label, groups in labels.items(): 
            group = ','.join(groups) 
            tags.append('%s (%s)' % (label, group)) 
        tag = ' / '.join(tags) 
    if not tag: 
        # This is an overlapping snip that belongs to another locus 
        continue 
 
    GenoExchange = ctx.Fetch(retstart=i, retmax=1, mode='text', report='GENXML') 
    # Create the population index 
    populations = {} 
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    for Population in GenoExchange.findall(ns_geno + 'Population'): 
        popId = Population.attrib['popId'] 
        pop = {} 
        pop['study'] = Population.attrib['handle'] 
        pop['label'] = Population.attrib['locPopId'] 
        popClass = Population.find(ns_geno + 'popClass') 
        pop['class'] = popClass.attrib['self'] 
        pop['group'] = [] 
        pop['subgroup'] = [] 
        populations[popId] = pop 
    # Retrieve the frequencies 
    for SnpInfo in GenoExchange.findall(ns_geno + 'SnpInfo'): 
        sys.stdout.flush() 
        rsId = SnpInfo.attrib['rsId'] 
        SsInfoList = SnpInfo.findall(ns_geno + 'SsInfo') 
        if SsInfoList: 
            for SsInfo in SsInfoList: 
                for ByPop in SsInfo.findall(ns_geno + 'ByPop'): 
                    popId = ByPop.attrib['popId'] 
                    pop = populations[popId] 
                    study = pop['study'] 
                    label = pop['label'] 
                    Class = pop['class'] 
                    distribution = {'A': 0, 'C': 0, 'G': 0, 'T': 0} 
                    for AlleleFreq in ByPop.findall(ns_geno + 'AlleleFreq'): 
                        allele = AlleleFreq.attrib['allele'] 
                        freq = AlleleFreq.attrib['freq'] 
                        distribution[allele] = freq 
                    sys.stdout.write('%s;%s;%s;%s;%s;%s;%s;%s;%s;%s\n'  
                                     % (locus, rsId, tag, study, label, Class, 
                                        distribution['A'], distribution['C'], 
                                        distribution['G'], distribution['T'])) 
        else: 
            sys.stdout.write('%s;%s;%s;No studies\n' % (locus, rsId, tag)) 
 
print 'Done' 
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Appendix G: Assayed SNPs. 
All 221 nonsynonymous SNPs assayed in the 480 EBV-transformed lymphoblastoid 
cell lines from unrelated healthy individuals. 
Gene rs # 
 
Gene rs # 
 
Gene rs # 
ALKBH3 rs2434470 EXO1 rs4149965 POLD1 rs1726801 
APEX1 rs1048945 
 
EXO1 rs735943 
 
POLE rs5744751 
APEX1 rs1130409 
 
EXO1 rs9350 
 
POLE rs5744934 
ATM rs17174393 
 
FANCA rs11646374 
 
POLE rs5745066 
ATM rs1800056 
 
FANCA rs17233497 
 
POLG rs2307441 
ATM rs1800057 
 
FANCA rs1800282 
 
POLG rs3087374 
ATM rs1800058 
 
FANCA rs2239359 
 
POLI rs3218786 
ATM rs1801516 
 
FANCA rs7190823 
 
POLI rs8305 
ATM rs2234997 
 
FANCA rs7195066 
 
POLL rs3730463 
ATM rs3218673a 
 
FANCA rs9282681 
 
POLL rs3730477 
ATM rs35813135 
 
FANCD2 rs3864017 
 
POLM rs28382644 
ATR rs2227928 
 
FANCE rs7761870 
 
POLN rs10011549 
ATR rs2229032 
 
FANCE rs9462088 
 
POLN rs10018786 
ATR rs2229033 
 
FANCM rs10138997 
 
POLN rs11725880 
ATR rs34124242 
 
FANCM rs1367580 
 
POLN rs2353552 
ATRX rs3088074 
 
FANCM rs3736772 
 
POLN rs9328764 
ATRX rs45439799 
 
FLJ35220 rs34933300 
 
POLQ rs1381057 
BLM rs11852361 
 
FLJ35220 rs35549084 
 
POLQ rs3218634 
BRCA1 rs16941 
 
HEL308 rs1494961 
 
POLQ rs3218649 
BRCA1 rs16942 
 
LIG1 rs3730947 
 
POLQ rs3218651 
BRCA1 rs1799950 
 
LIG1 rs3730980 
 
POLQ rs487848 
BRCA1 rs1799966 
 
LIG3 rs3744356 
 
POLQ rs532411 
BRCA1 rs28897674 
 
LIG4 rs1805388 
 
PRKDC rs4278157 
BRCA1 rs28897687 
 
LIG4 rs1805389 
 
PRKDC rs7830743 
BRCA1 rs4986850 
 
MBD4 rs10342 
 
PRKDC rs8178017 
BRCA1 rs4986852 
 
MBD4 rs140693 
 
RAD1 rs1805327 
BRCA1 rs799917 
 
MGMT rs12917 
 
RAD17 rs1045051 
BRCA2 rs1046984 
 
MGMT rs2020893 
 
RAD18 rs373572 
BRCA2 rs11571640 
 
MGMT rs2308321 
 
RAD23B rs1805329 
BRCA2 rs11571660 
 
MGMT rs2308327 
 
RAD51L1 rs34594234 
BRCA2 rs11571833 
 
MLH1 rs1799977 
 
RAD51L3 rs4796033 
BRCA2 rs144848 
 
MLH3 rs175080 
 
RAD52 rs11571463 
BRCA2 rs1799944 
 
MLH3 rs175081 
 
RAD52 rs4987206 
BRCA2 rs1799954 
 
MLH3 rs17782839 
 
RAD52 rs4987207 
BRCA2 rs28897708 
 
MLH3 rs28756982 
 
RAD52 rs4987208 
BRCA2 rs28897727 MMS19L rs12360068 
 
RAD9A rs2066492 
BRCA2 rs28897729 
 
MMS19L rs29001285 
 
RDM1 rs2251660 
BRCA2 rs28897731 
 
MMS19L rs3740526 
 
RECQL4 rs4244612 
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BRCA2 rs28897743 
 
MPG rs2308313 
 
RECQL4 rs4251691 
BRCA2 rs28897758 
 
MSH3 rs1650697 
 
RECQL5 rs35566780 
BRCA2 rs4987047 
 
MSH3 rs184967 
 
RECQL5 rs820196 
BRCA2 rs4987117 
 
MSH3 rs26279 
 
REV1 rs3087386 
BRIP1 rs4986764 
 
MSH4 rs5745325 
 
REV1 rs3087399 
BRIP1 rs4988350 
 
MSH4 rs5745459 
 
REV1 rs3087403 
C19orf40 rs2304103 
 
MSH4 rs5745549 
 
REV3L rs3204953 
C19orf40 rs3816032 
 
MSH5 rs1802127 
 
REV3L rs3218599 
CCNH rs2266690 
 
MSH5 rs2075789 
 
REV3L rs458017 
CHAF1A rs8100525 
 
MSH5 rs28381349 
 
REV3L rs462779 
CHAF1A rs9352 
 
MSH6 rs1042821 
 
RPA1 rs5030755 
CHEK1 rs506504 
 
MSH6 rs2020912 
 
RPA4 rs2642219 
DCLRE1A rs3750898 
 
MUS81 rs13817 
 
TDG rs2888805 
DCLRE1B rs12022378 
 
MUS81 rs545500 
 
TDG rs3953597 
DCLRE1C rs12768894 
 
MUTYH rs3219484 
 
TDP1 rs28365054 
EME1 rs12450550 
 
MUTYH rs3219489 
 
TELO2 rs2235624 
EME1 rs17714854 
 
NBN rs1805794 
 
TELO2 rs2248128 
EME1 rs3760413 
 
NEIL1 rs5745926 
 
TELO2 rs2667661 
ERCC2 rs13181 
 
NEIL3 rs13112358 
 
TP53 rs1042522 
ERCC2 rs1799792 
 
NEIL3 rs13112390 
 
WRN rs1346044 
ERCC2 rs1799793 
 
NEIL3 rs1876268 
 
WRN rs1800391 
ERCC4 rs1800067 
 
NEIL3 rs2048074 
 
WRN rs2230009 
ERCC5 rs1047769 
 
NEIL3 rs34193982 
 
WRN rs2725362 
ERCC5 rs17655 
 
NEIL3 rs7689099 
 
XPC rs2227999 
ERCC5 rs2227869 
 
OGG1 rs1052133 
 
XPC rs2228000 
ERCC6 rs2228526 
 
OGG1 rs17050550 
 
XPC rs2228001 
ERCC6 rs2228527 
 
PARP1 rs1136410 
 
XRCC1 rs1799782 
ERCC6 rs2228528 
 
PARP1 rs3219062 
 
XRCC1 rs25487 
ERCC6 rs2228529 
 
PARP2 rs3093921 
 
XRCC1 rs25489 
ERCC6 rs4253211 
 
PARP2 rs3093926 
 
XRCC1 rs25490 
EXO1 rs1047840 
 
PMS1 rs2066459 
 
XRCC1 rs25495 
EXO1 rs12122770 
 
PMS2 rs17420802 
 
XRCC1 rs25496 
EXO1 rs1776148 
 
PMS2 rs2228006 
 
XRCC2 rs3218536 
EXO1 rs4149909 
 
PMS2L3 rs17147225 
 
XRCC3 rs861539 
EXO1 rs4149910 
 
PMS2L3 rs17425318 
 
XRCC4 rs28360135 
EXO1 rs4149963 
 
PMS2L3 rs17435215 
  
 
 
238 
 
Appendix H: Common Nonsynonymous Variants 
135 SNPs from Fetch.py with empirically determined MAF of 4% or greater. 
Gene rs ID AA name Determined 
MAF 
ALKBH3 rs2434470 D228E 0.261 
APEX1 rs1048945 Q51H 0.041 
APEX1 rs1130409 D148E 0.475 
ATM rs1801516 D1853N 0.138 
ATR rs2227928 T211M 0.417 
ATR rs2229032 R2425Q 0.160 
ATRX rs3088074 Q929E 0.310 
BLM rs11852361 P868L 0.072 
BRCA1 rs16941 E1038G 0.350 
BRCA1 rs16942 K1183R 0.323 
BRCA1 rs1799950 Q356R 0.063 
BRCA1 rs1799966 S1613G 0.324 
BRCA1 rs4986850 D693N 0.073 
BRCA1 rs799917 L871P 0.336 
BRCA2 rs144848 N372H 0.290 
BRIP1 rs4986764 S919P 0.399 
C19orf40 rs2304103 S158L 0.042 
C19orf40 rs3816032 I192T 0.115 
CCNH rs2266690 V270A 0.201 
CHAF1A rs9352 V923A 0.467 
DCLRE1A rs3750898 H317D 0.237 
DCLRE1B rs12022378 H61Y 0.170 
DCLRE1C rs12768894 H243R 0.182 
EME1 rs12450550 I350T 0.290 
ERCC2 rs13181 K751Q 0.364 
ERCC2 rs1799793 D312N 0.340 
ERCC4 rs1800067 R415Q 0.077 
ERCC5 rs1047769 M254V 0.040 
ERCC5 rs17655 H1104D 0.213 
ERCC6 rs2228526 M1097V 0.200 
ERCC6 rs2228527 R1213G 0.190 
ERCC6 rs2228528 G399D 0.164 
ERCC6 rs2228529 Q1413R 0.190 
ERCC6 rs4253211 R1230P 0.110 
EXO1 rs1047840 K589E 0.384 
EXO1 rs1776148 E670G 0.373 
EXO1 rs4149963 T439M 0.074 
EXO1 rs4149965 V458M 0.270 
EXO1 rs735943 H354R 0.454 
EXO1 rs9350 P757L 0.157 
FANCA rs11646374 A412V 0.110 
FANCA rs17233497 S1088F 0.110 
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FANCA rs1800282 V6D 0.093 
FANCA rs2239359 G501S 0.385 
FANCA rs7190823 A266T 0.431 
FANCA rs7195066 D809G 0.340 
FANCA rs9282681 T1328A 0.110 
FANCE rs9462088 A502T 0.057 
FANCM rs10138997 S175F 0.052 
FANCM rs1367580 V878L 0.118 
FANCM rs3736772 P1812A 0.101 
FLJ35220 rs34933300 R112Q 0.258 
FLJ35220 rs35549084 V29I 0.050 
HEL308 rs1494961 V306I 0.496 
LIG4 rs1805388 T9I 0.165 
LIG4 rs1805389 A3V 0.050 
MBD4 rs10342 A273S/T 0.090 
MGMT rs12917 L84F 0.128 
MGMT rs2308321 I143V 0.138 
MGMT rs2308327 K178R 0.137 
MLH1 rs1799977 I219V 0.325 
MLH3 rs175080 P844L 0.458 
MMS19L rs12360068 A579V 0.043 
MMS19L rs3740526 G811D 0.450 
MSH3 rs1650697 I79V 0.220 
MSH3 rs184967 Q949R 0.156 
MSH3 rs26279 A1045T 0.284 
MSH4 rs5745325 A97T 0.270 
MSH5 rs2075789 P29S 0.100 
MSH6 rs1042821 G39E 0.170 
MUTYH rs3219484 V22M 0.079 
MUTYH rs3219489 Q324H 0.252 
NBN rs1805794 E185Q 0.324 
NEIL3 rs13112358 P443L 0.210 
NEIL3 rs13112390 Q471H 0.205 
NEIL3 rs2048074 R381-/R 0.210 
NEIL3 rs34193982 H286R 0.166 
NEIL3 rs7689099 P117R 0.107 
OGG1 rs1052133 P332A 0.229 
PARP1 rs1136410 V762A 0.146 
PARP2 rs3093926 R283Q 0.064 
PMS2 rs2228006 K541E 0.155 
POLD1 rs1726801 R119H 0.050 
POLE rs5744751 A252V 0.120 
POLE rs5744934 N1396S 0.137 
POLG rs2307441 E1143G 0.043 
POLG rs3087374 Q1236H 0.080 
POLI rs8305 A731T 0.306 
POLL rs3730477 R438W 0.221 
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POLN rs10011549 G336S 0.101 
POLN rs10018786 M310L 0.100 
POLN rs2353552 Q121H 0.128 
POLN rs9328764 R425C 0.101 
POLQ rs1381057 R2513Q 0.306 
POLQ rs3218634 L2538V 0.068 
POLQ rs3218649 T982R 0.365 
POLQ rs3218651 H1201R 0.163 
POLQ rs487848 A581V 0.068 
POLQ rs532411 A2304V 0.068 
PRKDC rs4278157 R2899C 0.060 
PRKDC rs7830743 I3434T 0.053 
PRKDC rs8178017 M333I 0.043 
RAD1 rs1805327 E281G 0.073 
RAD17 rs1045051 L546R 0.316 
RAD18 rs373572 Q302R 0.277 
RAD23B rs1805329 A249V 0.196 
RAD51L3 rs4796033 R185Q 0.130 
RDM1 rs2251660 C127W 0.148 
RECQL4 rs4244612 D267E 0.390 
RECQL4 rs4251691 Q1005R 0.460 
RECQL5 rs820196 D480G 0.232 
REV1 rs3087386 F257S 0.438 
REV1 rs3087399 N373S 0.127 
REV1 rs3087403 V138M 0.280 
REV3L rs3204953 V3064I 0.146 
REV3L rs458017 Y1156C 0.056 
REV3L rs462779 I1224T 0.184 
RPA1 rs5030755 T351A 0.112 
RPA4 rs2642219 T33A 0.306 
TDG rs2888805 V367M 0.108 
TELO2 rs2235624 R146Q 0.393 
TELO2 rs2248128 Q674R 0.220 
TELO2 rs2667661 E7G 0.230 
TP53 rs1042522 P72R 0.257 
WRN rs1346044 C1367R 0.257 
WRN rs1800391 M387I 0.075 
WRN rs2230009 V114I 0.065 
WRN rs2725362 L1074F 0.447 
XPC rs2227999 R492H 0.060 
XPC rs2228000 A499V 0.247 
XPC rs2228001 K939Q 0.398 
XRCC1 rs1799782 R194W 0.062 
XRCC1 rs25487 R399Q 0.365 
XRCC2 rs3218536 R188H 0.087 
XRCC3 rs861539 T241M 0.371 
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Appendix I: In silico analyses predicating functional effect of SNPs. 
Functionality of 134 common (MAFs>4%) nonsynonymous SNPs in DNA repair genes. 
Gene 
 
SNPrs.no. p.Name Align 
GVGD 
Polyphen SIFT 
ALKBH3 rs2434470 D228E C35 Possibly Damaging Damaging 
APEX1 rs1130409 D148E C0 Benign Tolerated 
APEX1 rs1048945 Q51H C15 Possibly Damaging Damaging 
ATM rs1801516 D1853N C15 Possibly Damaging Tolerated 
ATR rs2227928 M211T C0 Benign Tolerated 
ATR rs2229032 R2425Q C0 Benign Tolerated 
ATRX rs3088074 Q929E C0 Benign Tolerated 
BLM rs11852361 P868L C65 Probably Damaging Damaging 
BRCA1 rs16941 E1038G C65 Benign Damaging 
BRCA1 rs16942 K1183R C0 Benign Tolerated 
BRCA1 rs1799950 Q356R C0 Probably Damaging Damaging 
BRCA1 rs1799966 S1613G C0 Benign Damaging 
BRCA1 rs4986850 D693N C0 Benign Damaging 
BRCA1 rs799917 P871L C0 Benign Damaging 
BRCA2 rs144848 N372H C0 Benign Tolerated 
BRIP1 rs4986764 S919P C0 Benign Tolerated 
C19orf40 rs2304103 S158L C15 Benign Tolerated 
C19orf40 rs3816032 I192T C0 Benign Tolerated 
CCNH rs2266690 V270A C65 Possibly Damaging Damaging 
CHAF1A rs9352 A923V C15 Benign Tolerated 
DCLRE1A rs3750898 D317H C0 Possibly Damaging Damaging 
DCLRE1B rs12022378 H61Y C15 Possibly Damaging Damaging 
DCLRE1C rs12768894 H243R C25 Probably Damaging Damaging 
EME1 rs12450550 I350T C0 Benign Tolerated 
ERCC2 rs13181 K751Q C0 Benign Tolerated 
ERCC2 rs1799793 D312N C15 Benign Tolerated 
ERCC4 rs1800067 R415Q C35 Benign Damaging 
ERCC5 rs1047769 M254V C15 Probably Damaging Damaging 
ERCC5 rs17655 D1104H C0 Possibly Damaging Damaging 
ERCC6 rs2228526 M1097V C0 Benign Tolerated 
ERCC6 rs2228527 R1213G C65 Benign Tolerated 
ERCC6 rs2228528 G399D C0 Benign Tolerated 
ERCC6 rs2228529 Q1413R C0 Benign Tolerated 
ERCC6 rs4253211 R1230P C15 Probably Damaging Tolerated 
EXO1 rs1047840 E589K C0 Benign Tolerated 
EXO1 rs1776148 E670G C0 Benign Tolerated 
EXO1 rs4149963 T439M C0 Possibly Damaging Tolerated 
EXO1 rs4149965 V458M C0 Benign Tolerated 
EXO1 rs735943 H354R C0 Benign Tolerated 
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EXO1 rs9350 P757L C65 Probably Damaging Damaging 
FANCA rs11646374 A412V C0 Benign Tolerated 
FANCA rs17233497 S1088F C65 Possibly Damaging Damaging 
FANCA rs1800282 V6D C15 Possibly Damaging Tolerated 
FANCA rs2239359 G501S C0 Possibly Damaging Tolerated 
FANCA rs7190823 T266A C0 Benign Tolerated 
FANCA rs7195066 G809D C0 Benign Tolerated 
FANCA rs9282681 T1328A C0 Benign Tolerated 
FANCE rs9462088 A502T C0 Benign Tolerated 
FANCM rs10138997 S175F C0 Possibly Damaging Tolerated 
FANCM rs1367580 V878L C0 Benign Tolerated 
FANCM rs3736772 P1812A C0 Possibly Damaging Tolerated 
FLJ35220 rs34933300 R112Q C0 Benign Tolerated 
FLJ35220 rs35549084 V29I C0 Benign Tolerated 
HEL308 rs1494961 V306I C0 Benign Tolerated 
LIG4 rs1805388 T9I C65 Possibly Damaging Damaging 
LIG4 rs1805389 A3V C0 Benign Damaging 
MBD4 rs10342 A273S C0 Benign Tolerated 
MGMT rs12917 L84F C15 Benign Tolerated 
MGMT rs2308321 I143V C0 Benign Tolerated 
MGMT rs2308327 K209R C0 Benign Damaging 
MLH1 rs1799977 I219V C25 Benign Tolerated 
MLH3 rs175080 P844L C65 Benign Damaging 
MMS19 Rs12360068 A558V C65 Benign Tolerated 
MMS19 rs3740526 G790D C0 Benign Tolerated 
MSH3 rs1650697 I79V C0 Benign Tolerated 
MSH3 rs184967 Q949R C0 Benign Tolerated 
MSH3 rs26279 A1045T C0 Benign Tolerated 
MSH4 rs5745325 A97T C55 Benign Tolerated 
MSH5 rs2075789 P29S C0 Possibly Damaging Damaging 
MSH6 rs1042821 G39E C0 Possibly Damaging Tolerated 
MUTYH rs3219484 V22M C15 Benign Damaging 
MUTYH rs3219489 Q324H C0 Possibly Damaging Tolerated 
NBN rs1805794 E185Q C0 Benign Tolerated 
NEIL3 rs13112358 P443L C0 Benign Tolerated 
NEIL3 rs13112390 Q471H C0 Probably Damaging Tolerated 
NEIL3 rs34193982 H286R C0 Probably Damaging Tolerated 
NEIL3 rs7689099 P117R C65 Probably Damaging Damaging 
OGG1 rs1052133 P332A C25 Benign Damaging 
PARP1 rs1136410 V762A C65 Benign Tolerated 
PARP2 rs3093926 R283Q C35 Benign Tolerated 
PMS2 rs2228006 E541K C15 Benign Tolerated 
POLD1 rs1726801 R119H C0 Benign Tolerated 
POLE rs5744751 A252V C65 Benign Tolerated 
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POLE rs5744934 N1396S C0 Benign Damaging 
POLG rs2307441 E1143G C65 Possibly Damaging Damaging 
POLG rs3087374 Q1236H C0 Benign Damaging 
POLI rs8305 A731T C0 Benign Tolerated 
POLL rs3730477 R438W C0 Benign Damaging 
POLN rs10011549 G336S C55 Benign Tolerated 
POLN rs10018786 M310L C0 Benign Tolerated 
POLN rs2353552 Q121H C15 Possibly Damaging Damaging 
POLN rs9328764 R425C C0 Probably Damaging Tolerated 
POLQ rs1381057 Q2513R C0 Benign Tolerated 
POLQ rs3218634 L2538V C25 Benign Damaging 
POLQ rs3218649 T982R C0 Benign Tolerated 
POLQ rs3218651 H1201R C0 Possibly Damaging Damaging 
POLQ rs487848 A581V C65 Benign Tolerated 
POLQ rs532411 A2304V C0 Benign Damaging 
PRKDC rs8178017 M333I C0 Possibly Damaging Tolerated 
PRKDC rs4278157 R2899C C45 Possibly Damaging Tolerated 
PRKDC rs7830743 I3434T C0 Benign Tolerated 
RAD1 rs1805327 E281G C65 Possibly Damaging Damaging 
RAD17 rs1045051 L546R C65 Probably Damaging Damaging 
RAD18 rs373572 R302Q C0 Benign Tolerated 
RAD23B rs1805329 A249V C0 Benign Tolerated 
RAD51L3 rs4796033 R185Q C0 Benign Tolerated 
RDM1 rs2251660 C127W C0 Probably Damaging Tolerated 
RECQL4 rs4244612 E267D C0 Benign Tolerated 
RECQL4 rs4251691 R1005Q C0 Benign Tolerated 
RECQL5 rs820196 D480G C0 Benign Tolerated 
REV1 rs3087386 F257S C0 Benign Tolerated 
REV1 rs3087399 N373S C0 Benign Tolerated 
REV1 rs3087403 V138M C0 Benign Tolerated 
REV3L rs3204953 V3064I C25 Benign Tolerated 
REV3L rs458017 Y1156C C0 Benign Tolerated 
REV3L rs462779 T1224I C0 Benign Tolerated 
RPA1 rs5030755 T351A C0 Benign Tolerated 
RPA4 rs2642219 A33T C55 Benign Damaging 
TDG rs2888805 V367M C0 Benign Tolerated 
TELO2 rs2235624 Q146R C0 Benign Tolerated 
TELO2 rs2248128 Q674R C0 Possibly Damaging Damaging 
TELO2 rs2667661 E7G C0 Benign Tolerated 
TP53 rs1042522 P72R C0 Benign Tolerated 
WRN rs1346044 C1367R C65 Probably Damaging Tolerated 
WRN rs1800391 M387I C0 Benign Tolerated 
WRN rs2230009 V114I C0 Benign Tolerated 
WRN rs2725362 L1074F C0 Benign Tolerated 
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XPC rs2227999 R492H C0 Benign Tolerated 
XPC rs2228000 A499V C0 Benign Tolerated 
XPC rs2228001 Q939K C0 Benign Tolerated 
XRCC1 rs1799782 R194W C65 Probably Damaging Damaging 
XRCC1 rs25487 Q399R C0 Benign Damaging 
XRCC2 rs3218536 R188H C25 Benign Tolerated 
XRCC3 rs861539 T241M C15 Benign Tolerated 
245 
 
Appendix J: Analyses of variants (MAF>1%) and 12-week response, any toxicity and 
peripheral neuropathy. 
rs no. 
  
Response Any toxicity 
(except peripheral 
neuropathy) 
peripheral 
neuropathy 
Χ2 (df) p-value χ2 (df) p-value χ2 (df) p-value 
rs13181 0.36 (2) 0.84 0.35 (2) 0.84 6.66 (2) 0.036 
rs17655 3.30 (2) 0.19 0.07 (2) 0.97 1.62 (2) 0.44 
rs1799782 3.02 (2) 0.22 3.21 (2) 0.2 1.22 (2) 0.54 
rs1799977 1.62 (2) 0.45 1.11 (2) 0.57 n/a n/a 
rs1800067 0.25 (2) 0.88 1.68 (2) 0.43 0.49 (2) 0.78 
rs2227869 0.97 (1) 0.33 0.00 (1) 0.95 1.22 (1) 0.27 
rs2228527 1.71 (2) 0.43 5.34 (2) 0.069 0.98 (2) 0.61 
rs2228528 3.85 (2) 0.15 3.49 (2) 0.17 0.35 (2) 0.84 
rs2228529 1.50 (2) 0.47 5.51 (2) 0.064 0.97 (2) 0.61 
rs25487 9.57 (2) 0.0083 0.50 (2) 0.78 0.06 (2) 0.97 
rs25489 0.04 (1) 0.85 0.05 (1) 0.81 0.35 (1) 0.56 
rs861539 3.44 (2) 0.18 0.82 (2) 0.66 1.05 (2) 0.59 
rs1799977 1.62 (2) 0.45 1.11 (2) 0.57 0.16 (2) 0.92 
rs10011549 2.11 (2) 0.35 0.04 (2) 0.98 0.73 (2) 0.69 
rs1042522 1.05 (2) 0.59 1.16 (2) 0.56 2.34 (2) 0.31 
rs1045051 0.12 (2) 0.94 2.77 (2) 0.25 1.36 (2) 0.51 
rs1047840 4.90 (2) 0.086 1.11 (2) 0.57 0.30 (2) 0.86 
rs1048945 0.00 (1) 0.99 1.43 (2) 0.49 0.52 (1) 0.47 
rs1052133 3.69 (2) 0.16 0.53 (2) 0.77 3.42 (2) 0.18 
rs1130409 3.55 (2) 0.17 0.82 (2) 0.66 0.08 (2) 0.96 
rs1136410 4.23 (2) 0.12 3.23 (2) 0.2 4.22 (2) 0.12 
rs11571833 0.74 (1) 0.39 0.05 (1) 0.82 0.00 (1) 0.96 
rs11725880 1.31 (1) 0.25 2.37 (1) 0.12 0.01 (1) 0.93 
rs12022378 2.69 (2) 0.26 6.18 (2) 0.046 2.42 (2) 0.3 
rs12450550 1.50 (2) 0.47 2.68 (2) 0.26 4.34 (2) 0.11 
rs12768894 1.36 (2) 0.51 0.67 (2) 0.71 0.83 (2) 0.66 
rs12917 4.03 (2) 0.13 3.62 (2) 0.16 2.04 (2) 0.36 
rs13112390 1.44 (2) 0.49 0.07 (2) 0.97 0.20 (2) 0.91 
rs1346044 0.38 (2) 0.83 0.55 (2) 0.76 3.41 (2) 0.18 
rs1367580 0.61 (2) 0.74 4.53 (2) 0.1 2.39 (2) 0.3 
rs1381057 4.01 (2) 0.13 0.78 (2) 0.68 0.19 (2) 0.91 
rs144848 7.14 (2) 0.028 0.69 (2) 0.71 3.98 (2) 0.14 
rs1494961 4.49 (2) 0.11 0.62 (2) 0.73 0.09 (2) 0.96 
rs16942 0.19 (2) 0.91 5.12 (2) 0.077 1.14 (2) 0.56 
rs175080 1.21 (2) 0.55 0.25 (2) 0.88 2.91 (2) 0.23 
rs1776148 0.02 (2) 0.99 0.97 (2) 0.61 1.33 (2) 0.52 
rs1799950 1.65 (2) 0.44 1.39 (2) 0.5 0.11 (1) 0.74 
rs1799966 0.15 (2) 0.93 6.13 (2) 0.047 0.94 (2) 0.63 
rs1800058 1.26 (1) 0.26 3.04 (1) 0.081 5.50 (1) 0.019 
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rs1800282 0.66 (2) 0.72 1.57 (2) 0.46 0.60 (1) 0.44 
rs1800391 3.36 (2) 0.19 0.85 (2) 0.65 0.37 (2) 0.83 
rs1801516 0.44 (2) 0.8 0.47 (2) 0.79 0.89 (2) 0.64 
rs1802127 0.71 (1) 0.4 0.02 (1) 0.88 0.60 (1) 0.44 
rs1805327 4.00 (2) 0.14 0.68 (2) 0.71 0.20 (2) 0.91 
rs1805329 0.79 (2) 0.67 1.01 (2) 0.6 2.33 (2) 0.31 
rs1805388 6.29 (2) 0.043 4.26 (2) 0.12 1.16 (2) 0.56 
rs1805794 1.90 (2) 0.39 0.36 (2) 0.84 1.96 (2) 0.38 
rs184967 2.14 (2) 0.34 3.31 (2) 0.19 0.25 (2) 0.88 
rs1876268 0.21 (2) 0.9 0.04 (2) 0.98 0.36 (1) 0.55 
rs2066459 0.24 (1) 0.62 1.31 (1) 0.25 0.56 (1) 0.45 
rs2227928 0.80 (2) 0.67 0.21 (2) 0.9 0.27 (2) 0.87 
rs2228006 0.11 (2) 0.94 0.89 (2) 0.64 1.76 (2) 0.41 
rs2229032 0.82 (2) 0.66 1.26 (2) 0.53 0.83 (2) 0.66 
rs2229033 0.42 (1) 0.52 0.03 (1) 0.85 1.08 (1) 0.3 
rs2230009 4.55 (2) 0.1 0.56 (2) 0.76 0.73 (1) 0.39 
rs2235624 4.51 (2) 0.1 1.65 (2) 0.44 2.03 (2) 0.36 
rs2239359 1.39 (2) 0.5 1.32 (2) 0.52 0.83 (2) 0.66 
rs2248128 3.04 (2) 0.22 3.02 (2) 0.22 0.80 (2) 0.67 
rs2251660 1.37 (2) 0.5 0.85 (2) 0.65 1.28 (2) 0.53 
rs2266690 1.18 (2) 0.55 2.37 (2) 0.31 1.45 (2) 0.48 
rs2304103 0.41 (1) 0.52 0.45 (2) 0.8 0.99 (1) 0.32 
rs2307441 0.13 (1) 0.71 0.63 (1) 0.43 1.84 (1) 0.17 
rs2308321 0.75 (2) 0.69 3.47 (2) 0.18 1.24 (2) 0.54 
rs2308327 0.37 (2) 0.83 4.61 (2) 0.1 1.08 (2) 0.58 
rs2353552 2.23 (2) 0.33 0.05 (2) 0.98 2.87 (2) 0.24 
rs2434470 0.56 (2) 0.76 1.55 (2) 0.46 4.49 (2) 0.11 
rs26279 1.58 (2) 0.45 2.76 (2) 0.25 1.26 (2) 0.53 
rs2725362 5.10 (2) 0.078 5.90 (2) 0.053 0.84 (2) 0.66 
rs28360135 0.03 (1) 0.85 0.62 (1) 0.43 1.25 (1) 0.26 
rs28365054 0.10 (1) 0.75 0.22 (1) 0.64 1.02 (1) 0.31 
rs28756982 0.10 (1) 0.75 0.42 (1) 0.52 0.01 (1) 0.92 
rs2888805 4.92 (2) 0.086 2.04 (2) 0.36 2.29 (2) 0.32 
rs3087374 4.15 (2) 0.13 1.91 (2) 0.39 2.55 (2) 0.28 
rs3087386 0.70 (2) 0.71 1.65 (2) 0.44 0.13 (2) 0.93 
rs3087399 0.85 (2) 0.65 4.85 (2) 0.088 0.04 (2) 0.98 
rs3087403 4.04 (2) 0.13 2.89 (2) 0.24 2.97 (2) 0.23 
rs3093921 1.51 (1) 0.22 0.35(1) 0.55 4.86 (1) 0.027 
rs3093926 3.03 (2) 0.22 0.58 (2) 0.75 2.63 (2) 0.27 
rs3204953 0.54 (2) 0.77 1.69 (2) 0.43 0.11 (2) 0.95 
rs3218536 0.29 (2) 0.86 4.29 (2) 0.12 0.57 (2) 0.75 
rs3218599 0.02 (1) 0.89 0.12 (1) 0.73 2.07 (2) 0.36 
rs3218634 1.20 (2) 0.55 2.34 (2) 0.31 0.03 (1) 0.87 
rs3218649 3.02 (2) 0.22 0.03 (2) 0.98 1.18 (2) 0.55 
rs3218651 1.38 (2) 0.5 0.50 (2) 0.78 2.41 (2) 0.3 
rs3219484 5.31 (2) 0.07 2.57 (2) 0.28 2.19 (2) 0.34 
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rs3219489 1.20 (2) 0.55 2.61 (2) 0.27 0.44 (2) 0.8 
rs34193982 0.38 (2) 0.83 1.67 (2) 0.43 0.23 (2) 0.89 
rs34933300 3.42 (2) 0.18 2.57 (2) 0.28 0.14 (2) 0.93 
rs3730477 2.83 (2) 0.24 3.98 (2) 0.14 3.93 (2) 0.14 
rs373572 0.45 (2) 0.8 0.94 (2) 0.62 1.78 (2) 0.41 
rs3736772 1.55 (2) 0.46 3.19 (2) 0.2 4.00 (2) 0.14 
rs3750898 0.59 (2) 0.75 0.49 (2) 0.78 8.55 (2) 0.014 
rs3816032 1.00 (2) 0.61 0.31 (2) 0.86 0.68 (1) 0.41 
rs4149909 8.67 (1) 0.0032 3.11 (1) 0.078 0.58 (1) 0.45 
rs4149963 0.04 (2) 0.98 1.61 (2) 0.45 0.38 (2) 0.83 
rs4251691 0.75 (2) 0.69 0.41 (2) 0.81 1.79 (2) 0.41 
rs458017 1.83 (2) 0.4 4.36 (2) 0.11 1.60 (1) 0.21 
rs462779 0.45 (2) 0.8 2.35 (2) 0.31 0.97 (2) 0.62 
rs487848 1.22 (2) 0.54 2.39 (2) 0.3 0.07 (1) 0.79 
rs4986764 0.47 (2) 0.79 1.50 (2) 0.47 0.69 (2) 0.71 
rs4986850 0.23 (2) 0.89 7.30 (2) 0.026 4.92 (2) 0.086 
rs4987117 0.99 (2) 0.61 0.25 (2) 0.88 2.05 (1) 0.15 
rs5030755 1.54 (2) 0.46 1.87 (2) 0.39 2.91 (2) 0.23 
rs506504 2.97 (2) 0.23 0.57 (2) 0.75 2.55 (2) 0.28 
rs532411 0.46 (2) 0.79 2.87 (2) 0.24 0.07 (1) 0.79 
rs5744934 1.17 (2) 0.56 1.19 (2) 0.55 0.17 (2) 0.92 
rs5745066 0.72 (1) 0.4 0.25 (2) 0.88 0.10 (1) 0.75 
rs5745459 0.03 (1) 0.87 4.06(1) 0.044 0.80 (1) 0.37 
rs5745549 0.15 (2) 0.93 1.10 (2) 0.58 0.57 (1) 0.45 
rs7190823 0.32 (2) 0.85 0.84 (2) 0.66 0.20 (2) 0.91 
rs735943 0.91 (2) 0.63 2.58 (2) 0.28 0.93 (2) 0.63 
rs7689099 1.47 (2) 0.48 0.29 (2) 0.86 0.29 (2) 0.86 
rs7830743 4.16 (2) 0.12 1.46 (2) 0.48 1.58 (2) 0.45 
rs799917 0.20 (2) 0.9 5.45 (2) 0.066 0.57 (2) 0.75 
rs8100525 0.04 (1) 0.85 0.35 (1) 0.56 0.00 (1) 0.95 
rs8178017 1.36 (1) 0.24 0.02 (2) 0.99 0.39 (2) 0.82 
rs820196 0.67 (2) 0.72 0.66 (2) 0.72 0.56 (2) 0.76 
rs8305 1.02 (2) 0.6 3.27 (2) 0.2 0.81 (2) 0.67 
rs9328764 2.00 (2) 0.37 0.05 (2) 0.97 0.88 (2) 0.64 
rs9350 0.05 (2) 0.97 1.27 (2) 0.53 0.73 (2) 0.69 
rs9352 0.58 (2) 0.75 2.83 (2) 0.24 6.06 (2) 0.048 
rs2228000 0.12 (2) 0.94 1.41 (2) 0.5 2.93 (2) 0.23 
rs2228001 3.27 (2) 0.19 4.37 (2) 0.11 0.16 (2) 0.92 
rs34594234 1.71 (1) 0.19 0.08 (1) 0.78 2.76 (1) 0.097 
rs17714854 4.74 (1) 0.029 2.06 (1) 0.15 0.65 (1) 0.42 
rs17782839 3.29 (1) 0.07 0.66 (1) 0.42 0.31 (1) 0.58 
rs1800056 0.27 (1) 0.6 2.37 (1) 0.12 0.00 (1) 0.96 
rs7761870 1.69 (1) 0.19 5.18 (2) 0.075 0.95 (1) 0.33 
rs1800057 0.03 (1) 0.87 1.78 (1) 0.18 0.54 (1) 0.46 
rs3218786 2.07 (1) 0.15 3.33 (2) 0.19 0.42 (1) 0.52 
rs1799944 0.50 (1) 0.48 0.07 (1) 0.79 1.95 (1) 0.16 
248 
 
rs12360068 0.93 (1) 0.33 0.22 (1) 0.64 0.61 (1) 0.43 
rs10138997 0.29 (2) 0.86 0.42 (2) 0.81 0.71 (1) 0.4 
rs11852361 3.17 (2) 0.2 0.72 (2) 0.7 0.24 (2) 0.89 
 
n/a – not assessed. 
 
